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ABSTRACT 
 
Cancer is a leading cause of death worldwide and viral infections such as HBV/HCV and 
HPV have been known to be responsible for up to 20% of cancers in low- and middle-income 
countries. Approximately 500,000 of these deaths are due to oesophageal squamous cell 
carcinoma (OSSC) alone, one of the major cancers in Eastern and Southern Africa, Latin 
America and Asia. Previous studies have shown HPV DNA to be integrated in nearly 40% of 
oesophageal tumours whereas it was present in only 3% of normal healthy asymptomatic 
individuals, implicating it as a possible risk factor.  
The aim of this study was to compare the roles and effects of the E6 gene from the low risk 
HPV11 and high risk HPV18 on the cellular gene expression profile in order to identify genes 
required for the initiation of cellular transformation and also to identify genomic alterations 
associated with oesophageal squamous cell carcinoma. The low risk HPV11 and high risk 
HPV18 E6 genes were cloned into an adenoviral vector and used to transform normal HaCaT 
cells to induce high-level expression of these genes in these cells. RNA isolated from these 
cells was used in DNA microarray analysis to elucidate the signalling pathways and networks 
that are differentially regulated by E6 during the early stages of transformation. Significantly 
differentially expressed genes (≥2.0/≤-2.0) were selected for further analysis.   
The E6 gene from both HPV11 and HPV18 was capable of inducing cellular transformation 
via the dysregulation of signalling pathways and networks and by exploiting the NFκB 
signalling pathway in predisposing normal cells toward malignancy. HPV11E6 was shown to 
have a much reduced effect compared to HPV18E6, probably due to its involvement in the 
degradation of p53.  In order to investigate whether any other integrated viral sequences may 
be involved in the aetiology of the disease, whole genome sequencing (WGS) was performed 
on the DNA isolated from tumour biopsies of four patients with histologically confirmed 
diagnosis of OSSC. 
Paired-end sequencing was performed on the Illumina HiSeq2000, with 2x100 bp reads. 
Reads were aligned to the Homo sapiens reference genome (NCBI37) using ELAND and 
CASAVA software. Structural variants (SV) reported from the alignment were collated with 
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gene loci, (upstream, downstream and overlapping) using the variant effect predictor of 
ENSEMBL. The affected genes were subsequently cross-checked against the genetic 
association database for disease and cancer associations. All the reads were aligned to a 
customised BWA human reference viral genome in order to identify integrated viruses 
present in the tissue. In addition to viral insertions, several deletions (e.g. BCLAF1) were 
shown to be early events in the progression of OSSC via their ability in induce dysregulation 
of apoptosis and the induction of inflammation. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 Oesophageal Cancer 
 
Oesophageal cancer begins to grow in the lining of the oesophagus, and can penetrate the 
wall of the oesophagus to spread to other parts of the body via the lymphatic system (Fig. 
1.1). There are two major types of oesophageal cancer: (i) Oesophageal adenocarcinoma 
(OAC), which occurs at the gastro-esophageal junction and is mainly associated with gastric 
reflux; (ii) Oesophageal squamous cell carcinoma (OSCC), which is prevalent in the 
developing countries of Africa, Latin America and Asia, occurs in the upper part of the 
oesophagus that is lined with squamous cells and is mainly associated predominantly with 
smoking, consumption of alcohol and very hot liquids (Hendricks & Parker, 2002; Mqoqi et 
al., 2004). The different sites of oesophageal cancer stem from the different aetiologies; the 
sequelae of gastro-esophageal reflux disease involve mostly the distal part of the oesophagus 
(Meining et al., 2004), whereas the effects of the nutritional changes on the other hand are 
present in the upper and middle third of the oesophagus (Siewert & Ott, 2007).  
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Location of the frequently occurring subtypes of oesophageal cancer. A: Oesophageal 
adenocarcinoma (OAC) occurs mainly in the lower third of the oesophagus and at the gastro-oesophageal 
junction. B: Oesophageal squamous cell carcinoma (OSCC) is generally diagnosed in the upper and middle 
third of the oesophagus. (Source: http://www.hopkins-gi.org)  
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1.2 Epidemiology of Oesophageal Cancer 
 
Oesophageal cancer is the eighth most common cancer in the world with an estimated 
456,000 new cases in 2012 (3.2% of the total), and the sixth most leading cause of cancer-
related mortality death worldwide with an estimated 400,000 deaths (4.9% of the total)  
(Jemal et al., 2009; Ferlay et al., 2010; Melhado et al., 2010; Ferlay et al., 2014). It is also the 
fifth most common cancer in the developing world, with approximately 450,000 newly 
diagnosed patients each year (Parkin et al., 1993; Enzinger & Mayer, 2003; Pohl & Welch, 
2005; Lepage et al., 2008; Pennathur et al., 2013). The incidence of oesophageal cancer 
varies widely according to geographical region and racial background, with  greater than 100-
fold differences observed between high incidence areas such as China and Iran and low 
incidence areas such as Western Africa (hul Park & Moon, 2008; Melhado et al., 2010). 
These wide variations in incidence are often observed between areas in close geographical 
proximity (Zaridze et al., 1992). The male to female incidence rate ratio also varies widely 
with ratios greater than 20:1 in France to near equality or even higher female cases in high 
incidence areas such as Iran (Melhado et al., 2010). Worldwide, a higher incidence of 
oesophageal cancer is seen in men with an average 3–4 fold increased rate for OSCC and a 
7–10 fold increased rate for OAC compared to women (Vizcaino et al., 2002).  
The incidence rates of oesophageal cancer vary internationally with more than 15-fold in men 
(ASR 22.3 per 100 000 in Southern Africa compared to 1.4 in Western Africa), and almost 
20-fold in women (ASR 11.7 per 100 000 in Southern Africa compared to 0.6 in Micronesia 
and Polynesia). The highest mortality rates are found in both sexes in Eastern and Southern 
Africa and in Eastern Asia (Figure 1.2, Globocan 2008). There is also a marked regional 
variation in incidence (MuÑoz & CastellsaguÉ, 1994). Mortality rates closely follow those of 
incidence. Mortality rates are elevated in Eastern Asia (14.1 per 100,000) and Southern 
Africa (12.8 per 100,000) in men, and in Eastern Africa (7.3 per 100,000) and Southern 
Africa (6.2 per 100,000) in women, this maybe due to the relatively late stage of diagnosis 
and the poor efficacy of treatment (Berrino et al., 1995; Ferlay et al., 2014). 
A unique epidemiological feature of oesophageal cancer is its uneven geographic distribution, 
with high incidence areas within demarcated geographic confines (Kamangar et al., 2006). 
These geographic ‘hot spots’ include areas in Northern Iran, Kazakhstan, South Africa, 
Northern China, Southern and Eastern Africa where annual incidence rates can exceed more 
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than 100 cases per 100 000 population annually (Umar & Fleischer, 2008; Eslick, 2009; 
Pennathur et al., 2013). In contrast, the incidence rates in most of Western and Middle Africa 
and Central America are much lower (Jemal et al., 2009). 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Age-standardized oesophageal cancer incidence rates by sex and world area. Incidence rates 
vary internationally by nearly 16-fold, with the highest rates found in Southern and Eastern Africa and Eastern 
Asia and lowest rates observed in Western and Middle Africa and Central America in both males and females. 
Oesophageal cancer is 3 to 4 times more common among males than females. Values for each world area 
correspond to incidence of oesophageal cancer per 100,000 individuals among males (left) and females (Right). 
(Source: GLOBOCAN 2008) 
 
 
 
 
 
 
 
 
 
Figure 1.3 Worldwide age-standardized incidence rates (per 100,000 individuals) of oesophageal cancer in 
both sexes. Incidence rate groups are represented by colours on the world map, ranging from green (low 
incidence areas) to yellow (medium incidence areas) and red (high incidence areas). The incidence of OSCC is 
the highest in developing countries such as Southern Africa, China, and South America. However, high 
incidence areas are also observed in some European countries such as the United Kingdom, France, and 
Portugal. Source: (Ferlay et al., 2010; Ferlay et al., 2014) 
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There is extreme geographic variation in the incidence of oesophageal carcinoma with 
differences of as much as 300-fold between areas of greatest and least prevalence within a 
given country or between countries (Ferlay et al., 2010; Ferlay et al., 2014), Fig. 1.3. 
On the African continent, a number of reports have documented a very high incidence of 
OSCC in South Africa with a few reports regarding the occurrence of OSCC in Central and 
Eastern Africa (Hendricks & Parker, 2002; Matsha et al., 2007; Leichman & Thomas, 2011). 
In parts of central and western Kenya, OSCC ranks among the most common cancers while 
in Uganda and Tanzania it is less common (Wakhisi et al., 2005).  
1.3 Aetiology of OSCC 
1.3.1 Alcohol 
The mechanism of effect of alcohol is uncertain; it may act as a direct irritant to the 
oesophageal epithelium, may increase susceptibility to other carcinogens or may contribute to 
dietary deficiencies that predispose subjects to OSCC (Holmes & Vaughan, 2007). Many 
case-control studies have shown both independent and synergistic effects of alcohol and 
smoking (Crew & Neugut, 2004). Alcohol and tobacco use accounts for the majority of the 
excess risk of developing OAC in US black males (Melhado et al., 2010). Alcohol 
consumption peaked in the United States in 1980 to 1981 and recent declines in alcohol 
consumption correlates with declines in OAC incidence (Brown & Devesa, 2002). In South 
Africa, alcohol consumption has been strongly associated with increased risk of developing 
OSCC in the rural areas, particularly where the consumption of homemade traditional maize 
beer is common (Sammon, 1992; Matsha et al., 2006). 
In the United Kingdom a case-control study conducted on alcohol, smoking and body mass 
index (BMI) as risk factors for both OSCC and OAC, confirmed an association of alcohol 
and OSCC estimating an odds ratio (OR) of 3.39 for subjects consuming more than 34 Units 
of alcohol per day with a positive dose-response relationship (Lindblad et al., 2005). A case-
control study in Italy and Switzerland showed OSCC with family history of cancer as the 
primary exposure and smoking and alcohol together as secondary exposures, for those 
without a family history of oesophageal cancer the OR for current smokers consuming ≥49 
drinks per week was 15.5 compared with non smokers consuming less alcohol (Garavello et 
al., 2005). In the high risk areas of the central Asian oesophageal cancer belt, smoking and 
alcohol consumption play a less significant role in the pathogenesis of OSCC (Melhado et al., 
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2010). Alcohol consumption is rare in Golestan, Iran and is therefore unlikely to be a major 
cause of OSCC (Brown & Devesa, 2002; Pourshams et al., 2005).  
1.3.2 Smoking 
In Africa, as in other parts of the world with a high incidence of oesophageal cancer, smoking 
and alcohol consumption feature as the most common risk factors for oesophageal cancer 
(Gamliel, 2000; Pacella-Norman et al., 2002). Prospective epidemiologic data shows that 
smoking greatly increases the risk of OSCC, with smokers having a 5-fold higher risk than 
non-smokers and with risk for heavy smokers increasing nearly 10-fold (Blot & McLaughlin, 
1999). The risk of OSCC decreases relatively rapidly after smoking cessation, with 
substantial declines within 5 to 10 years (Crew & Neugut, 2004). A study in Taiwan also 
found an increased risk of OSCC with smoking; however, it was found to be a smaller risk 
increase than for alcohol consumption. The OR for current smokers was 4.2 and for former 
smokers 3.4, as compared to subjects who had never smoked (Lee et al., 2005).  
1.3.3 Chronic Inflammation 
 
Epidemiologic studies support the thesis that acute inflammation contributes to the regression 
of cancer in contrast to chronic inflammatory diseases, which are frequently associated with 
increased risk of cancers (Balkwill & Mantovani, 2001; Lu et al., 2006). In China, 65% of 
males and 63.5% of females from a high risk population undergoing endoscopy had chronic 
oesophagitis (Munoz et al., 1982). In a similar study in northern Iran, chronic oesophagitis 
was seen in 80% of subjects, with a high incidence even in young patients (Crespi et al., 
1979). In the Transkei, 24% of adults from a high risk area had oesophagitis detected by 
oesophageal cytology smears; significantly greater than in an adjacent low risk area 
(Jaskiewicz et al., 1987). A study carried out in a high risk region of China, followed a cohort 
of patients with cytological diagnoses of normal oesophageal epithelium, oesophagitis and 
oesophageal dysplasia over 13.5 years and found that oesophagitis conferred no greater risk 
of invasive OSCC than normal oesophageal epithelium. The risk of subsequent oesophageal 
cancer increased with the degree of dysplasia, with high grade dysplasia and carcinoma in 
situ having a similar risk, bringing into question the role of chronic inflammation in the 
pathogenesis of OSCC (Wang et al., 2005). 
Caustic injury, which causes intense inflammation and stricturing, was also shown to increase 
the risk of OSCC approximately 1000-fold, with the time from ingestion to presentation 
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varying. Since accidental ingestion often occurs in children, the resulting tumours tend to be 
observed in a younger age group than other oesophageal cancers (Appelqvist & Salmo, 1980; 
Kim et al., 2001; Kochhar et al., 2006). 
1.3.4 Genetic Predisposition 
 
Epidemiologic evidence shows environmental risk factors for OSCC; however, only a subset 
of exposed individuals will develop OSCC, suggesting that genetic factors may be involved 
in its pathogenesis (Melhado et al., 2010). OSCC is a frequent form of cancer that shows 
striking variations in geographic distribution, reflecting exposure to specific environmental 
factors that are still poorly defined. It develops as the result of a sequence of 
histopathological changes that typically involve oesophagitis, atrophy, mild to severe 
dysplasia, carcinoma in situ and finally invasive cancer (Mandard et al., 2000).  
Genetic changes associated with the development of OSCC include mutations in the p53 
gene, disruption of cell-cycle control in G1 by several mechanisms (inactivation of 
p16MTS1, amplification of Cyclin D1, alterations of retinoblastoma (RB)), activation of 
oncogenes (e.g., EGFR, c-MYC) and inactivation of several tumour suppressor genes. Loss of 
heterozygosity on chromosome 17q25 has been linked with tylosis, a rare autosomal 
dominant syndrome associated with high predisposition to OSCC. Microsatellite marker loss 
of heterozygosity(LOH) studies have also shown that allelic losses on chromosomes 1p, 3p, 
5q, 9,11q, 13q, 17 and 18q are frequent in OSCC (Mandard et al., 2000). 
Early epidemiologic studies suggested increased susceptibility amongst Turkmen compared 
to Persians in the high risk Caspian littoral of Iran. These studies further proposed that the 
high incidence of OSCC along the trade route may be due to high penetrance of susceptibility 
genes, spread by Turkmen and similar groups who had a nomadic lifestyle and migrated from 
East Asia, inhabiting much of the Silk route most likely as a result of trading activity (Akbari 
et al., 2006).  
A number of the alcohol dehydrogenases (ADH), that oxidize ethanol to acetaldehyde that is 
in turn oxidized to aldehyde by aldehyde dehydrogenase (ALDH), have been implicated in 
the pathogenesis of OSCC (Lao-Sirieix et al., 2010). Acetaldehyde has been demonstrated to 
be carcinogenic and genetic variations resulting in functional differences in ADH and ALDH 
activity that lead to increased levels of acetaldehyde in alcohol drinkers may be an important 
risk factor (Druesne-Pecollo et al., 2009). The ALDH2 gene encodes the ability to metabolize 
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acetaldehyde with the ALDH2*2 allele producing an inactive protein unable to metabolize 
acetaldehyde; however, individuals who are ALDH2*2*2 homozygotes are protected from 
OSCC whilst ALDH2*1*2 heterozygotes have increased risk (Melhado et al., 2010). In 
ALDH2*1*2 heterozygotes the increased risk was modified by alcohol consumption with no 
appreciable increase in risk among non-drinkers and with moderately increased risk in 
moderate drinkers (OR 2.49; 95% CI 1.39–4.49) and the highest risk (OR 7; 95% CI 3.07–
13.6) was found in heavy drinkers (Lewis & Smith, 2005; Dong et al., 2008). 
Xenobiotics are activated to carcinogens by phase 1 enzymes and subsequently detoxified by 
phase 2 enzymes such as cytochrome p450 1A1 (CYT1A1) and glutathione S-transferase M1 
(GSTM1) respectively (Zhuo et al., 2009).  Evidence suggests that genetic polymorphisms of 
these genes may influence the balance between metabolic activation and detoxification of 
toxicants and are thus related to individual susceptibility to oesophageal cancer. But whether 
a CYP1A1 or GSTM1 polymorphism is a risk factor for oesophageal cancer remains largely 
uncertain (Hiyama et al., 2007; Matejcic et al., 2011). 
1.3.5 Infectious Factors 
 
Microorganisms have an aetiological role in oesophageal carcinogenesis either by producing 
carcinogens or promoters, or by acting directly on host cells with the chronic inflammatory 
processes caused by infectious microorganisms resulting in sustained regenerative 
proliferation of cells and increase in risk of cancer development (Chang et al., 1992). 
Syrjanen and colleagues found condyloma-like lesions in the specimens of oesophageal 
cancer providing a link with HPV infection for the first time (Syrjanen et al., 1982). Some 
studies have also shown HPV induced cytopathic changes leading to infection of the 
oesophagus and confirmed by immunohistochemical techniques demonstrating HPV antigens 
in squamous cell papilloma (Syrjanen, 1982; Chang et al., 1990).  
Subsequently, DNA hybridization studies and polymerase chain reaction techniques disclosed 
HPV DNA sequences in both benign and malignant oesophageal lesions (Winkler et al., 
1985; Kulski et al., 1986). By also using the filter in situ hybridization (FISH) method mixed 
with DNA probe containing HPV types 11, 16, and 18, HPV was also found in 22.0% (2/9) 
of patients without cytologic atypia, 50.0% (3/6) with mild dysplasia, 80.6% (25/31) with 
moderate dysplasia, 67.9% (19/28) with severe dysplasia and 66.7% (4/6) with invasive 
OSCC (Galloway & McDougoll, 1989; Chang et al., 1990). A study done in Transkei, South 
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Africa, a high risk area for oesophageal cancer, also implicated HPV 11 and HPV 39 as 
aetiological agents in OSCC (Matsha et al., 2002).                                                
1.3.6 Other Factors 
 
Increased risk of OSCC has been shown with exposure to radiation, both in patients exposed 
to therapeutic radiation and in atomic bomb survivors (Blot & McLaughlin, 1999). 
Occupational exposures including asbestos, perchloroethylene and combustion products have 
also been associated with OSCC in some studies (Crew & Neugut, 2004). Experimental 
induction of OSCC in mice has been reported with an incidence related to the intensity of the 
radiation administered (Gates & Warren, 1968). The effects of radiation appear to differ 
according to age at the time of exposure, dose, duration of radiation and the tissue irradiated 
(Mullen et al., 1979). 
An association case-control study of occupational exposures and the risk of both OSCC and 
OAC in Sweden found significant associations for OSCC with three occupational groups: 
concrete and construction (OR=2.2), food and tobacco processing (OR=5.1), and hotel and 
restaurant workers (OR=3.9). The hypothesis advanced was that among concrete and 
construction workers, airborne particulates may be trapped in airways and swallowed, 
thereby exposing the oesophageal mucosa to carcinogens. Hotel and restaurant workers on 
the other hand may be exposed to passive smoke, frying fumes, or the study results could 
reflect residual confounding by individual consumption of tobacco and alcohol (Jansson et 
al., 2006). 
1.4 Human Papillomavirus (HPVs)  
1.4.1 HPV Classification 
 
Human Papillomaviruses are epitheliotropic non-enveloped small double-stranded circular 
DNA viruses that show a tropism for squamous epithelium (Sapp & Bienkowska‐Haba, 
2009). There are nearly 150 different HPV types recognized, of which 120 HPV types are 
fully sequenced (Moody & Laimins, 2010). HPVs have been traditionally referred to as 
‘‘types’’, with a type representing a cloned full-length HPV genome whose L1 nucleotide 
sequence is at least 10% dissimilar from that of any other HPV type (Rautava & Syrjänen, 
2012). The HPV types have also been grouped into mucosal or cutaneous types, based on 
their tropism for specific epithelial sites. Mucosal HPV types found preferentially in 
precancerous and cancerous lesions have been designated as ‘high-risk’ types and these 
9 
 
include types 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70. Mucosal HPVs 
found in benign genital warts and other non-malignant lesions are generally labelled as ‘low-
risk’ types, the most important ones being HPV 6, 11, 42, 43, and 44 (Zur Hausen, 2002). 
Most genital and mucosal HPVs belong to the alpha genus while the skin types are included 
in the beta genus (Fig. 1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Phylogenetic tree containing the sequences of 118 papillomavirus types. The numbers at the 
ends of each of the branches identify an HPV type; c-numbers refer to candidate HPV types. All other 
abbreviations refer to animal papillomavirus types. The outermost semicircular symbols identify papillomavirus 
genera, e.g. the genus alpha-papillomavirus. The number at the inner semicircular symbol refers to 
papillomavirus species (De Villiers et al., 2004). 
 
 
The alpha papillomaviruses also include cutaneous viruses such as HPV2 that cause common 
warts and are only very rarely associated with cancers (De Villiers et al., 2004). The beta 
papillomaviruses are associated with cutaneous infections in humans and exist in latent form 
in the general population. Although in immune-compromised individuals and in patients 
suffering from the inherited disease Epidermodysplasia Verruciformis (EV), they can spread 
unchecked and become associated with the development of non-melanoma skin cancer 
(Harwood & Proby, 2002; Pfister, 2003). The additional genera, gamma, mu and nu include 
also HPV types associated with skin papillomas and skin warts and generally do not progress 
to cancer (Pfister, 1992; Shamanin et al., 1994; De Villiers et al., 2004). 
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1.4.2 HPV Genome 
 
The circular, double-stranded DNA genomes of all HPVs are approximately 8kb in size. 
HPVs are small non-enveloped viruses (~55nm in diameter) with an icosahedral capsid 
(Longworth & Laimins, 2004). Molecular cloning and sequencing of the papillomaviruses 
have revealed a genomic organization typical of all members of the HPV family, with 8 or 9 
open reading frames (ORFs) found on the same DNA strand. These ORFs encode for proteins 
categorised into early and late proteins according to their expression during the virus life 
cycle (Longworth & Laimins, 2004; Tommasino, 2014). 
The HPV genome can be divided into three main regions: (i) a coding region containing the 
early genes E1, E2, E4, E5, E6, and E7 that are responsible for transcription, viral genome 
replication and transformation of the host cell; (ii) a region containing the late genes the 
major (L1) and minor (L2) capsid proteins which encode the structural capsid protein. The L1 
protein is the primary structural element, with infectious virions containing 360 copies of the 
protein organised into 72 capsomeres (Modis et al., 2002); (iii) a non-coding region, termed 
the long control region (LCR) sometimes referred to as the upstream regulatory region 
(URR), which is localized between ORFs L1 and E6 and contains transcriptional, post-
transcriptional and replicative cis-regulatory elements (Graham, 2008; Thierry, 2009) see Fig. 
1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Genomic organization of the HPV genome. Schematic representation of the HPV 
circular genome showing the location and arrangement of the early (E) and late genes (L1 and L2) as 
well as the upstream regulatory region (URR) adapted from (Munoz et al., 2006). 
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1.4.3 High and low risk HPV infections 
 
The continuous expression of both the HPV E6 and E7 protein is required for the 
maintenance of cervical cancers, with the two viral proteins exerting distinct effects on cell 
survival, proliferation and integration and rearrangement of foreign DNA (Kessis et al., 1996; 
Duensing & Munger, 2002; DeFilippis et al., 2003; Jabbar et al., 2012). The high-risk E6 
proteins have the ability to form a tripartite complex with p53 and the cellular ubiquitin ligase 
E6-associated protein (E6AP) leading to proteosome-mediated p53 degradation (Huibregtse 
et al., 1993a). The Low-risk E6 proteins on the other hand binds p53 with a lower affinity 
than the highrisk types and has no significant ability to bind E6AP to stimulate p53 
degradation (Storey et al., 1998). This loss of the p53-mediated DNA damage response in 
cells expressing high-risk HPV E6 predisposes the host cell to cancer progression.  
The high-risk E6 proteins also have a C-terminal PDZ-binding domain and are capable of 
binding and stimulating the degradation of several cellular targets that contain PDZ motifs, 
such as human homologue of Dlg (hDlg) and human homologue of the Drosophila scribble 
protein (hSrib), that are thought to be involved in the regulation of cell growth and 
attachment (Zeitler et al., 2004). PDZ binding is thought to be a conserved feature of all high-
risk E6 proteins, and it has been implicated in the loss of cell polarity seen in HPV associated 
cervical cancers. It has also been shown to be necessary for the stimulation of epithelial 
hyperplasia in transgenic animals (Nakagawa & Huibregtse, 2000; Nguyen et al., 2003b). 
There are discordant observations that both the high-risk and low-risk forms of E6 are 
capable of binding and inactivating p73 (Marin et al., 1998; Park & Androphy, 2002). In 
addition, high-risk E6s are also capable of activating NF-κB, although the mechanism is not 
known there is evidence that it may depend upon the PDZ binding motif (Nees et al., 2001; 
Havard et al., 2005; Yuan et al., 2005; James et al., 2006; D’Costa et al., 2012). The E6 
proteins from both low- and high-risk mucosal types are also thought to be able to inhibit the 
interferon response causing the down-regulation of multiple interferon responsive genes 
(Nees et al., 2001). 
1.4.4 Molecular mechanisms of HPV induced carcinogenesis 
1.4.4.1 HPV induced Genomic instability 
 
Genomic instability has been observed in multiple epithelial cells expressing the E6 and E7 
protein (Smith et al., 1989; Hashida & Yasumoto, 1991; Reznikoff et al., 1994; White et al., 
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1994; Steenbergen et al., 1998; Duensing & Munger, 2002). Although the E6 and E7 proteins 
are necessary for maintenance of the transformed phenotype, they are incapable of directly 
transforming cells. The High-risk E6 and E7 are thought to independently induce genomic 
instability in normal cells, which is a characteristic of high-risk HPV-induced malignancies 
(White et al., 1994). The ability of E6 to induce genomic instability reflects its ability to 
inhibit the function of p53 (Havre et al., 1995), that leads to the disruption of normal DNA 
repair processes resulting in genetic change. The genomic instability induced by E7 reflects 
its effect on centrosome biogenesis and the consequent defects in segregation of daughter 
chromosomes during cell division while the induction of genetic instability is thought to be 
an early event in HPV-induced cancers, occuring before integration of the virus into host 
chromosomes (Duensing et al., 2001). These events are not limited to high-risk E6 and E7 
proteins but are also seen in cells expressing their low-risk counterparts (Rihet et al., 1996). 
1.4.4.2 HPV induced DNA damage response 
 
E6 and E7 have been shown to independently induce DNA damage and increase the 
frequency of foreign DNA integration into the host genome (Kessis et al., 1996; Duensing & 
Munger, 2002). This is thought to reflect the activity of both E6 and E7 in inhibiting p53-
mediated cell-cycle arrest and correlates with the ability of E6 to bind and inactivate p53 and 
E7 ability to not only disrupt the function of the cell-cycle regulator pRb but also to inactivate 
p21 (Funk et al., 1997; Song et al., 1998). Abrogation of the DNA damage responses may 
contribute to the accumulation of genetic alterations leading to malignant progression 
(Moody & Laimins, 2010). 
1.4.4.3 HPV induced Immortalization 
 
The E6 and E7 proteins of mucosal high-risk HPVs, which act independently or 
synergistically, have transforming activity in tissue culture and are capable of immortalizing 
multiple cell types including cervical, human foreskin keratinocytes and mammary epithelial 
cells (Hawley-Nelson et al., 1989; Hudson et al., 1990; Halbert et al., 1991; Wazer et al., 
1995). The E5 protein can also enhance the immortalization of keratinocytes in combination 
with both E6 and E7 (Stöppler et al., 1996). The immortalization potential of E6 in mammary 
epithelial cells and keratinocytes has not only been linked to its inactivation of p53 but also to 
its ability to induce the expression of telomerase (Dalal et al., 1996; Kiyono et al., 1998; 
McMurray & McCance, 2004). The use of K14E6/E7 transgenic mouse model has also 
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shown the persistence of cervical cancers in the cervicovaginal junction and outer cervix than 
in the cervix proper following exogenous estrogen treatment and withdrawal. Thus, 
suggesting that the outer cervix and cervicovaginal region may be more proliferative and 
more sensitive to estrogen than the cervix proper, explaining the rapid onset of recurrent 
disease (Spurgeon et al., 2014). 
1.4.4.4 HPV induced Cell Proliferation and differentiation 
 
HPV infections induce cell proliferation within the differentiating layers of the epithelium 
that are otherwise devoid of replicating cells (Zur Hausen, 2002). High risk E6 has been 
shown to induce suprabasal DNA synthesis, a p53-independent activity that correlates with 
its ability to bind PDZ-domain proteins (Song et al., 1999; Nguyen et al., 2003a). Depending 
on the titre and nature of the infecting papillomavirus type, the time between initial infection 
and the appearance of productive papillomas can vary with latency occurring when 
inoculating titres are low (Campo, 1995; Zhang et al., 1999). E6 PDZ binding is also thought 
to mediate suprabasal cell proliferation (Nguyen et al., 2003a; Nguyen et al., 2003b) and may 
contribute to the development of metastatic tumours by disrupting normal cell adhesion. 
 1.4.4.5 HPV induced Immune Response 
 
Interferon (IFN) is activated following viral infection and HPV proteins act at several levels 
to interfere with this response (Beglin et al., 2009). In cells in which HPV has integrated, 
both the E6 and E7 are expressed at higher levels and have been implicated in causing 
resistance to the effects of interferon (Nees et al., 2001; Beglin et al., 2009). Both the low and 
high risk E6 proteins are capable of inhibiting the interferon response causing the down 
regulation of multiple interferon responsive genes (Nees et al., 2001). The high risk E6 and 
E7 repress STAT1, a key transcription factor that regulates the IFN response with the high 
risk E6 directly binding to the IFN regulatory factor 3 (IRF3) that inhibits transactivation of 
IFN transcription (Ronco et al., 1998). They both also target the double-stranded RNA 
Protein Kinase R (PKR) inhibiting protein synthesis, through phosphorylation of the eIF2a 
proteins.  E6 in addition blocks PKR kinase activity by relocalizing it to cytoplasmic P-
bodies, which are sites of mRNA storage and degradation (Hebner et al., 2006).  
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1.4.4.6 HPV induced Apoptosis 
 
High-risk HPV E6 proteins are capable of extending the proliferative capacity of infected 
cells by inhibiting p53 dependent growth and blocking apoptosis in response to aberrant 
proliferation through several mechanisms, resulting in the induction of genomic instability 
and the accumulation of cellular mutations (Moody & Laimins, 2010). They also inhibit 
apoptotic signaling in response to growth suppressive cytokines through interaction with the 
tumour necrosis factor (TNF)-α receptor TNFR1, FAS-associated protein with death domain 
(FADD) and caspase 8 (Filippova et al., 2002; Filippova et al., 2004; Garnett et al., 2006). 
Both the low and high risk mucosal E6s can also bind to the pro-apoptotic proteins Bax and 
Bak leading to their degradation (Thomas & Banks, 1999). By utilizing the apoptotic 
signalling pathways high risk E6 are able to promote replication in differentiating cells 
(Moody et al., 2007). 
1.4.5 Association of HPV in OSCC 
 
Following the observation of characteristic cytopathic changes of HPV infection usually seen 
in condylomatous lesions, in both benign oesophageal epithelial tissue and malignant 
oesophageal tumours, a link between HPV and OSCC was made (Syrjanen et al., 1982). An 
increase in OSCC has also been observed in HIV-infected individuals (Rastegar, 2010; 
Stebbing et al., 2010), while HPV infection has been found in chronic oesophageal irritation 
and oesophageal cancer (Syrjanen, 1982; Chang, 1990; Chang et al., 1992). The infection of 
the oesophagus by HPV was also confirmed by immunohistochemical techniques 
demonstrating HPV structural antigens L1 and L2 in squamous cell papilloma (Hille et al., 
1986; Hale et al., 1989). The HPV DNA sequences in both benign and malignant 
oesophageal lesions have also being disclosed through DNA hybridization studies and 
polymerase chain reaction techniques (Syrjanen, 1982; Winkler et al., 1985; Kulski et al., 
1986; Chang et al., 1990; Benamouzig et al., 1992).  
A clear trend exists between HPV detection rates and geographical area corresponding to 
OSCC incidence rates, with studies conducted in high-risk regions for OSCC incidence 
reporting higher rates of HPV in OSCC specimens than studies carried out in low-risk regions 
(Matsha et al., 2007; Antonsson et al., 2010; Zhang et al., 2010; Cui et al., 2011; Malik et al., 
2011). HPV infection rates have also been found to be higher in developing countries than in 
developed nations (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans, 1995). HPV positivity prevalence in oesophageal cancer  globally has ranged from 
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0–71% in oesophageal tumour samples examined (Sur & Cooper, 1998) with the wide range 
being attributed to differences in the sensitivity of detection methods used and in the tumour 
samples examined (Hendricks & Parker, 2002).  
HPV was also detected in 26–71% of oesophageal squamous carcinoma samples from South 
African patients with the low-risk HPV types 6,11 and 39 being reported more frequently in 
oesophageal tumour tissues from high-risk regions than low-risk areas (Williamson et al., 
1991; Cooper et al., 1995; Lavergne & de Villiers, 1999; Matsha et al., 2002; Matsha et al., 
2006; Liyanage et al., 2013b; Schafer et al., 2013). A meta-analysis of studies demonstrated 
that HPV increased the risk of OSCC by three-fold thus providing the strongest evidence of a 
potential role for HPV in the aetiology of OSCC (Liyanage et al., 2013a).  
1.4.6 The HPV E6 Protein 
 
HPV E6 is a cysteine-rich protein of approximately 150 amino acids whose major structural 
characteristic is the presence of two zinc-binding regions, referred to as E6N and E6C. Both 
domains contain two cysteine motifs Cys-X-X-Cys that are conserved in the E6 proteins of 
all HPV types (Tommasino, 2014). Although it is not clear whether the Cys-X-X-Cys motifs 
are important for the ability of E6 to bind DNA non-specifically, the importance of these 
motifs for HPV E6 proteins has been implicated in transformation, transcriptional activation, 
immortalization and association with cellular proteins (Mallon et al., 1987; Grossman et al., 
1989; Vousden et al., 1989; Kanda et al., 1991; Foster et al., 1994; Rapp & Chen, 1998) see 
Fig. 1.6.  
 
 
 
 
Figure 1.6: Basic structure of HPVE6 Protein. Schematic representation of HPV16 E6 showing the position 
of amino acids and the CXXC motifs that form zinc complexes important for the E6 structure and function. The 
consensus PDZ-binding motif (ETQL) is shown positioned at the C terminus, adapted from (Tommasino, 2014). 
The E6 protein is regarded as a multifunctional protein in that it acts as a transcriptional 
transactivator by being coupled to its ability to transform and immortalize cells. In addition, 
the high risk E6 is capable of inducing immortalization of primary cell cultures, while the low 
risk E6 augments the ability of E7 to immortalize cells. Furthermore, the E6 modulates 
normal cellular processes by binding to cellular proteins E6AP and E6BP. The E6-E6AP 
complex can bind in vitro to p53 (Huibregtse et al., 1993a) although the deregulation of the 
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p53 growth suppressor function appears to be separate from the E6 involvement in the 
degradation of p53 (Lechner et al., 1992; Lechner & Laimins, 1994). The E6 also targets the 
degradation of p53 (Hubbert et al., 1992; Scheffner et al., 1992; Band et al., 1993; Foster et 
al., 1994; Mayers & Androphy, 1995) in a process that requires a ternary complex between 
E6, E6AP and p53 (Scheffner et al., 1994), while the low-risk HPVs, such as HPV-6 and 
HPV-11, do not have the capacity to degrade p53.The High risk HPVE6 and to a lesser extent 
low risk HPVE6 is also able to inhibit the expression of p53-regulated genes by directly 
interacting with the transcriptional co-activators CBP and p300 (Patel et al., 1999).  
Both the low risk and high risk E6 are capable of inhibiting the apoptotic response via the 
degradation of Bak, a member of the Bcl-2 family, through the interaction with E6AP and the 
ubiquitin proteasome pathway (Thomas & Banks, 1998; Jackson et al., 2000; Underbrink et 
al., 2008). Furthermore, high risk E6 activates host-cell telomerase, which might be 
associated with the loss of alleles in chromosomes 3p and 10p in-turn representing a late 
event in the steps towards immortalization (Klingelhutz et al., 1996; Steenbergen et al., 
1996). The high risk E6 also induces hTERT transcription during cell immortalization 
through the maintenance of telomerase activity (Liu et al., 2008). 
HPV E6 are capable of regulating the expression of miRNAs in cells (Martinez et al., 2008; 
Wang et al., 2009; McKenna et al., 2010; Wald et al., 2011). High risk HPVE6 down 
regulates both miR-34a which is involved in targeting cell cycle control genes (Wang et al., 
2009) and miR-218 which is involved in regulating the expression of LAMB3 (Martinez et 
al., 2008), that may play a role in cervical cancer cell growth. High risk HPVE6 also down 
regulates miR-23b which may also be important for regulating cell migration by causing the 
up regulation of urokinase plasminogen activator gene (Yeung et al., 2011). It is likely that 
HPVE6 regulates miRNAs through its interaction with transcriptional factors and signaling 
proteins (Vande Pol & Klingelhutz, 2013).  
1.5 Genomic Alterations in Cancer 
 
Cancers arise as a result of changes having occurred in the DNA sequence of cancer cells 
genome (Yang et al., 2010). Almost all cancer genomes contain nucleotide sequence changes 
compared with the germline of the cancer patient (Vogelstein & Kinzler, 1993). These 
variations include the genomic alterations that promote cancer, termed drivers and alterations 
present in the cancer genome that do not promote cancer, referred to as passengers (Davies et 
al., 2005; Stratton et al., 2009). It has been shown that the accumulation of genetic variations 
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can give rise to tumourigenesis in three types of genes namely stability genes, oncogenes and 
tumour-suppressor genes (Vogelstein & Kinzler, 2004). The human cells have been known to 
protect themselves against any lethal effects of cancer causing genetic mutations however; it 
is the defectiveness of a subset of genes that give rise to the development of cancer 
(Vogelstein & Kinzler, 2004; Yeang et al., 2008). Thus, the accumulation of genetic 
alterations in the tumour suppressor genes and oncogenes is thought to play a key role in 
cancer development (Nowell, 1976; Donahue et al., 2006). The most common genomic 
alterations in the cancer genome include nucleotide substitution mutations, 
Insertion/Deletions (InDels), copy number variations (CNV), chromosomal rearrangements 
and nucleic acids of oncogenic viruses (Weir et al., 2004; Chin & Gray, 2008; Stratton et al., 
2009). All these acquired changes may influence the rate of occurrence of genetic alterations 
(Balmain et al., 2003). Given that InDels are more likely to be drivers of mutation, a 
substantial number of InDels in the coding sequence (CDS) of cancer genes is not surprising , 
since Indels are often deleterious as evidenced by their frequent association with human 
disease (Zoghbi & Orr, 2000; Kondrashov & Rogozin, 2004; Yang et al., 2010). InDels have 
also been shown to be mutational components of gene and pseudogene evolution that are 
important in the long-term evolution of genome size (Petrov et al., 2000; Nedelcu, 2001; 
Gregory, 2004). In addition, InDels have also been associated with apoptosis mechanisms, 
phenotypic change and activity of surface antigen (Burch et al., 1997; Ferro & Pfeffer, 2001; 
Rocha & Blanchard, 2002). Thus, the abundance of InDels, which have a comparatively 
greater influence than SNPs, is consistent with the abnormal function and devastating 
characteristics of cancer (Yang et al., 2010). 
1. 5.1 Genomic Alterations in OSCC 
 
Genomic alterations contribute to human tumorigenesis by altering the expression levels of 
critical oncogenes and tumour suppressor genes (TSG) (Ying et al., 2012).  The 
understanding of the genomic abnormalities in OSCC is limited to studies of small cohorts, 
hence  the need to extensively identify genomic abnormalities underlying OSCC in-order to 
elucidate it’s molecular basis and guide the development of effective targeted therapies (Luo 
et al., 2006; Hirasaki et al., 2007; Bass et al., 2009; Hu et al., 2009; Beroukhim et al., 2010; 
Hu et al., 2010).  
Previous reports have shown OSCC to have a higher somatic mutational rate to breast 
carcinoma and glioblastoma multiforme, but less than head and neck squamous cell 
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carcinoma (HNSCC), oesophageal adenocarcinoma (OAC) and lung squamous cell 
carcinoma (SQCC) (Stransky et al., 2011; Agrawal et al., 2012; Cancer Genome Atlas 
Research Network, 2012; Dulak et al., 2013). The transitions (Ti) were the most common 
mutations followed by transversions (Tv) in OSCC (Song et al., 2014). Compared with OAC, 
HNSCC and lung (SQCC) the overall pattern of the mutation spectrum in OSCC was similar 
to that of HNSCC but different from that of lung SQCC which is dominated by transversions 
(Stransky et al., 2011; Dulak et al., 2013). 
Sequencing of OSCC samples has identified several recurrently mutated OSCC relevant 
genes and led to the conclusion that OSCC cases from different geographic regions might 
differ genetically (Agrawal et al., 2012; Gao et al., 2014; Song et al., 2014). Some of the most 
frequent copy number variations that might contribute to OSCC carcinogenesis involved 
3q26, 4q, 5p, 8q24.3, 7q, 9p21, 10q21, 11q13.3, 18p11.3 (Yang et al., 2000; Janssen et al., 
2002; Miller et al., 2003; Luo et al., 2006; Law et al., 2007; Yang et al., 2008; Bass et al., 
2009; Hu et al., 2009; Lin et al., 2014).While the regions known to have high level deletions 
containing candidate TSGs were; 4q21.23-21.3, 8p22, 10p11, 13q31.1, 14q32, 16q22-23, 
18q11-23 (Sun et al., 2005; Ying et al., 2006; Ying et al., 2012).  
Cancer genes known to be frequently mutated in OSCC clustered in several cancer pathways 
including cell cycle, apoptosis and DNA damage control pathways (Vogelstein et al., 2013). 
Eight significantly mutated genes have been reported in OSCC, six of which are well known 
OSCC implicated genes (TP53, RB1, CDKN2A, PIK3CA, NOTCH1 and NFE2L2). The 
ADAM29 gene has not been previously described in OSCC but is frequently mutated in 
melanoma and FAM135B gene that has not been previously linked to cancer (Wei et al., 
2011; Song et al., 2014). Other genes which have also been frequently mutated on OSCC 
include; MSH3, ADH4, EGFR, ERBB4 and PTEN  (Han et al., 1998; Chou et al., 2002; Yin et 
al., 2003; Matsumoto et al., 2005; Guo et al., 2006; Hanawa et al., 2006; Lee et al., 2006; 
Hiyama et al., 2007; Mir et al., 2008; Vogelsang et al., 2012; Vogelsang et al., 2014).  
A recent study aimed at creating a comprehensive catalogue of cancer genes revealed 33 
novel candidate genes related to immune evasion, cell proliferation, protein homeostasis, 
genome stability, chromatin regulation, RNA processing and apoptosis. The loss-of-function 
mutations in these genes would be expected to contribute to oncogenesis, some of these genes 
included RHEB, PCBP1, SOS1, ELF3, TRIM23, ALPK2 and BCLAF1 (Lawrence et al., 
2014). 
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The analyses of genomic alterations in multiple tumour types has led to two observations: (i) 
there is a substantial difference in genomic alterations  from tumours originating in the same  
tissue (Cancer Genome Atlas Network, 2012) and (ii) similar patterns of genomic alteration 
are observed in tumours from different tissues of origin (Cancer Genome Atlas Research 
Network, 2013). These phenomena of cross cancer similarity and intracancer heterogeneity 
represents an opportunity in designing new therapeutic protocols based on the genomic traits 
of tumours (Ciriello et al., 2013; Garraway et al., 2013; Garraway, 2013).      
1.5.2 Viral Integration in Cancer 
Viruses have been shown to cause cellular transformation by the expression of viral 
oncogenes and genomic integration in altering the activity of cellular tumour suppressors and 
by inducing inflammation that promotes oncogenesis (Tang et al., 2013; Lin et al., 2014). 
Although human oncogenic viruses belong to different virus families and utilize diverse 
strategies to contribute to cancer development, they have been shown to share many common 
features. These have included their ability to establish long-term persistent infections while 
evading the host immune response (McLaughlin-Drubin & Munger, 2008). Despite the viral 
aetiology of several cancers, viruses may often contribute to, but are thought not to be 
sufficient for carcinogenesis and other co-factors such as chronic inflammation, host cellular 
mutations and the host immunity must be involved in the transformation process. Thus, a key 
feature of the oncogenic viruses is the long-term interactions between virus and host as this 
leads to molecular events that may enable the eventual virus mediated carcinogenesis 
(Parsonnet, 1999). 
Six human viruses have been considered by the International Agency for Research on Cancer 
(IARC) as being carcinogenic based on sufficient evidence supporting their aetiologic 
association with human cancers (burkitt lymphoma, melanoma, cancer of the conjunctiva, 
OSCC, cervical cancer, anogenital cancers and head and neck cancers). These are Epstein-
Barr virus, Hepatitis B Virus(HBV), several types of human papilloma viruses (HPV), human 
T-cell lymphotropic virus type 1, Hepatitis C Virus (HCV), and Kaposi’s sarcoma-associated 
herpesvirus (Parkin, 2006). Other viruses with potential roles in human malignancies include; 
Human endogenous retrovirus (HERV)-K113 and K115, human mammary tumor virus 
(HMTV), Torque teno virus (TTV) and Merkel cell polyomavirus (MCPyV) (Nishizawa et 
al., 1997; Gifford & Tristem, 2003; Burmeister et al., 2004; Holland & Pogo, 2004; 
Kremsdorf et al., 2006; Park et al., 2006; Lee & Lee, 2007; Houben et al., 2010; Kofman et 
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al., 2011; Banks et al., 2012; Zwolińska et al., 2013; Hampras et al., 2014; Miner et al., 
2014). However, although viruses are widespread in the general population, only a small 
fraction of infected people develop neoplastic disease, indicating the crucial role of some 
presently unknown genetic factors (Mazzaro et al., 2005). Some viruses have been known to 
integrate into the host genome thereby interrupting gene functions or inducing chromosomal 
instability, while other viruses rarely integrate into a host genome. Thus, detecting the 
existence of viruses and their integration sites in host genomes is paramount in understanding 
their molecular mechanisms in disease development (Feitelson & Lee, 2007; Lace et al., 
2011; Jiang et al., 2012; McLaughlin-Drubin et al., 2012; Sung et al., 2012; Arzumanyan et 
al., 2013; Lasithiotaki et al., 2013; Panagiotakis et al., 2013; Pascale et al., 2013).  
Next Generation Sequencing (NGS), involving the use of advanced bioinformatic analysis 
pipelines has allowed for the unbiased discovery of known as well as novel viruses integrated 
within several human tissue types (Feng et al., 2008; Daly et al., 2011; Yu et al., 2012; Chiu, 
2013; DeBoever et al., 2013; Khoury et al., 2013; Naeem et al., 2013; Schelhorn et al., 2013; 
Zhao et al., 2013). A perfect example of the NGS approach has been in the determination of 
the full viral structure and human integration sites of MCPyV (Duncavage et al., 2011). The 
use of unmapped (nonhuman) sequencing reads from NGS of cancer specimens has enabled 
the identification of viral integration sites (Samuels et al., 2013). This was shown during 
alignment, in the case of paired-end read data a good indicator for a possible integration site 
is when discordant pairs can be detected whereby one read is aligned to the viral genome and 
its mate is aligned to the human genome (Jiang et al., 2012; Chen et al., 2013; Cimino et al., 
2014). Thus, integration of the viral genome into the host cell chromosome suggests that 
persistent viral infection is vital for malignant cell transformation and carcinogenesis (Zhang 
et al., 2011; Zhang et al., 2011). 
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1.6 Objective of this study 
 
To determine the role of viral sequences on the initiation of cellular transformation and the 
identification of genomic alterations associated with malignant transformation. 
1.6.1 Aims of this study 
 
This study aims to better understand the aetiology and molecular mechanisms involved in the 
development of OSCC. This will be achieved in three ways; 
1. Determining the role and effects of HPV-11E6 and HPV-18E6 in the transformation 
of HaCaT cells from the normal to the malignant state. 
2. Evaluating and comparing the effects of both HPV11E6 and HPV18E6 on gene 
expression patterns during the early stages of transformation. 
3. Identifying structural variants, primarily large structural variants (insertions and 
deletions) and integrated viral sequences that may be associated with oesophageal 
squamous cell carcinoma (OSCC).  
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CHAPTER TWO  
Expression of HPVE6 in Human 
Keratinocytes 
 
2.1 Introduction 
 
Human papillomaviruses (HPV) have been implicated as causative agents in a variety of 
human squamous cell carcinomas, including those of the skin, cervix, anogenital region, 
upper respiratory tract, and digestive track (Syrjänen et al., 1982; Matsha et al., 2002). 
Currently nearly 150 different HPV types are recognized of which 120 have been fully 
sequenced, some of which are frequently associated with cancers and are considered high risk 
HPV (types 16 and 18) whereas others give rise to warts and benign lesions and are 
considered low risk (types 6, 11, and 33) (Matsha et al., 2002; Rautava & Syrjänen, 2012). 
Much basic and clinical research has focused on the high risk HPV types than on the low risk 
types despite the substantial financial burden imposed by low risk HPV types on the health 
systems (Hu & Goldie, 2008). Although most studies are also usually performed using either 
the E6 protein from the high risk HPV’s or most frequently involve concurrent expression of 
both the E6 and E7oncogenes the molecular mechanisms by which the low risk HPV E6 
protein may contribute to malignant progression are not fully understood (Reznikoff et al., 
1994; Zhang et al., 2007; Pim & Banks, 2010). 
The high risk HPV E6 and E7 function as oncoproteins, with the primary activity of the high-
risk form of E6 being to target p53 for degradation, via complex formation with the cellular 
ubiquitin ligase E6-AP (Scheffner et al., 1990; Werness et al., 1990; Huibregtse et al., 1991; 
Huibregtse et al., 1993a; Laimins, 1993; Scheffner et al., 1993; Scheffner et al., 1994; 
Huibregtse & Beaudenon, 1996; Kubbutat & Vousden, 1996; Mantovani & Banks, 1999). 
The inactivation of p53 in turn compromises the integrity of the cellular genome and lead to 
DNA damage and chromosomal instability, resulting in increased cell proliferation and 
tumour development (Schaeffer et al., 2004; Cheng et al., 2007; Cooper et al., 2007). As a 
consequence of the E6-mediated p53 inactivation, p21 gene transcription is also inhibited 
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(Cho et al., 2002). Although degradation of p53 by E6 is specific to high risk HPV types, the 
low risk forms of E6 may also bind to p53 although at a low affinity (Crook et al., 1991; Li & 
Coffino, 1996). On the other hand the high risk E7 acts by binding to members of the Rb 
tumour suppressor protein family and inhibits their ability to modulate the function of E2F 
transcription factors while the low-risk E7 proteins bind to Rb with a 10-fold lower affinity 
(Dyson et al., 1989; Munger et al., 1989; Heck et al., 1992).  
Various cell types have been used in investigating the underlying mechanisms of HPV 
induced malignant progression such as the prostate gland (Weijerman et al., 1994), cervix 
(Woodworth et al., 1988) and ovaries (Tsao et al., 1995). The normal human keratinocyte 
(HaCaT) cell line offers a suitable model to study regulatory mechanisms in the 
differentiation of human epidermal cells and provides a valuable model system for the study 
of the role of oncogenes and other factors in the process of malignant transformation of 
human epithelial cells (Boukamp et al., 1988).  
A major barrier to understanding the progression from initial infection to cellular 
transformation has been the lack of in vitro models that allow infection, replication and 
persistence of the viral genome in epithelial cells (Lee et al., 2004). The use of recombinant 
adenoviral vectors has been shown to hold great promise for gene transfer in basic research as 
well as for clinical treatment of many diseases (Kozarsky & Wilson, 1993; Kay & Woo, 
1994). They have been shown to be able to transduce foreign genes efficiently into both 
cultured cells and many target organs in vivo, without its viral genome undergoing frequent 
rearrangements. Futhermore, the inserted foreign genes are generally maintained without 
change through successive rounds of viral replication (Mizuguchi & Kay, 1998; Vorburger & 
Hunt, 2002). 
This chapter describes the construction of a recombinant adenovirus capable of high level 
transient expression of the biologically active HPV E6 from the low risk HPV11 and high 
risk HPV18 and to compare the roles and effects of these two HPVE6 proteins in inducing 
cellular transformation on normal human keratinocyte (HaCaT) cells. 
2.2 Results 
2.2.1 Construction of Recombinant Adenovirus Vector 
 
The assembly and production of recombinant adenovirus was accomplished in three stages 
(Fig. 2.1). Firstly a mammalian expression cassette with E6 constructs from either HPV11 or 
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HPV18 was excised from pcDNA3.1 and cloned into a pShuttle2 vector.  After amplification 
in Escherichia Coli DH5α, the expression cassette was excised from pShuttle2 and ligated to 
Adeno-X Viral DNA (the adenoviral genome). Lastly, the recombinant Adeno-X vector was 
packaged into infectious adenovirus by transfecting human embryonic kidney (HEK) 293 
cells and harvested by lysing the transfected cells. HaCaT cell lines were then infected with 
the recombinant adenovirus inorder to transiently express the gene of interest as described in 
sections 6.12.  
 
                               
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 Construction of recombinant adenovirus. The pShuttle2 allowed for the cloning of HPVE6 
constructs into the mammalian expression cassette, which consisted of the human cytomegalovirus immediate 
early promoter/enhancer (PCMV IE), a multiple cloning site (MCS), and the SV40 polyadenylation signal (SV40 
poly A). Following amplification in Escherichia Coli DH5α the expression cassette which was flanked by 
unique I-Ceu I and PI-Sce I restriction sites was excised and then “shuttled” into Adeno-X Viral DNA by in 
vitro ligation. The products were then treated with SwaI to linearize non-recombinant Adeno-HPVE6 DNA and 
amplified in Escherichia Coli. DNA was isolated and digested with PacI to expose the inverted terminal repeats 
(ITRs) located at either end of the genome. Finally the recombinant Adeno-HPVE6 constructs were packaged 
into infectious adenovirus by transfecting human embryonic kidney (HEK) 293 cells and harvested by lysing the 
transfected cells (Clontech Expression, 2012).  
2.2.1.1 Preparation of Ultra-Competent Escherichia Coli DH5α Strain 
 
The method of Inoue et al., (1990) was used for the preparation of ultracompetent 
Escherichia coli DH5α, with a slight modification of the Hanahan, (1983) technique. This 
method offers a simple and efficient method for plasmid transfection, enabling improved 
transformation efficiencies when cloning large plasmids with an extremely high transforming 
frequency (1-3 x 109 cfu/ug of plasmid DNA) as described in section 6.1. Transformation 
efficiency was defined as the number of colony forming unit (cfu) produced by 1 μg of 
plasmid DNA, and was measured by performing a control transformation reaction using a 
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known quantity of DNA, then calculating the number of cfu formed per microgram of DNA 
(Tu et al., 2005).     
2.2.1.2 Construction of Recombinant pShuttle2 
 
pcDNA3.1 vector containing the E6 genes from either HPV11 or HPV18 were kindly 
donated by Dr. Lawrence Banks (ICGEB Trieste). The E6 inserts were released by digestion 
with NheI and NotI and cloned into the multiple cloning site (MCS) of the pShuttle2 vector as 
shown in Fig. 2.1. The pShuttle2 vector was then propagated in Escherichia Coli DH5α, and 
the transformation efficiencies of the pShuttle calculated as shown in Table 2.1. 
 
Table 2.1: The transformation efficiency of respective pShuttle2 per microgram DNA  
 
Plasmid DNA Conc. CFU/Plate Dilution factor Transformation 
efficiency 
pShuttle2 11E6 0.35ng/ul 444 1000 1.3x109 
pShuttle2 18E6 0.27ng/ul 292 1000 1.1x109 
 
2.2.1.2.1 Confirmation of E6 inserts sequence identities 
 
After the recombinant plasmids had been propagated in Escherichia Coli DH5α, they were 
isolated as described in section 6.2 and sequenced using the universal T7 primers. A BLASTn 
search showed 100% sequence identity to the HPV11E6 (Accession number: FN870475.1) 
and HPV18E6 (Accession number: EF422110.1) sequences on the NCBI nucleotide database. 
2.2.1.2.2 Release of the E6 inserts from the recombinant pShuttle2  
 
The restriction endonucleases PI-SceI / I-CeuI were used to excise the newly constructed 
expression cassette from the recombinant pShuttle2 E6 constructs (Fig. 2.1), and were then 
“shuttled” into Adeno-X viral DNA by in vitro ligation, to generate a circular recombinant 
E1/E3-deleted adenoviral genome that carries a ColE1 origin of replication and an ampicillin 
resistance marker for propagation and selection in Escherichia Coli DH5α. SwaI digestion 
was performed to linearize any non-recombinant (i.e. self-ligated) pAdeno-X DNA. 
2.2.1.3 Analysis of Recombinant Adeno-HPVE6 Constructs 
 
The identity of the recombinant pAdeno-HPV (large plasmid >32kb) E6 constructs were 
determined by restriction enzyme digestion and PCR analysis. In restriction analysis the 
presence of the expression cassette was verified by digestion with XhoI and analysis done on 
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1 % agarose gels (Fig. 2.2A). The pAdeno-HPVE6 constructs were screened for the presence 
of pShuttle2 derived expression cassettes using the Adeno-X forward and reverse PCR 
primers, to specifically amplify a 287-bp (Fig. 2.2B) fragment that spanned the ICeuI ligation 
site in pAdeno-X (Fig. 2.1). Only recombinant pAdeno-HPVE6 templates were amplified 
since non-recombinants lacked the shuttle sequence needed for annealing with the reverse 
primer. The E6 constructs were also verified using the HPV11E6 and HPV18E6 specific 
primers (Fig. 2.2C) designed to give different size fragments for the two genes. 
 
 
 
Fig. 2.2 Confirmation of HPVE6 Constructs. A: Verification of expression cassette following digestion with 
XhoI of both the HPVE6 constructs an Adeno-X positive control (Pc) and the pShuttle2 vector negative control 
(Nc). B: Verification of recombinant Adeno-HPVE6 constructs by PCR with the Adeno-X forward and reverse 
PCR primers which specifically amplified a 287-bp sequence that spanned the ICeuI ligation site. C: 
Verification of HPV E6 constructs using HPV11E6 and HPV18E6 specific primers with pShuttle vector as a 
negative control (Nc). In each case three different clones of each construct were selected for analysis (a, b, c). 
2.2.1.4 Propagation and purification of recombinant AdenoHPVE6 
 
Before Adeno-HPVE6 constructs could be packaged, the recombinant plasmids were 
digested with PacI to expose the inverted terminal repeats (ITRs) located at either end of the 
genome (Fig. 2.1). The ITRs contain the origins of adenovirus DNA replication and had to be 
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positioned at the termini of the linear Adenovirus DNA molecule to support the formation of 
the replication complex (Tamanoi & Stillman, 1982). The recombinant Adeno-HPVE6 
constructs were then packaged into infectious adenovirus by transfecting human embryonic 
kidney (HEK) 293 cells (Fig. 2.3A). After overnight incubation the cells displayed a 50% 
cytopathic effect (CPE) (Fig. 2.3B) and were harvested by lysing with three consecutive 
freeze thaw cycles to prepare a primary adenoviral stock.  The titer of the primary adenoviral 
amplification stock (Fig. 2.4) was determined using the End-point dilution assay to measure 
the number of infectious viral particles as described in section 6.7. 
 
 
                       
 
 
Fig. 2.3 Production of recombinant adenovirus. HEK293 cells at a density of (~106 cells) were seeded in a 
10cm culture plate and incubated at 37°c in a humidified atmosphere maintained at 5% CO2 until 70% 
confluent;  A: HEK293 cells before packaging of recombinant Adeno-X vector into infectious adenovirus. B:  
HEK293 cells transfected with PacI digested Adeno-HPVE6 showing 50% CPE after overnight incubation. 
CPE was visualized using the Olympus CKY41 light microscope and the cells harvested by lysing with three 
consecutive freeze thaw cycles to generate a primary adenoviral stock.  
 
2.2.1.5 Purification of Recombinant Adenovirus 
 
Purification and concentration of the recombinant adenovirus was done using the Adeno-X 
Maxi Purification Kit (Clontech Purification, 2013), as it is a faster and safer alternative to 
cesium chloride gradient centrifugation. The kit also allowed for the purification of high 
yields of recombinant adenovirus directly from the cell pellet. 
 
B A 
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Fig. 2.4 End-point dilution assay. HEK 293 cells were plated in a 96-well plates at a density (~104 cells per 
well) in 100 μl of growth medium and incubated overnight. Serial dilutions of respective HPVE6 virus was then 
added to each well in columns 1–10 and virus free growth medium was also added to wells in columns 11–12 
which served as controls for the viability of non-infected cells. The plates were then covered and incubated in a 
humidified CO2 (5%) incubator for 10 days at 37°C. CPE was visualized using the Olympus CKY41 light 
microscope and the viral titer determined by calculating the fraction of CPE-positive wells in each row as 
described in section 6.7. A: Titer determination of the primary adenoviral amplification stock of HPV11E6.  
B: Titer determination of the primary adenoviral amplification stock of HPV18E6. 
 
 
A multiplicity of infection (MOI.) of 1 was calculated from the titer of the primary stock (Fig. 
2.4) which was used to determine the optimal amount of virus required to seed into cell 
culture dishes (Table. 2.2).  
 
 
Table 2.2: Optimal amount of virus required to seed culture dishes for amplification and  
                  purification of adenovirus 
 
Adeno-x 
plasmid 
Primary Stock 
titer 
Cells used to 
determine MOI 
MOI-1 Quantity of 
virus per dish 
HPV11E6 1.3x109 3.57x105 0.3µl 12µl 
HPV 18E6 1.0x109 3.57x105 0.4µl 16µl 
 
To produce greater quantities of high titer adenovirus, seven 150 mm HEK 293 cell culture 
dishes with 1.46x107 cells/dish were each seeded with the calculated quantity of adenoviral 
E6 constructs (Table. 2.2) until a 50% cytopathic effect (CPE) was observed and harvested by 
lysing with three consecutive freeze thaw cycles. 
 
 
 
A B 
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2.2.1.6 Determination of Recombinant Adenovirus titer 
 
Once the recombinant adeno-HPVE6 constructs were harvested, purification was done using 
the Adeno-X Maxi Purification Kit (Clontech Purification, 2013) to remove any traces of 
growth medium that might interfere with the absorbance at 260 nm. The titer of the harvested 
recombinant adeno-HPVE6 constructs (Table 2.3) was then determined using the OD260 assay 
(Clontech Expression, 2012). 
 
Table 2.3: Viral titer of recombinant AdenoHPVE6 constructs  
 
 
2.2.1.7 HPV E6 Constructs Confirmation  
In order to verify that the encapsidated adenoviral genome contained a full length copy of the 
HPV E6 construct, PCR analysis was done using the HPV11E6 and HPV18E6 specific 
primers (Fig. 2.2C) as a quick and efficient way of evaluating the constructs. The insert 
identities were confirmed by sequencing the E6 constructs using specific promoter CMV 
primers.  A BLASTn search showed 100% nucleotide sequence identity to the HPV11E6 
(Accession number: FN870475.1) and HPV18E6 (Accession number: EF422110.1) 
sequences on the NCBI database. The sequences were interpreted using the Chromas 
software version 2.01 (McCarthy, 2004) as shown on Fig. 2.5. 
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Fig. 2.5: Partial image of NCBI HPVE6 Nucleotide sequence quality confirmation. A: Nucleotide sequence 
identity of part of the HPV11E6 insert in adenoHPV11E6 using specific CMV promoter primers shows an 
excellent quality of the sequence using the chromas 2.01 software. B: Nucleotide sequence identity of part of 
HPV18E6 insert in adenoHPV18E6 using specific CMV promoter primers shows an excellent quality of the 
sequence using the chromas 2.01 software 
 
2.2.1.8 Infection of target cells (HaCaT) 
2.2.1.8.1 Determination of multiplicity of infection (MOI) 
MOI is typically used to determine the probability and distribution of infectious events in a 
population of cells. The MOI needed to efficiently transmit a gene of interest into a particular 
host cell depends on the biological properties of the target cell line and therefore, must be 
determined empirically. An excessively high MOI can be toxic to cells however; an 
extremely low MOI may not allow the accurate evaluation of the effect of the transgene in the 
infected cell line (Buttgereit et al., 2000). In order to achieve a 100% viral infectivity rate in 
the HaCaT cells, a MOI of 10 and 100 were calculated using the respective viral titers from 
Table 2.3 and the quantity of virus required to achieve the respective MOI’s shown on Table 
B 
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2.4. A time dependent study (Fig. 2.6) showed that cells infected for 48 hours with MOI 100 
gave the highest viral infectivity.  
 
                 Table 2.4: Quantity of virus per MOI  
 
 
 
2.2.1.8.2 Polycations augment Adenovirus mediated gene transfer 
We observed that by infecting HaCaT cells for 48 hours with MOI 100 alone did not achieve 
a 100% infectivity rate. Thus, we opted to employ the use of polycations specifically DEAE-
dextran which has been shown to improve infection efficiency. It was reported that MOI was 
not an accurate predictor of the efficiency of infection and an increase in MOI did not 
necessarily improve transduction efficiency (Deyrieux & Wilson, 2007). Thus adenovirus 
adsorption kinetics was thought to be affected by a number of factors such as inoculum 
volume, adsorption time, virus concentration and the potential implications of charge 
interactions for cell binding and entry of adenoviruses (Arcasoy et al., 1997; Nyberg-
Hoffman et al., 1997). Gene transfer was shown to be augmented by the addition of 
polycations such as polybrene, poly-l-lysine, DEAE-dextran and protamine by enabling the 
association between the negatively charged eukaryotic membrane and the adenovirus capsid 
also carrying a net negative surface charge (Fasbender et al., 1997; Lanuti et al., 1999). The 
addition of polybrene (6–8 μg/mL) was reported to dramatically improve the transduction 
efficiency of adenoviral infection on HaCaT cells to between 80–90% (Jacobsen et al., 2006; 
Deyrieux & Wilson, 2007).  
This study employed four techniques for infecting HaCaT cells; (i) cells were plated then 
infected through spin inoculation only, (ii) the virus and cells were mixed together before 
plating, (iii) cells were plated and infected with the virus with the aid of DEAE dextran and 
spin inoculation and (iv) the virus and cells were mixed together with the DEAE dextran 
before plating. The third technique using spin inoculation with 7.5µg/ml DEAE-dextran 
increased the transduction efficiency compared to the other techniques as shown by the 
increased levels of HPV18E6 protein using western blot analysis (Fig. 2.7). HeLa cells and 
uninfected HaCaT cells acted as positive and negative controls respectively. The same results 
were also observed for HPV11E6, although not with western blot analysis due to lack of HPV 
11E6 antibodies but with all the other experiments where HPV11E6 was used for infecting 
cells. 
Cells Per Well MOI HPV11E6 HPV18E6 
5.0 x 105 10 0.17µl 0.16µl 
5.0 x 105 100 1.7µl 1.6µl 
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Fig. 2.6: qRT-PCR determination of MOI. HaCaT cells were infected with the indicated HPVE6 constructs 
with the aid of DEAE dextran and spin infection at MOI 10 and MOI 100 and the levels of mRNA expression 
determined at various time points as described in section 6.13. Infection of cells with MOI 100 for 48hours 
showed the highest viral infectivity 
 
 
 
 
 
 
 
 
 
 
 
                     
Fig. 2.7: Transduction Efficiency. HaCaT cells were infected with HPV18E6 using four different methods. 
Firstly cells were plated after reaching 70% confluence and infected through spin inoculation only, in the second 
instance the virus and cells were mixed together before plating, thirdly cells were plated after reaching 70% 
confluence and infected with the virus with the aid of DEAE dextran and spin inoculation and finally the virus 
and cells were mixed together with the help of DEAE dextran before plating. HeLa cells and HaCaT uninfected 
cells acted as positive and negative controls respectively. Incubation was done for 48hrs at 37°c after which 
100µg of Protein was loaded on a 12% SDS-Page Gel. The results showed the addition of DEAE dextran with 
spin inoculation gave a higher expression of the protein compared to the other techniques as described in section 
6.12. 
2.2.2 Confirmation of HPV E6 Expression 
Confirmation of the levels of HPV11E6 and HPV18E6 was achieved by measuring both 
mRNA by qRT-PCR (Fig. 2.8) and protein by western blotting (Fig. 2.9) while confocal 
microscopy (Fig. 2.10) showed the protein localization as described below. 
2.2.2.1 HPV E6 mRNA expression  
Expression of HPV E6 mRNA in HaCaT cells was confirmed by qRT-PCR, using either 
HPV11E6 or HPV18E6 specific primers, which firstly, demonstrated the expression of both 
HPV11E6 and HPV18E6 in HaCaT cells and also confirmed the specificity of the products in 
both cell lines (Fig. 2.8A). Secondly, the qRT-PCR showed that both p21 and p53 transcripts 
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were not affected in cells infected with HPV11E6 but were downregulated in cells infected 
with HPV18E6 (Fig. 2.8B). HeLa cells were used in both cases as positive control for 
HPV18E6 mRNA. 
              
 
 
Fig. 2.8: qRT-PCR confirmation of HPV11E6 and HPV18E6 mRNA levels. HaCaT cells were infected with 
either HPV11E6 or HPV18E6 and the levels of the E6, P21 and P53 mRNA measured by qRT-PCR. A: 
HPV11E6 and HPV18E6 specific primers were used to detect the respective HPVE6. HeLa cells were used as 
positive control for HPV18E6 mRNA as described in section 6.17. B: Transcription of p21 and p53 genes 
following infection of HaCaT cells with the respective HPVE6 constructs. Both p21 and p53 were not affected 
in cells infected with HPV11E6 but were downregulated in cells infected with HPV18E6 and in HeLa cells. The 
figure represents the average of three replicates for each infection. 
 
2.2.2.2 Effect of HPV11E6 and HPV18 E6 expression on p53 and p21  
 
Western blotting analysis confirmed the presence of HPV18E6, p21 and p53 proteins 
following the infection of HaCaT cells with either HPV11E6 or HPV18E6 (Fig. 2.9). The 
p21 and p53 protein levels were downregulated in cells expressing HPV18E6 compared to 
those expressing HPV11E6 and in the HaCaT control cells. 
 
               
 
Fig. 2.9: HPV11E6 and HPV18E6 Protein detection. HaCaT cells were infected with either HPV11E6 or 
HPV18E6 and the protein levels of the HPV18E6, P21 and P53 were measured. Western blotting using 
HPV18E6 antibodies showed the presence of HPV18E6 in HaCaT cells infected with the HPV18E6 constructs 
and in HeLa cells which are known to constitutively express the HPV18E6 protein. p21 and p53 protein levels 
were downregulated in cells expressing HPV18E6 compared to those expressing HPV11E6 and the HaCaT 
control cells.    
    
A B 
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2.2.2.3 Confocal Microscopy 
 
The localization of HPV18E6 and p53 in HaCaT cells, expressing either HPV11E6 or 
HPV18E6, was investigated through confocal microscopy, using the respective specific 
primary antibodies as described in section 6.19. HPV18E6 is primarily localized in the 
nucleus in HaCaT cells expressing HPV18E6 and in HeLa cells. Whereas, HPV18E6 is not 
detected in HaCaT control cells and in HaCaT cells infected with HPV11E6. In HPV11E6 
expressing cells p53 was observed to be primarily localised to the nucleus with some diffused 
staining in the cytoplasm, whereas in HPV18E6 expressing cells, p53 was observed at lower 
levels than either in the control or HPV11E6 expressing cells. There also appears to be some 
increased cytoplasmic staining (degradation products) in the latter.  
 
             
 
Fig. 2.10: HPV E6 Protein Localization. HaCaT cells were plated on a microscope cover slip placed in a 6-
well cell culture dish at a density (~105 cells per well) in triplicate. After overnight incubation cells were 
infected with the respective HPVE6 virus at MOI 100 and incubated in a humidified CO2 (5%) incubator for 48 
hours at 37°C. The cells were then incubated in appropriate antibodies fixed and stained before being analysed 
using a confocal microscope (Zeiss LSM 510 Meta with NLO) as described in section 6.19. A1: HaCaT control 
cells incubated with HPV18E6 specific primary antibody showing absence of HPV18E6. A2: HaCaT control 
cells incubated with p53 primary antibody showing nuclear and cytoplasmic localization of p53. B1: HaCaT 
cells expressing HPV11E6 incubated with HPV18E6 specific primary antibody showing lack of HPV18E6. B2: 
HaCaT cells expressing HPV11E6 incubated with p53 primary antibody showing nuclear and cytoplasmic 
localization of p53. C1: HaCaT cells expressing HPV18E6 incubated with HPV18E6 specific primary antibody 
showing nuclear localization of HPV18E6. C2: HaCaT cells expressing HPV18E6 incubated with p53 primary 
antibody showing degradation of p53 in the nucleus and cytoplasmic p53 degradation products D1: HeLa cells 
expressing HPV18E6 incubated with HPV18E6 specific primary antibody showing nuclear localization of 
HPV18E6. D2: HeLa cells expressing HPV18E6 incubated with p53 primary antibody showing absence of 
p53in the nucleus and cytoplasmic p53 degradation products. 
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2.2.3 Characterisation of the effects of HPV E6 on HaCaT cells 
2.2.3.1 Morphology 
The HPV E6 gene from both the constructs did not visibly modify the morphology of HaCaT 
cells (Fig. 2.11). HaCaT cells expressing both HPV11E6 and HPV18E6 showed typical 
epithelial cell morphology similar to the control cells. 
 
 
    
Fig. 2.11: Effects of HPVE6 on Cellular Morphology. HaCaT cells were plated in a 10cm culture dish at a 
density (~106 cells) until 70% confluent. The cells were then infected with the respective HPVE6 at MOI 100 
and incubated in a humidified CO2 (5%) incubator for 48 hours at 37°C. The cells were visualized using an 
Olympus CKY41 light microscope. A: HaCaT control cells. B: HaCaT cells expressing HPV11E6. C: HaCaT 
cells expressing HPV18E6 
2.2.3.2 Effects of HPVE6 on the Cell Cycle 
 
The effect of HPV E6 expression on the cell cycle (Fig. 2.12) showed that the cell cycle 
distribution in HaCaT cells expressing HPV11E6 was comparable to the control HaCaT cells, 
i.e. no difference in the cell cycle phases. However HaCaT cells expressing HPV18E6 
showed a significant increase (p<0.05) in the percentage of cells in the G2-M phase 
compared to the control HaCaT cells, leading to the deregulation of the cell cycle.  
                        
Fig. 2.12: Effects of HPV11E6 and HPV18E6 on the Cell Cycle. HaCaT cells were plated in triplicate on 
three clones from each HPVE6 virus in a 10cm culture dish at a density (~106 cells) until 70% confluent. The 
cells were then infected with the respective HPVE6 at MOI 100 and incubated in a humidified CO2 (5%) 
incubator for 48 hours at 37°C. Cells were then harvested and flow cytometric cell cycle analysis was carried 
out using a BD FACS ™ Calibur flow cytometer (BD Biosciences, CA, USA). For each sample, at least 20,000 
cells were measured for DNA content. Analysis of the results was performed using ModFit LT software (Verity 
Software House) to calculate the percentage of cells in each stage of the cell cycle as described in section 6.20. 
HaCaT cells expressing HPV18E6 showed a significantly higher number of cells in the G2-M phase of the cell 
cycle compared to HaCaT cells expressing HPV11E6 and HaCaT control cells. 
A B C 
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2.2.3.3 Cellular Transformation 
Cellular transformation induced by HPV11E6 and HPV18E6 was assessed through the use of 
the soft agar colony formation assay. This is a common method for monitoring anchorage 
independent growth (one of the hallmarks of cell transformation) and is considered a reliable 
and commonly used in vitro assay for detecting cellular transformation of cells. For this 
assay, HaCaT cells expressing the respective HPVE6 proteins were cultured in soft agar 
medium for 21 days and the colonies were analyzed morphologically using crystal violet 
staining for the presence of pink colonies indicating cellular transformation (Fig. 2.13).  
While no colony formation was visible in the control HaCaT cell, few colonies were visible 
in cells expressing HPV11E6 and many more were visible in cells expressing HPV18E6. This 
showed the ability of both HPV11E6 and HPV18E6 to induce cellular transformation with 
HPV18E6 having a much stronger effect. 
 
         
 
 
Fig. 2.13: Colony formation by HPV E6. HaCaT cells were plated on a microscope cover slip placed in a 6-
well cell culture dish at a density (~105 cells per well) in triplicate. After overnight incubation the cells were 
infected with the respective HPVE6 at MOI 100 and incubated in a humidified CO2 (5%) incubator for 48 hours 
at 37°C as described in section 6.21. Cells were then stained with 0.5 ml of 0.005% Crystal Violet for more than 
1 hour and pink colonies were counted using an Olympus CKY41 light microscope A: No colony formation was 
visible for the HaCaT control. B: Few and tiny colony formation visible from the HaCaT cells expressing 
HPV11E6. C: Many and large colony formation visible from the HaCaT cells expressing HPV18E6.  
 
 
2.3 Discussion 
 
While considerable information is available on the diverse set of functions of high risk 
HPVE6, little is known about the function(s) of low risk HPVE6 proteins and the possible 
role that they may play in the process of cellular transformation. The aim of this chapter was 
to compare the effects of the E6 proteins from HPV11 (low risk) and HPV18 (high risk) and 
to evaluate the effect of these two types of E6 proteins on cellular gene expression and 
transformation. The HPV11E6 and HPV18 E6 genes were cloned into an adenoviral vector to 
induce, high level transient expression of these genes in the HaCaT cells. RNA isolated from 
A B C 
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these cells was later used in DNA microarray analysis to study and compare the effects of the 
E6 gene on cellular gene expression patterns during the early stages of cellular 
transformation. 
Historically the detection of HPV E6 proteins in cells has proved problematic, largely 
because of a lack of high avidity E6 antisera and the low levels of E6 expression in cells 
(Slebos et al., 1995).  In order to overcome this problem studies have used adenoviral vectors 
to infect a broad range of human cells to yield high levels of gene transfer (Vorburger & 
Hunt, 2002). Although efficient adenovirus mediated gene transfer into cultured epithelial 
and endothelial cells has been reported, these cells are resistant to adenovirus infection and 
require high MOI’s and a relatively long physical contact time between the adenovirus and 
target cell for significant gene transfer (Arcasoy et al., 1997). One way to compensate for the 
low efficiency of viral transduction is the use of high MOI’s, but this approach has the 
drawback of inducing strong inflammatory responses. Jacobsen et al., (2006) showed that a 
more suitable way to significantly increase the adenovirus transduction efficiency was by the 
improvement of the viral adsorption by polycations such as DEAE dextran. 
The lack of HPV11E6 specific antibodies has seen most studies employing indirect 
identification methods such as a green fluorescent protein (GFP) tag on HPV11E6 fusion 
proteins (Sun et al., 2008) or haemagglutinin (HA) tag (Guccione et al., 2002) in an effort to 
show the expression of HPV11E6. Although Watson et al., (2003) showed that the use of N- 
or C-terminal epitope tagged forms of E6 may not give a true reflection of E6’s biology as 
the presence of tags could affect the function of the oncoprotein. In this study some of the 
downstream effects of HPV11E6 were measured indirectly by determining the levels of p21 
and p53 proteins. Expression of the p21 and p53 genes in cells expressing HPV11E6 was 
comparable to the HaCaT control cells as opposed to cells expressing HPV18E6 which 
showed a marked reduction of these proteins. These findings demonstrated that cells 
expressing HPV18E6 were capable of binding and degrading p53, leading to the inactivation 
of the p21 gene which is thought to synergize with tumour suppressors and antagonize 
oncogenes to protect against cancer (Abbas & Dutta, 2009).This was consistent with other 
studies that have shown p21 gene transcription to be inhibited as a consequence of the 
HPVE6 mediated p53 degradation, and its reduced expression has also been reported in 
invasive squamous cell carcinoma (Cho et al., 2002; Cheng et al., 2007; Huang et al., 2010; 
Tagle et al., 2014). 
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High risk E6 proteins have been shown to work via several mechanisms to interfere with p53 
function. They recruit the cellular E3 ubiquitin ligase E6-associated protein (E6AP) to a 
trimeric complex with p53, leading to the subsequent ubiquitination and degradation of p53 
(Scheffner et al., 1990; Crook et al., 1991; Huibregtse et al., 1991). Interestingly, low risk E6 
proteins are also able to form complexes with E6AP (Oh et al., 2004; Brimer et al., 2007); 
however this union does not result in the degradation of p53 (Li & Coffino, 1996) suggesting 
that other cellular factors may be targets for the low risk E6-E6AP complex. In this study the 
increased levels of p53 and p21 proteins in cells expressing low risk HPVE6 type, compared 
with those expressing high risk HPVE6 type could be attributed to a number of factors. It 
could represent a stress response to viral infection (Prives & Hall, 1999), and the p53 
expression could also play a role in controlling the initial burst of amplificational replication 
that occurs after viral entry (Cox, 1997).  Alternatively the elevation of p53 could also occur 
as a result of p53 stabilization by binding with E6 protein, particularly with low risk types in 
which degradation does not occur (Giannoudis & Herrington, 2000).  
To confirm that the HPV18 E6 induced degradation of p53 levels, confocal microscopy was 
also used to determine whether there was a shift in the localisation of p53 in cells expressing 
E6 from a low-risk compared to a high-risk HPV type. In HPV11E6 expressing cells p53 was 
observed to be primarily localised to the nucleus with some diffused staining in the 
cytoplasm, whereas in HPV18E6 expressing cells, p53 was observed at lower levels than 
either in the control or HPV11E6 expressing cells. These results may explain the reduced 
effect of HPV11E6 compared to HPV18E6 in inducing cellular transformation even though it 
has been shown to able to bind and inactivate but not degrade p53. These results are 
consistent with studies by Stewart et al., (2005) who showed that high risk HPV18 E6 but not 
low risk HPV11E6 was able to accumulate predominantly in the nucleus. They also showed 
that both HPV18E6 and p53 when co-expressed shuttled from the nucleus to the cytoplasm 
where the p53 is degraded. 
Morphological changes in epithelial cells as a result of HPV E6 oncoproteins have been 
reported after many passages (Shen et al., 2002). A previous study by Kaczkowski et al., 
(2012) demonstrated that cultures transfected with HPV types; HPV11, HPV16 or HPV45 
grew much slower than control transfected cells. This slow growth rate may be attributed to 
death of part of the cell population as a result of HPV killing the cells or cells switching on 
the apoptosis programme in response to HPV. This effect was however not observed in the 
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current study as the morphology of cells expressing HPVE6 was unchanged compared to the 
HaCaT control cells. 
Normal mammalian cells exhibit G1 and G2 cell cycle arrest in response to DNA damage, in 
order to allow cells time to repair the damage before initiating replicative DNA synthesis or 
mitosis (Painter & Young, 1980; Denekamp, 1986). In this study, cells expressing HPV11E6 
did not disrupt the cell cycle, as opposed to cells expressing HPV18E6 which showed an 
increase in percentage of cells in the G2/M phase. This was hypothesised to be due to 
inactivation/degradation of p53 by HPV18E6 that inturn resulted in G2/M delay. This 
interaction between oncogenic HPVE6 and p53 suggested a plausible mechanism for the 
enhanced accumulation of genetic alterations. This was necessary for cellular transformation 
that occurred with a much stronger effect in high risk HPV as opposed to low risk HPV 
infection. The HPV infected cells expressing E6 were predisposed to acquisition of genetic 
alterations in a manner similar to that observed in cells with mutant p53 (Kessis et al., 1993).  
The interrelation between the increased G2/M population of cells and HPV18E6 expression 
in the present study was not readily apparent as the ability of HPVE6 to bind to other cellular 
proteins apart from p53 limits the interpretation of these findings (Chen et al., 1995; Imai et 
al., 1997; Kiyono et al., 1997; Gao et al., 1999; Taylor et al., 1999). This was also supported 
by Hamada et al., (2009) who applied kinetic mathematical models to show that, regardless 
of the DNA damage level, there were delays in the G2/M progression and that apoptosis was 
only induced in situations where extensive DNA damage occurred. 
Cell transformation studies provide information about the involvement of oncogenes and 
other genetic changes in the initiation and progression of cancer. Transformation of normal 
cells by viral genes is a frequent approach to inducing early events in the development of a 
malignant phenotype. In the current study, cellular transformation was shown through 
monitoring of anchorage independent growth on HaCaT cells. Growth of cells in soft agar 
showed that the HaCaT control cell did not induce colony formation while cells expressing 
HPV11E6 were able to form colonies, albeit very few and small compared to cells expressing 
the high risk HPV18E6. Consistent with these findings (Boukamp et al., 1988; Boukamp et 
al., 1990; Ren et al., 2006) have also shown that mock transfected HaCaT cells did not form 
soft agar colonies whereas, tissue culture studies have demonstrated that HPVE6 and E7 
genes exhibit immortalizing properties in human foreskin keratinocytes (Hawley-Nelson et 
al., 1989; Hudson et al., 1990; Woodworth et al., 1990; Griep et al., 1993) and alter 
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keratinocyte differentiation (Munger et al., 1989; Hudson et al., 1990; Woodworth et al., 
1990). The ability of cells expressing the low risk HPVE6 to form colonies may be attributed 
to the overall similarity of the high risk HPV E6 proteins to the low risk HPV E6 proteins as 
it seemed likely that they possessed common signalling pathways in inducing cellular 
transformation (Huibregtse & Beaudenon, 1996; Oh et al., 2004). 
Taken together, these findings significantly extend the understanding of HPVE6 mediated 
p53 degradation and show that both the low risk HPV11E6 and high risk HPV18E6 proteins 
were implicated in cellular transformation. Although HPV per se cannot account for cellular 
transformation (Schlegel et al., 1988), it was hypothesized that both the HPVE6 proteins 
might play a role in the transformation of HaCaT cells through the activation or inactivation 
of other cellular processes apart from the binding and inhibition of p53. Similar results were 
also reported by Chen et al., (1993) who postulated the functional inactivation of p53 as an 
effector mechanism for HPV mediated cellular transformation, but that it is not sufficient to 
confer cellular transformation on its own.  
To the best of our knowledge this is the first study to have shown early stages of HPVE6 
infection especially the ability of the low risk HPV11E6 in enabling cellular transformation. 
Although other studies have also speculated on the ability of HPV11E6 in achieving cellular 
transformation this study entailed the use of an adenoviral vector with the aid of polycations 
to highly express HPVE6 in an effort to identify genes associated with the initiation of 
cellular transformation which has not been shown before.  
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CHAPTER THREE  
Effects of HPVE6 on Cellular Gene 
Expression Patterns 
 
3.1 Introduction 
 
Human papillomaviruses (HPV) mediated carcinogenesis is mainly due to the oncogenic 
activities of the viral proteins E6 and E7. The classical function of E6 is to induce the 
degradation of p53 via direct binding to the ubiquitin ligase E6AP, inhibiting p53-dependent 
signaling upon stress stimuli and contributing to tumorigenesis (Scheffner et al., 1990; 
Werness et al., 1990; Scheffner et al., 1993). On the other hand the E7 oncoprotein acts by 
binding to members of the Rb tumour suppressor protein family and inhibits their ability to 
modulate the function of E2F transcription factors (Dyson et al., 1989; Zur Hausen, 2002).  
The E6 proteins from both low risk and high risk HPV also regulate the immune response by 
causing the down regulation of multiple interferon responsive genes (Nees et al., 2001). They 
both can bind to Tyk2 of the Jak-Stat pathway (Li et al., 1999). The high risk E6 also binds to 
IRF3 and inhibits its ability to activate interferon-responsive genes (Ronco et al., 1998). The 
ability of the HPVE6 to interact with both p53 and p300/CBP likely also plays a role in 
interferon response regulation (Hebner et al., 2006).  
The inhibition of the apoptotic signaling has also been reported. Both low and high risk 
HPVE6s bind and degrade the pro-apoptotic protein Bak (Thomas & Banks, 1999) 
independent of its p53 degradation function, suggesting that E6’s interaction with Bak 
appears to be conserved between both the low and high risk HPVE6s types (Klingelhutz & 
Roman, 2012). The high risk HPV E6s can also bind to procaspase 8 which can prevent E6-
expressing cells from responding to apoptotic stimuli (Tungteakkhun & Duerksen-Hughes, 
2008). E6 from both low risk and high risk HPVs also  bind to and degrade the human mini-
chromosome maintenance 7 (hMCM7) protein leading to chromosomal abnormalities in HPV 
infected cells, although binding of high risk E6 proteins appears to be stronger than that of 
low risk E6 proteins (Kukimoto et al., 1998; Howie et al., 2009).  
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The introduction of DNA microarray technology has had a dramatic impact on cancer 
research, allowing researchers to analyze the expression of thousands of genes and relate 
gene expression patterns to clinical phenotypes (Alizadeh et al., 2000; García-Escudero & 
Paramio, 2008). The power of DNA microarray has been demonstrated in the studies of a 
wide variety of malignancies including cancers of prostate, breast, liver, oesophagus, 
pancreas, ovary, stomach lung, and head and neck (Tonin et al., 2001; Al Moustafa et al., 
2002; Han et al., 2002; Luo et al., 2002). These microarray studies have revealed large sets of 
genes that are differentially expressed between tumour and normal cells, including those 
genes known to be important for neoplastic transformation (Bhattacharjee et al., 2001; Garber 
et al., 2001; Belbin et al., 2002; Guo, 2003). 
This chapter assesses the biological changes in the transformed HaCaT cells described in 
chapter two. The analysis compares the regulation of molecular pathways by genes being 
uniquely expressed or shared by both the low risk and high risk HPVE6 types and their 
implication in oesophageal cancer progression. 
3.2 Results 
3.2.1 Assessment of RNA integrity 
The assessment of RNA integrity is a critical first step in obtaining meaningful gene 
expression data as intact RNA is a key element for successful microarray or qRT-PCR 
analyses (Lightfoot, 2002; Mueller et al., 2004). RNA was extracted as three biological 
replicates from HaCaT control cells and HaCaT cells expressing either HPV11E6 or 
HPV18E6. The RNA concentration and the optical density 260/280 of the samples were 
quantified using the NanoDrop 2000/2000c Spectrophotometer (Thermo Scientific, IL, USA), 
values of 1.8–2.0 were considered indicative of relatively good quality RNA (Bojarczuk et 
al., 2014). RNA integrity was then determined on an Agilent 2100 Bioanalyzer, to assess the 
degradation of the samples prior to its use in the downstream applications. This provided an 
electrophoretic tracing and a RNA integrity number (RIN) for judging RNA quality 
(Schroeder et al., 2006). RNA integrity was determined by samples having a RIN of between 
7.0 and 10.0 (Kawasaki, 2006), (Table 3.1). 
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                                 Table 3.1: RNA integrity assessment 
   
Sample RINa 260/280b 260/230c Comment 
HaCaT-A 9.2 1.99 2.11 Pass 
HaCaT-B 9.6 1.99 2.0 Pass 
HaCaT-C 9.3 1.99 2.1 Pass 
HPV11E6-A 9.8 1.97 2.23 Pass 
HPV11E6-B 9.9 1.97 2.19 Pass 
HPV11E6-C 10.0 1.87 2.23 Pass 
HPV18E6-A 9.8 1.95 2.21 Pass 
HPV18E6-B 9.9 1.96 2.16 Pass 
HPV18E6-C 9.7 1.94 2.24 Pass 
 
a = Measure of the degradation of RNA samples based on a numbering system from 1 to 10,  
      with 1 being the most degraded and 10 being the most intact  
b = 1.8-2.0 (indicative of relatively good quality RNA) 
c = 1.8-2.2 (secondary measure indicative of relatively good quality RNA) 
 
 
3.2.2 DNA Microarray analysis 
 
Once the samples had passed the quality control they were used for DNA microarray analysis 
at the Centre for Proteomic and Genomic Research (CPGR). Human gene ST 2.0 arrays were 
used for gene expression on an affymetrix platform (Affymetrix, 1999) as depicted in Fig.3.1. 
Data analysis was done using the Partek® Genomics Suite™ 6.6 software (Partek Inc., 2014). 
The raw data was first normalized using Robust Multi-array Average (RMA); a normalisation 
method used to account for technical variation between the arrays and consisted of three 
steps: a background adjustment, quantile normalization and summarisation (Bolstad et al., 
2003; Irizarry et al., 2003).  
After normalization a preliminary data analysis on the samples was done using Principal 
Components Analysis (PCA) to explore whether differences or similarities existed between 
the samples. There was a clear difference between HPVE6 expressing cells and the 
uninfected HaCaT control cells, while there was some similarity between the HPV11E6 and 
HPV18E6 expressing cells as shown by the overlap of genes (Fig. 3.2A). 
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Fig. 3.1 DNA microarray work flow on an affymetrix platform.  The DNA samples were first fragmented 
into single stranded DNA and labelled after which a hybridization mix cocktail was added before being loaded 
into the human gene ST 2.0 array. The chip Array was then incubated in a hybridization oven for 17 hours 
followed by washing and staining in the fluidics station 450/250. The array was then scanned using the 
GeneChip® Scanner 3000 which computed the probe intensity data as .CEL files that were then analysed using 
the Partek® Genomics Suite™ 6.6 software (Affymetrix, 1999). 
 
 
Histogram plots were also used to determine whether genes that are expected to be 
differentially regulated have larger or smaller intensity values so as to view the distribution of 
the intensities and identify any outliers. All the samples were shown to follow the same 
distribution pattern indicating that there are no obvious outliers in the data (Fig. 3.2B).  
               
 
Fig. 3.2: Exploratory data analysis of HaCaT cells expressing HPVE6: A. PCA Analysis: This plots one dot 
for each of the samples, HaCaT cells expressing HPVE6 show some resemblance to each other and not with the 
control cell. B. Histogram Plots: This plots one line for each of the samples with the intensity of the probes 
graphed on the X-axis and the frequency of the probe intensity on the Y-axis. In this dataset, all the samples 
follow the same distribution pattern indicating that there are no obvious outliers in the data. Green: HaCaT 
control cells; Red: HPV11E6; Blue: HPV18E6 
 
 
Analysis of variance (ANOVA) was used to identify the differentially expressed genes and a 
list of genes was generated that was significantly different between the samples. Global 
differences in gene expression patterns induced by HPV11E6 and HPV18E6 are 
demonstrated in Fig.3.3 as a heat map of fold changes compared to the HaCaT control. A 
clear difference is seen with HPV18E6 having induced a higher number of up-regulated 
A B 
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genes compared to HPV11E6. The heat map represents a combination of the standardized 
gene expression level of each gene in each sample. A list of the most significantly 
differentially expressed genes was then generated using volcano plots set at a fixed fold-
change cut-off of between –2.0 and 2.0 with a significance FDR of ≤ 0.05 (Wen et al., 1998; 
Tamayo et al., 1999). From the volcano plots HaCaT cells expressing HPV18E6 had a higher 
number of expressed genes compared to HaCaT cells expressing HPV11E6 Fig. 3.4.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Hierarchical Clustering of HaCaT cells expressing HPVE6. The resulting graph illustrates the 
standardized gene expression level of each gene in each sample with all the gene intensities being adjusted to a 
mean of zero and the standard deviation to one. Up-regulated genes have positive values and displayed in red. 
Down-regulated genes have negative values and displayed as blue. Each gene is represented in one column, and 
each sample is represented in one row. HPV18E6 dataset showed a greater number of upregulated genes 
compared HPV11E6.The left dendogram side bars represent; Red: HaCaT control cells; Yellow: HPV11E6; 
Green: HPV18E6 
 
 
 
 
 
Fig. 3.4: Volcano plots of HaCaT cells expressing HPVE6 vs HaCaT control cells. In the plot, each dot 
represents a gene. The X-axis represents the fold change and the Y-axis represents the p-values. The genes up-
regulated are on the right side and the down-regulated genes are on the left side. The genes become more 
statistically significant with increasing Y-axis. A: HPV11E6 dataset showed a lower number of expressed genes 
compared B: HPV18E6. 
A B 
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Once the list of the most significantly differentially expressed genes was generated, a Venn 
diagram (Pirooznia et al., 2007) was used to identify genes that were uniquely induced by 
either HPV11E6 or HPV18E6 and genes that were shared between the two datasets. A total 
of 3210 genes were significantly differentially expressed, out of these genes 1416 were 
uniquely induced by HPV18E6 while HPV11E6 uniquely induced 923 genes (Fig. 3.5). An 
overlap of 871 genes was induced by both HPVs. This result was consistent with the PCA 
result (Fig. 3.2A) which showed both HPV11E6 and HPV18E6 shared some differentially 
regulated genes when compared to control HaCaT cells. The results generated from the Venn 
diagram (Fig. 3.5) were used for the subsequent gene ontologies, pathway and network 
analysis. 
 
                             
 
Fig. 3.5: Venn diagram of significantly differentially expressed genes (both up- and down-regulated). 
There was a distinct difference in the gene expression patterns of HPV11E6 and HPV18E6.  HPV18E6 was 
shown to uniquely express 1416 genes (Red) while HPV11E6 uniquely expressed 923 genes (Yellow).  There 
was an overlap of 871 genes expressed by both HPVs (Orange) 
 
3.2.3 Validation of Microarray data 
The large numbers of gene expression measurements obtained in a typical microarray 
experiment; do yield large numbers of false positive or negative results (Tan, 2004). Thus 
microarray results require verification and validation by a complementary gene expression 
profiling method (Quellhorst et al., 2005). The data generated in the microarray analysis was 
validated by qRT-PCR on selected up- and down-regulated genes from both the HPV11E6 
and HPV18E6 datasets (Table 3.2 & 3.3).  
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Up-regulated Down-regulated 
Gene 
Symbol 
 
Gene Name 
Fold    
Change 
Gene 
Symbol 
 
Gene Name 
Fold 
Change 
PLAT 
 
Plasminogen Activator, Tissue 
 
4.3 
 
STARD7 
 
StAR-Related Lipid Transfer Domain 
Containing 7 
-4.1 
 
TNFSF10 
 
Tumour  Necrosis Factor 
(Ligand) Superfamily, Member 
10 
4.2 
 
BRCA1 
 
Breast Cancer 1, Early Onset 
 
-3.1 
 
TP53INP1 
 
Tumour  Protein P53 Inducible 
Nuclear Protein 1 
4.1 
 
OR2M7 
 
Olfactory Receptor, Family 2, 
Subfamily M, Member 7 
-3.0 
 
GADD45A 
 
Growth Arrest And DNA-
Damage-Inducible, Alpha 
3.8 
 
IFI6 
 
Interferon, Alpha-Inducible Protein 6 
 
-2.4 
 
BUB1 
 
Budding Uninhibited By 
Benzimidazoles 1 
3.5 
 
MCM2 
 
Minichromosome Maintenance 
Complex Component 2 
-2.3 
 
BHLHE41 
 
Basic Helix-Loop-Helix 
Family, Member E41 
3.4 
 
TMEM27 
 
Transmembrane Protein 27 
 
-2.2 
 
FBP1 
 
Fructose-1,6-Bisphosphatase 1 
 
3.3 
 
NOX1 
 
NADPH Oxidase 1 
 
-2.1 
 
LXN 
 
Latexin 
 
3.1 
 
JUN 
 
Jun Proto-Oncogene 
 
-2.1 
 
EPPK1 
 
Epiplakin 1 
 
3.0 
 
SNAR-E 
 
Small ILF3/NF90-Associated RNA E 
 
-2.1 
 
PIGR 
 
Polymeric Immunoglobulin 
Receptor 
2.9 
 
CXCL11 
 
Chemokine (C-X-C Motif) Ligand 11 
 
-2.1 
 
Up-regulated Down-regulated 
Gene 
Symbol 
Gene Name Fold 
Change 
Gene 
Symbol 
Gene Name Fold 
Change 
CEACAM5 
 
Carcinoembryonic antigen related 
cell adhesion molecule 5 
22.7 
 
ANKRD1 
 
Ankyrin Repeat Domain 1 (Cardiac 
Muscle) 
-4.8 
 
CYP24A1 
 
cytochrome P450, family 24, 
subfamily A, polypeptide 1 
13.5 
 
BCLAF1 
 
BCL2-Associated Transcription 
Factor 1 
-4.5 
 
MMP12 Matrix metalloproteinase-12 11.7 FST Follistatin -4.0 
GNE 
 
 
Glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine 
kinase 
10.2 
 
 
TRAJ59 
 
 
T Cell Receptor Alpha Joining 59 
(Non-Functional) 
 
-4.0 
 
 
S100A7 
 
S100 Calcium Binding Protein A7 
 
10.0 
 
PTHLH 
 
Parathyroid Hormone-Like Hormone 
 
-3.9 
 
PNLIPRP3 
 
Pancreatic Lipase-Related Protein 3 
 
9.9 
 
IFI44L 
 
Interferon-Induced Protein 44-Like 
 
-3.7 
 
FABP4 
 
Fatty Acid Binding Protein 4, 
Adipocyte 
9.6 
 
THBS1 
 
Thrombospondin 1 
 
-3.3 
 
SERPINB4 
 
 
Serpin Peptidase Inhibitor, Clade B 
(Ovalbumin), Member 4 
 
9.0 
 
 
ODC1 
 
 
Ornithine Decarboxylase 1 
 
 
-3.2 
 
 
AKR1C2 
 
Aldo-Keto Reductase Family 1, 
Member C2 
8.4 
 
ZIC1 
 
Zinc finger of the cerebellum  
Family Member 1 
-3.2 
 
TRIM31 
 
Tripartite Motif Containing 31 
 
8.4 
 
TGFB2 
 
Transforming Growth Factor, Beta 2 
 
-3.1 
 
Table 3.2: HPV11E6 Top 10 up- and down-regulated genes based on either the extent of up or 
down-regulation or on their known involvement in carcinogenesis 
 
Table 3.3: HPV18E6 Top 10 up- and down-regulated genes based on either the extent of up or 
down-regulation or on their known involvement in carcinogenesis 
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The qRT-PCR results showed that trends in expression change for the selected genes were 
consistent with the microarray results, verifying that the microarray results were accurate and 
reliable (Fig. 3.6).  
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Fig. 3.6: qRT-PCR validation of microarray data. Selected genes with altered expression in response to 
HPVE6 in A: HPV11E6 & B: HPV18E6. Fold change shown was normalized to GAPDH mRNA levels and 
qRT-PCR figures represent the average of three replicates for each infection with the error bars indicating 
standard deviation.   
    
 
 
A 
B 
HPV11E6 
HPV18E6 
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An in depth analysis of the functional significance of gene expression was undertaken by 
examining genes that were both common and unique to HPV11E6 and HPV18E6. This was 
done by analysing the gene ontologies, signalling pathways and networks in which the 
significantly differentially expressed genes were involved. 
3.2.4 Gene Ontology 
 
To determine whether the differentially expressed genes were biologically meaningful in 
relation to the disease phenotype, the GOTree Machine (GOTM) (Zhang et al., 2004) was 
utilized to annotate gene functions and classify them into functional categories. Gene 
ontology was used to identify biological processes that were enriched for genes differentially 
expressed in both HPV11E6 and HPV18E6. Gene ontology (GO)  processes that were present 
in both HPV11E6 and HPV18E6 would indicate in which way they were similar in their 
effects on cellular gene expression, while GO processes that were unique to either HPV11E6 
or HPV 18E6 would provide insight into the distinct manner that the low risk and high risk 
HPVE6 genes affect cellular genes. By using all the genes in the human genome (Lander et 
al., 2001; ENCODE Project Consortium, 2004; Clamp et al., 2007; Pertea & Salzberg, 2010; 
Wu et al., 2011) as the reference gene set, this study integrated GO categories that were 
enriched in the set of 3210 genes (Fig. 3.5). Raw p-values generated from GOTM were 
adjusted using the false discovery methods and the overall significance level was set at α 
<0.05. 
The results revealed numerous GO functions of differentially expressed genes (DEGs), 
HPV18E6 seen to exhibit more DEGs compared to HPV11E6 and that participated in a 
variety of functions associated with the greater cancer phenotype. These included 
metabolism, response to stress, cell proliferation, protein binding, cell cycle control and cell 
communication. Importantly, these DEGs were also involved in cell shape and cytoskeletal 
re-organization; all well known features of cancer cells. The results in Fig. 3.7A revealed 
numerous biological processes unique to HaCaT cells expressing HPV11E6 with 536 genes 
being involved in the metabolic processes. Further resolution of significantly enriched 
biological process (Fig. 3.7B) revealed response to stimulus and stress. Biological processes 
unique HaCaT cells expressing HPV18E6 also had 797 genes (Fig. 3.8A) being associated 
with the metabolic processes with further resolution of significantly enriched biological 
process revealing response to stimulus and stress, cell communication, cell cycle and cell 
signalling (Fig. 3.8B). A look at the commonly DEGs by both HPV11E6 and HPV18E6 also 
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had 504 genes (Fig. 3.9A) being associated with the metabolic processes with a further 
resolution of significantly enriched biological process being involved in response to stimulus 
and stress, cell communication and signal transduction. The regulation of the metabolic 
process as the most regulated biological process by the HPVE6 DEGs was anticipated since 
tumours are known to be metabolically active and develop a highly specialized metabolic 
profile (Griffin & Shockcor, 2004; Zhou et al., 2009; Fulda et al., 2010), the regulation of 
important functions such as cell cycle, cell communication and signalling suggested an 
elevated cell proliferation capacity as a result of HPVE6 gene expression. Since these DEGs 
appeared to have key enriched GO functions fitting the cancer hallmarks the next step was to 
map these genes to known pathways so as to gain more insight into the underlying biology of 
these DEGs since pathway analysis reduced complexity and has increased explanatory power 
as opposed to the GO analysis. 
3.2.5 Pathway Analysis 
 
Pathway analysis is a computational approach used to investigate network behaviour as a 
system (Viswanathan et al., 2008) and it has become the first choice for extracting and 
explaining the underlying biology for high-throughput molecular measurements (Khatri et al., 
2012). To determine the possible mechanisms underlying the significantly differentiated 
genes a detailed pathway analysis was performed using the Ingenuity™ Pathway Analysis 
(IPA). This transformed the significantly differentiated genes into a set of relevant networks 
based on structured content from Ingenuity’s Pathways Knowledge Base (IPKB). The results 
are presented graphically based on scoring of the ratio of significant genes present in the 
canonical pathway to the total number of genes in the canonical pathway. The threshold level 
was set at p < 0.05. The Kyoto Encyclopedia of Genes and Genomes (KEGG) software was 
also used to integrate current knowledge on molecular interaction networks in biological 
processes. These analyses determined which pathways were dysregulated at the early stages 
of HPVE6 gene expression in HaCaT cells. 
The results from the pathway analysis corresponded with the GO enrichment analysis results 
and showed a common trend in the regulation of pathways involved with signalling as a 
result of HPVE6 expression. Calcium signalling came out as the top significantly enriched 
pathway induced by HPV11E6 (Fig. 3.10A). This pathway has previously been associated 
with enhanced cell proliferation and impaired apoptosis (Capiod et al., 2008). 
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Fig. 3.7: Biological Processes by HaCaT cells expressing HPV11E6. A: Graphical representation enriched biological processes of DEGs. B: A directed acyclic graph 
showing a further resolution of the enriched biological processes of the DEGs (names in red) and their ancestor categories. Metabolic processes involved in response to 
stimulus specifically response to chemical stimulus, inorganic substance and endogenous stimulus were seen to be highly activated 
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Fig. 3.8: Biological Processes by HaCaT cells expressing HPV18E6. A: Graphical representation enriched biological processes of DEGs. B: A directed acyclic graph 
showing a further resolution of the enriched biological processes of the DEGs (names in red) and their ancestor categories. Metabolic processes involved in response to 
stimulus specifically response to chemical stimulus, response to stress, cell communication, cell cycle and signalling were seen to be highly activated. 
 
 
 
A B 
53 
 
             
 
Fig. 3.9: Biological Processes by HaCaT cells expressing both HPV11E6 & HPV18E6. A: Graphical representation enriched biological processes of DEGs. B: A directed 
acyclic graph showing a further resolution of the enriched biological processes of the DEGs (names in red) and their ancestor categories. Metabolic processes involved in 
response to stimulus specifically response to chemical stimulus, cell communication, signalling and signal transduction were seen to be highly activated. 
A B 
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Other pathways of importance that were also dysregulated by HPV11E6 included JNK 
signalling, mTOR signalling and GADD45 signalling that have previously been associated 
with viral infections and growth and development (Shuai & Liu, 2003; Alekseev et al., 2009; 
Laplante & Sabatini, 2012).  
HPV18E6 induced the molecular mechanisms of cancer as the top dysregulated canonical 
pathway (Fig. 3.10B), while the DEGs shared by both HPV11E6 and HPV18E6 induced 
PI3K/AKT signaling as the top most regulated pathway (Fig. 3.10C). 
HPV18E6 also induced other major signalling pathway involved in inter- and intra-cellular 
communication that lead to malignant phenotypes including the  Ras/integrin signaling, AKT 
signaling, TGF-β/BMP signaling and WNT signalling (Fig 3.11). Other pathways of 
importance that were also dysregulated by HPV18E6 included CCR3 signaling in eosinophils 
that has previously been associated with an infiltration of eosinophils in oesophageal 
squamous cell carcinoma patients (Fukuchi et al., 2011), Integrin signalling was also another 
pathway that has previously been associated with mutant p53 in metastasis (Muller et al., 
2009; Selivanova & Ivaska, 2009).  
Airway Pathology in Chronic Obstructive Pulmonary Disease (COPD) canonical pathway 
was one of the interesting pathways that were dysregulated by HPV18E6 a pathway 
associated with cigarette smoking (Fig. 3.12), which is one of the predisposing factors of 
OSCC. Attention is also drawn to the up-regulation of IL8, MMP1 and MMP9 that have been 
shown to work together in conferring oesophageal tumorigenesis (Mukherjee et al., 2010; 
Shiau et al., 2013).  
Other pathways also induced by the shared DEGs of both HPV11E6 and HPV18E6 as 
confirmed by the KEGG cancer pathway included the Cell cycle regulation, molecular 
mechanisms of cancer and TGF-β signalling Fig. 3.13. 
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Fig. 3.10: IPA Canonical Pathway Analysis. Top pathways in which significant differentially expressed genes 
were enriched, following the expression of, A: HPV11E6; B: HPV18E6; C: HPV11E6 & HPV18E6 in HaCaT 
cells. Bars represent -log (p-value) for disproportionate representation of affected genes in the selected pathway, 
yellow boxed line represents the ratio of affected genes to the total number of genes in a pathway.  
 
A. HPV11E6 
B. HPV18E6 
C. HPV11E6 & HPV18E6 
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Fig. 3.11: Effect of significantly differentiated genes (Red) on different signaling pathways and their involvement at different stages of oncogenesis following the expression 
of HPV18E6 as represented by the KEGG Cancer pathway. Most of the DEGs were seen to regulate the cell cycle, apoptosis and the WNT pathway.
 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12: Chronic Obstructive Pulmonary Disease (COPD) Canonical Pathway. Showing DEGs, following 
the expression of, A: HPV11E6 induced the upregulation of CXCL2 gene only. B: HPV18E6 induced the 
upregulation of IL8, MMP1 and MMP9 genes. Red coloured genes indicate increased expression while the 
uncoloured genes were not identified as differentially expressed by HPVE6 but were rather integrated into the 
computationally generated pathway on the basis of the evidence stored in the IPA knowledge memory indicating 
a relevance to this pathway. 
 
B. HPV18E6 
 
A. HPV11E6 
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Fig. 3.13: Effect of significantly differentiated genes (Red) on different signaling pathways and their involvement at different stages of oncogenesis following the expression 
of both HPV11E6 & HPV18E6 as represented by the KEGG Cancer pathway. Most of the DEGs were seen to regulate the cell cycle and WNT pathway
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3.2.6 Network Analysis 
 
 The IPA gene network system was used to generate networks to show how the significantly 
differentially expressed genes co-operate at the molecular level following HPVE6 expression. 
This process makes the assumption that the highly interconnected networks are likely to 
represent significant biological function and these are ranked on the basis of their scores. The 
score is a numerical value used to rank networks according to their degree of relevance to the 
network eligible genes in the network, as well as the total number of analyzed network 
eligible genes and the total number of genes in the Ingenuity Knowledge Base that could 
potentially be included in networks (Tanaka et al., 2014).  
The three top networks with the highest score following the expression of HPV11E6 (Table. 
3.4) included gene products associated with NFkB and PI3K complex. While the top networks 
dysregulated following the expression of HPV18E6 (Table. 3.5) included gene products 
associated with TNF, a cytokine implicated in cancer and autoimmune diseases (Locksley et 
al., 2001) and NFkB, known to play a critical role in carcinogenesis (Tian et al., 2006). The 
top networks dysregulated following the expression of the shared DEGs by both HPV11E6 
and HPV18E6 (Table 3.6) included gene products associated with the NFkB complex. 
The expression of HPVE6 resulted in a significant up-regulation of NFkB, as well as the 
downstream genes and it was apparent that this pathway was induced by HPVE6. Even 
though these genes did not appear on the list of the selected top 10 up- or – down-regulated 
genes, the observed fold-changes were significantly higher than in the control cell lines. For 
this reason, further computational and experimental exploration of the regulation of NFkB 
was carried out, to elucidate the consequences of the upregulation of this inflammatory 
pathway by HPVE6.  
The expression of HPV11E6 (Fig. 3.14) showed most of the genes that regulate NFkB are 
down-regulated, and are mostly involved in cellular movement and inflammatory response. 
Whereas, following the expression of HPV18E6 (Fig. 3.15), most of the genes that regulate 
NFkB are up-regulated, and are mostly important in encoding cellular growth, cell cycle and 
inflammatory response. The shared genes that regulate NFkB following the expression of 
both HPV11E6 and HPV18E6 (Fig. 3.16) are also mostly up-regulated and are shown to be 
important in cellular movement, cell death and cell cycle. 
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a – Numerical value used to rank networks according to their degree of relevance between the network eligible  
      genes in the network, DEGS in the network and the total number of genes in the Ingenuity Knowledge Base  
      that could potentially be included in networks 
b - Number of DEGS associated with the network 
 
 
 
 
 
 
a – Numerical value used to rank networks according to their degree of relevance between the network eligible  
      genes in the network, DEGS in the network and the total number of genes in the Ingenuity Knowledge Base  
      that could potentially be included in networks 
b - Number of DEGS associated with the network 
 
DEGs in Network Scorea Focus 
DEGsb 
Top Functions 
CASR,CCL27,CD46,CDK5,CYR61,ERBB2,ERK,ERK1/2,Foc
al adhesion kinase, GAB1, Hsp70, Hsp90, HTR7, ITGB1, 
KPNA2, LIMK1, MET, MMP19, MYCN, NBN, NOV, NQO1, 
P38 MAPK, PACRG, PDGF, Pkc(s), PPP1CC, PTGES, 
PTMA, PXN, RBP1, RGS4, SERPINE1, VEGFC, XRCC3 
26 
 
 
27 
 
 
Cellular Movement, Cellular 
Development, Cellular 
Growth and Proliferation 
 
ADD2,Akt,AMIGO2,Ap1,CCL5,COL2A1,DDIT3,DRD2,Histo
ne h3,HLA-A,IFN Beta, IFNG, IL18, IL1RAP, Interferon 
alpha, LDL, LGMN, MAP2K4, MICU1,MYD88, NFkB 
(complex), OAS1, PI3K(complex),PI3K(family),PRKCD, 
RARRES3, Ras, RHOB,RNA polymerase II, RPL12, SNW1, 
TCR, TNFRSF10B,XRCC5 
18 
 
 
 
22 
 
 
 
Cell Death and Survival, 
Inflammatory Disease, 
Inflammatory Response 
 
ABL1,ATXN1,BAG1,BCL2L1,BRCA1,EGFR,EPO,GH1,GHR
,GPX1,GRIN1,GZMA,IGF1R,IL15,IL15RA,IL1B,JAK2,MOA
P1,NR3C1,PDCD10,PPP1R15A,PPP2CA,PPP2R1B,PPP3R1,P
RKCD,PRLR,RIN1,SBDS,SDCBP,SOX4,STAT5A,STAT5B,S
TK25,STK17B,TNFRSF1A 
13 
 
 
18 
 
 
Cell Death and Survival, 
Cellular Growth and 
Proliferation, Cellular 
DEGs  in Network Scorea Focus  
DEGs b 
Top Functions 
BCL2L2,CBX5,CHRNA5,CREBBP,Cyclin A, CYP2B6, 
CYP2C19,DKK1,E2F2,E2F4,EFNA1,ENC1,HAS2,Histone 
h3,Histone h4, IL3RA, JMJD6, LRP5, MLL, MYBL2,NR1I3, 
NR3C1,PIK3CB,PRKAR1B,PRKCB,RB1,RBL1, SON, 
SUMO2,  THBD, TNFSF9, TNFSF11,TYMS,USP4 
27 
 
 
31 
 
 
Cellular Growth and 
Proliferation, Cell Death and 
Survival, Cellular 
Development 
Akt,AXL,BTG2,CAT,DES,ERBB3,FPR2,IFN Beta, 
IFNA2,IL8,IL32,IL1RL1,IL1RN,IRAK1,IRAK2,IRF1,IRF2,
LTF,MMP9,NFkB (complex), NFKBIA, PI3K (family), Ras, 
RIPK2, RRM2, RUSC2, SHH, SUMO4, TICAM1,TNFAIP3, 
TNFSF4, TNFSF18,TRIP6,UBD,USP18 
25 
 
 
30 
 
 
Cellular Development, 
Cellular Growth and 
Proliferation, Hematological 
System Development and 
Function 
ABL1, ARNTL, BBC3, CASP2, CDKN1A, CDKN2A, 
CREBBP,E2F1,FOXO3, HIVEP1,LIG1, MDM2, MYC, 
NVL,PHF1,PIM1,PTEN,RB1,REL,RGS3,RPL5,RPL11,SAT
1,SFN,SNAI1,SYNE2,TERT,TP73,TP53I3,TRIM32,U2AF2 
8 
 
 
17 
 
 
Cell Cycle, Cellular Growth 
and Proliferation, Cancer 
Table 3.4: Most significant three gene networks of DEGs following expression of HPV11E6 
 
Table 3.5: Most significant three gene networks of DEGs following expression of HPV18E6 
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a – Numerical value used to rank networks according to their degree of relevance between the network eligible  
      genes in the network, DEGS in the network and the total number of genes in the Ingenuity Knowledge Base  
      that could potentially be included in networks 
b - Number of DEGS associated with the network 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEGs  in Network Scorea Focus  
DEGs b 
Top Functions 
ADCY,ADRB2,Ap1,APOH,ARF6,CCL2,CDH1,CP
T1A,CYP1B1,ELF3,ERK,FGFR1,GATA4,GNAI2,
GNAS,HDAC3,HNF4G,ITGA2,ITGB4,JUN,LDL,M
AP3K1,MAP3K8,Mapk,MCL1,Mek,MUC4,N-
cor,NFkB(complex),P38MAPK,Pkc(s),PTGS2, 
RPL30,  SDC4, USP11 
22 
 
 
25 
 
 
Cellular Movement, Cell 
Death and Survival, 
Cancer 
ABL1,ANKRD1,ARHGDIB,CARM1,CCL19,CLU,
CSNK1A1,CTSD,DBP,E2F4,EIF4G1,HEXB,HEY1,
HIST1H3A, MREG,NDRG1, NFKB2, ORAI1, 
PCGF2, PPP1R13L, PTTG1, PYCARD, RELA, 
SMAD3,TAP2,TGFB2,TMPO,TNIP2,TOP1,TOP2A
,TP53,TP53BP2,TWIST1,USP2,WASF1 
10 
 
 
16 
 
 
Cell Death and Survival, 
Gene Expression, Cellular 
Development 
ACACA,AGTR1,BSN,CKAP4,CNGA3,CYP1A1,DI
O1,EPO,FASN,Fcgr3,FOXO3,GATA3,HDAC1,HT
R2B,IL6,IL7,IL1B,KDM5B,KIF2C,MT1X,NAA10,
ORM1,PHF21A,PLS3,PRKAA2,PRKAB1,PRKAG1
,RAB11FIP5,RPS6KA1,S1PR2,SCNN1A,SGK1,SR
EBF1,TF,TREM1 
9 
 
 
15 
 
 
Cell Cycle, Hematopoiesis, 
Cardiovascular System 
Development and Function 
Table 3.6: Most significant three gene networks of DEGs following expression of both HPV11E6   
                & HPV18E6 
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Fig. 3.14: Network of NFκB interacting genes. IPA was used to construct a network of DEGs identified around NFκB complex following the expression HPV11E6 in 
HaCaT cells. The fold changes for the genes were superimposed onto this network showing most of the genes being down-regulated. The genes in this network are important 
in cellular movement and inflammatory response. Straight line (direct interaction) and broken line (indirect interaction) and the intensity of the colour indicating the degree of 
regulation i.e. Green indicated reduced expression, red indicated increased expression while the uncoloured genes were not identified as differentially expressed by HPVE6 
but were rather integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory indicating a relevance to this 
network. 
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Fig. 3.15: Network of NFκB interacting genes. IPA was used to construct a network of DEGs identified around NFκB complex following the expression HPV18E6 in 
HaCaT cells. The fold changes for the genes were superimposed onto this network showing most of the genes being up-regulated. The genes in this network are important in 
cellular growth, cell cycle and inflammatory response. Straight line (direct interaction) and broken line (indirect interaction) and the intensity of the colour indicating the 
degree of regulation i.e. Green indicated reduced expression, red indicated increased expression while the uncoloured genes were not identified as differentially expressed by 
HPVE6 but were rather integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory indicating a relevance to 
this network. 
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Fig. 3.16: Network of NFκB interacting genes. IPA was used to construct a network of shared DEGs identified around NFκB complex following the expression of both 
HPV11E6 and HPV18E6 in HaCaT cells. The fold changes for the genes were superimposed onto this network showing most of the genes being up-regulated. The genes in 
this network are important in cellular movement, cell death and cell cycle. Straight line (direct interaction) and broken line (indirect interaction) and the intensity of the colour 
indicating the degree of regulation i.e. Green indicated reduced expression, red indicated increased expression while the uncoloured genes were not identified as differentially 
expressed by HPVE6 but were rather integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory indicating a 
relevance to this network. 
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3.3 Discussion 
 
DNA microarray analysis was used to explore the gene expression patterns in HaCaT cells 
during the early stages of the E6 gene expression, from either the low risk HPV11 or the high 
risk HPV18. The microarray data was first normalised so as to minimize the effects that were 
caused by technical variations; this allowed the data to be comparable in order to find the 
actual biological changes (Smyth & Speed, 2003; Fujita et al., 2006). 
The gene expression pattern in the HPVE6 expressing cells was shown to be significantly 
different using PCA and hierarchical clustering analysis with some similarity between the 
HPV11E6 and HPV18E6 induced patterns as shown by the overlap of genes with the PCA. 
This was consistent with previous studies that showed an overall similarity in the high-risk 
HPV18E6 and low-risk HPV11E6 induced proteins due to probable common biochemical 
activities (Huibregtse & Beaudenon, 1996; Oh et al., 2004). Other studies also suggested that 
low-risk forms of E6 bind to p53 with a low affinity (Werness et al., 1990; Huibregtse et al., 
1993b; Li & Coffino, 1996). The in vivo and in vitro functional inactivation of p73 by both 
high-risk HPV18E6 and low-risk HPV11E6 has also been demonstrated previously (Park et 
al., 2001).These results suggested that both the high risk HPV18E6 and low risk HPV11E6 
possibly share some common biological pathways capable of deregulating gene expression 
and suggested a role for HPV11E6 in cellular transformation. 
It is notable that the “metabolic process” was the most significantly enriched gene ontology 
function in the biological processes having the highest number of DEGs affected by HPVE6. 
This possibly may be as a result of increased energy metabolism that could enhance HPV 
replication since HPV replicates in terminally differentiating cells that are likely to have a 
low nutrient supply (Vande Pol & Klingelhutz, 2013). Importantly, these DEGs were also 
involved in the deregulation of cell shape, cell proliferation, transport and cytoskeletal re-
organization; all of which are well known features of cancer cells. Previous studies have 
shown that the process of cellular transformation is closely linked to dysregulated 
proliferation, leading to metabolic transformation (El Mjiyad et al., 2011). Although the 
specific mechanisms of transformation vary among viruses, the net effect is often the same as 
with DNA damaging effects inducing cellular mutations and viral oncoproteins leading to 
constitutive activation or stabilization of oncogenes or inactivation of tumour suppressor 
genes to facilitate cellular transformation (Noch & Khalili, 2012).  
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The DEGs induced by both HPV18E6 and HPV11E6 were involved in response to cell 
signalling, cell communication and signal transduction processes. This result meant that 
HPV11E6 induced genes had the ability to influence processes known to induce cellular 
transformation. Thus, these activities may reflect common pathways being utilized by both 
types of low and high risk E6 viruses during their productive life cycles. 
The course of cellular transformation begins with dysregulation of cell signaling processes 
induced by genetic, environmental factors or can be triggered by oncogenes encoded by 
viruses that are known to induce malignant transformation (Noch & Khalili, 2012). HPVE6 
and Herpes Simplex Virus 1 (HSV1) are known to suppress IFN signaling in order to allow 
more efficient replication (Yokota et al., 2004). In this study HPV11E6 was shown to 
regulate a number of signalling pathways such as the JAK1, JAK2 and TYK2 interferon 
signalling. Li et al., (1999) also reported that Tyrosine kinase 2 (Tyk2) associates with E6, 
with the Tyk2/E6 interaction being stronger with HPV18E6 than HPV11E6, this was because 
HPV18E6 binds to the Interferon Regulatory Factor 3 (IRF3) and inhibits its ability to 
activate interferon-responsive genes (Ronco et al., 1998). A possible explanation for the 
difference between the low and high risk HPVE6 may lie within the transactivation capacity 
of HPVE6, which is mediated through interactions with the transcriptional machinery.  
The expression of HPV18E6 in this study lead to deregulation of pathways that were not 
affected by expression of HPV11E6; with the most significant being the Molecular 
Mechanisms of Cancer pathway, CCR3 Signalling in Eosinophilis, IL8 Signalling and the 
Airway Pathology in Chronic Obstructive Pulmonary Disease (COPD) Pathway. The 
regulation of the cancer pathway as the most significantly regulated pathway upon HPV18E6 
expression was not unexpected, since genetic alterations such as mutations or deletions of 
genes are known to drive tumour progression by generating mutations in oncogenes and 
tumour suppressor genes (Fearon & Vogelstein, 1990). HPV18E6 is known to account for at 
most 16-30% of cervical cancers and is considered a major cause of other cancers (Ajay et 
al., 2012; Yang et al., 2014). HPV18E6 is also known to cause transformation, 
immortalization and promote carcinogenesis primarily by binding to p53, resulting in 
deregulation of cell cycle checkpoints (Scheffner et al., 1993; Boyer et al., 1996; Bischof et 
al., 2005). This was evident in the current study where genes such as CyclinD1, CyclinE, Rb, 
E2F, MMPs, IL8, Ras, HIF-α, P300CBP and WNT  were  up-regulated following the 
expression of HPV18E6 and these were involved in the dysregulation of  biological processes 
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implicated with cellular transformation especially cell proliferation, apoptosis, cell cycle and 
angiogenesis known hallmarks of cancer (Hanahan & Weinberg, 2011). The expression of 
HPV18E6 also lead to the upregulation of CCL26 and CCR3 genes that have both being 
implicated with the dysregulation of CCR3 signalling in eosinophilis pathway. It was 
hypothesised that these genes dysregulated this pathway through the recruitment of 
eosinophils to sites of HPV18E6 infection leading to tissue damage by the release of reactive 
oxygen species (ROS) and toxic granule proteins (Kampen et al., 2000; Sabroe et al., 2000). 
This was consistent with data on an oesophageal squamous cell carcinoma (OSCC) patient 
following oesophagectomy that also showed a marked eosinophil infiltration to the 
oesophagus (Fukuchi et al., 2011).  
The COPD Pathway was also one of the interesting pathways that were significantly 
dysregulated by the expression of HPV18E6 and not by HPV11E6, since the COPD pathway 
was not directly related to HPV infection or oesophageal cancer but it showed an up-
regulation of IL8, MMP1 and MMP9 genes that are implicated in OSCC. MMPs have been 
shown to be elevated in many cancers including OSCC (Shima et al., 1992; Mathew et al., 
2002; Ishibashi et al., 2004; Samantaray et al., 2004; Gu et al., 2005; Li et al., 2009; 
Mukherjee et al., 2010), and have been closely associated with persistent inflammation and 
cancer progression (Balkwill & Mantovani, 2001; Bingle et al., 2002; Coussens & Werb, 
2002; Owen et al., 2004; Björklund & Koivunen, 2005). Gene profiling studies have also 
associated MMP1 and MMP2 involvement with the ability of human breast cancer cells to 
metastasize spontaneously from the primary mammary tumour to the lungs of 
immunodeficient mice (Minn et al., 2005). IL-8 has been associated with metastasis in 
several cancers, its expression correlates with angiogenesis and tumorigenicity in numerous 
xenograft and orthotopic in vivo models (Deryugina & Quigley, 2006). Other studies have 
also reported the overexpression of IL8 in human prostate cancer cells, with concomitant up-
regulated MMP9 expression and collagenase activities promoting tumour cell growth and 
metastasis (Inoue et al., 2000). It is possible from these results, that HPV18E6 expression 
may potentiate cellular transformation of HaCaT cells via the deregulation of MMP and IL8 
genes; this was supported by our earlier results presented in chapter two. 
The most significantly dysregulated pathways as a result of DEGs shared by both HPV11E6 
and HPV18E6 included the PI3K/AKT signalling, telomerase signalling and the cell cycle 
regulation. Previous studies have shown that the PI3K/AKT pathway is overactive in many 
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types of tumour cells and exhibits significant impact on glycolysis by stimulating expression 
of key glycolytic enzymes (Sabbatini & McCormick, 1999; Elstrom et al., 2004). Thus it may 
be hypothesised that HPVE6 mediated cellular transformation through this pathway may lead 
to concomitant increases in glucose uptake and glycolytic flux, further strengthening the 
cellular transformation potential (Noch & Khalili, 2012).  
It is known that integrins are expressed at low levels in normal epithelial tissues, but that they 
are upregulated during wound healing and in squamous cell carcinoma (Breuss et al., 1995). 
Integrins also promote the invasive growth of carcinomas that have become resistant to the 
anti-proliferative effect of TGF-β by enabling matrix degradation through the recruitment of 
activated MMP2 (Guo & Giancotti, 2004). It is possible that DEGs shared by both the 
datasets deregulate the PI3K/AKT pathway by activating matrix-degrading proteases through 
elevation of integrins. Roymans & Slegers, (2001), also demonstrated that an increase in copy 
number of specific phosphatidylinositol 3-kinase genes or molecular mutation of these genes, 
lead to a gain of function reflected by a higher or a constitutive expression of the 
phosphatidylinositol 3-kinase lipid kinase activity and to the oncogenic transformation of 
many cell types.  
The deregulation of the telomerase signalling pathway by the shared DEGs could be due to 
the DNA damage response system following the expression of HPVE6 although its role in 
cellular transformation could not be ascertained. Other studies have shown that the high risk 
HPV E6 was capable of stimulating telomerase activity independent of the effects of E6 on 
p53 (Klingelhutz et al., 1996; Gewin & Galloway, 2001). Keratinocytes expressing wild type 
HPV16E6 were shown to have an extended lifespan but did not become immortal 
(Klingelhutz et al., 1994), indicating that telomerase activation and E6 mediated degradation 
of p53 are insufficient for their immortalization. This was also supported by the studies of 
Klingelhutz et al., (1996) who showed that telomerase activation was an intrinsic but 
insufficient, component of cellular transformation by HPVE6. 
The deregulation of the cyclins and cell cycle regulation pathways by the shared HPVE6 
DEGs presented in this study is consistent with other studies that have shown that cell cycle 
progression is regulated by biochemical reactions that involving cyclins and cyclin-dependent 
kinases. This regulation prevented the replication of damaged or altered DNA (Southern & 
Herrington, 1998). The high risk HPV18 E6 also abrogates multiple cell cycle checkpoints 
that contribute to genomic instability (Hanahan & Weinberg, 2011). The E6 proteins of the 
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high-risk HPVs are capable of binding to cell cycle regulatory proteins, and interfere with 
both the G1/S and G2/M cell cycle checkpoints more effectively than the E6 proteins of the 
low-risk HPVs (Southern & Herrington, 1998; Cho et al., 2002; Brenna & Syrjänen, 2003; 
Davy & Doorbar, 2007). This was confirmed by the upregulation of G2/M specific genes 
E2F1 and CDKN2B by HPV18E6 (see Fig. 3.11). The inability of the low risk as opposed to 
the high-risk HPV types to induce immortalization and transformation reside in their abilities 
to interact with the cell cycle components that result in the loss of multiple cell cycle 
checkpoints responsible for maintaining host genome fidelity (Syrjänen & Syrjänen, 1999; 
Southern & Herrington, 2000). It was therefore postulated in this study that the expression of 
the shared HPVE6 DEGs may promote cellular transformation through the deregulation of 
the cell cycle process. 
The Molecular mechanisms of cancer pathway was also one of the interesting canonical 
pathways deregulated by the shared HPVE6 DEGs although its expression was much lower 
than when it was induced by the HPV18E6 DEGs. The up-regulated genes as a result of the 
shared HPVE6 DEGs expression included TGFβ, E2F, BAD and COX2 that are involved in 
the deregulation of the cell proliferation and sustained angiogenesis biological processes (Li 
& Neaves, 2006; Greenhough et al., 2009; Santarpia et al., 2010; Koontongkaew, 2013). The 
results from this study clearly show that the expression of HPV11E6 had a much weaker 
effect towards dysregulating cancer signalling pathways as opposed to HPV18E6. This being 
consistent with the ability of HPV18E6 to bind to more cellular proteins such as the E6AP, 
E6BP, paxillin, p300/CBP and PDZ domain proteins such as hDLG, MUPP1, MAGI1 and 
hScrib, compared to HPV11E6 that was shown to be able to bind to fewer cellular protein 
such as zyxin, GPS2, Bak, and MCM7 (Chen et al., 1995; Kiyono et al., 1997; Kuhne & 
Banks, 1998; Kukimoto et al., 1998; Gardiol et al., 1999; Patel et al., 1999; Thomas & Banks, 
1999; Zimmermann et al., 1999; Glaunsinger et al., 2000; Lee et al., 2000; Pim et al., 2000; 
Degenhardt & Silverstein, 2001a; Degenhardt & Silverstein, 2001b; Park et al., 2001; Gardiol 
et al., 2002; Oh et al., 2004). It can thus be hypothesised that the expression of HPVE6 
predisposes normal cells toward malignancy.  
In order to show how the significantly differentiated genes worked together at the molecular 
level following HPVE6 expression, gene networks were generated using the IPA gene 
network system on the assumption that the highly interconnected networks were likely to 
represent significant biological function. The network analysis assembled the top three 
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networks following HPVE6 expression. The networks with the highest score in DEGs by 
HPV11E6 included gene products associated with ERK/MAPK and the NFκB (complex), 
whereas the networks with the highest score in DEGs by HPV18E6 included gene products 
associated with TNF and the NFκB (complex) while with the shared DEGs dataset the highest 
scoring network included gene products associated with the NFκB (complex). The top 
functions of these networks included cellular movement, cellular development, cellular 
growth, cell proliferation, cancer, inflammatory response and the cell cycle. These results 
thus, validated the pathway analysis results that showed the deregulation of the inflammatory 
and cell cycle pathways through HPVE6 expression. It is possible that the expression of 
HPVE6 can target different genes to achieve the same goal of lowering the capability of the 
host cell to repair its DNA leading to cellular transformation.  
The over expression and activation of cellular oncogenes by the ERK/MAPK cascade have 
been reported in many human carcinomas (Loda et al., 1996; Mishima et al., 1998; Lessard et 
al., 2001). It was also suggested that ERK1 expression is an early marker of cervical 
carcinogenesis as well as other human epithelial neoplasias (Loda et al., 1996; Branca et al., 
2004).  TNF is a multifunctional proinflammatory cytokine involved in the regulation of a 
wide spectrum of biological processes including cell proliferation and differentiation and has 
also been implicated in cancer and autoimmune diseases (Locksley et al., 2001). The 
expression of TNF by infiltrating mononuclear cells correlates with spontaneous regression of 
papillomas (Hagari et al., 1995).  
From the top networks in our study NFκB complex was associated with the most gene 
products following HPVE6 expression and included mostly genes that encoded growth 
factors and cytokines. This was confirmed in other studies that showed NFκB signaling as a 
key event in virus induced carcinogenesis (Hussain et al., 2011). NFκB functions as an 
oncogene through its ability to stimulate cell proliferation and survival and is constitutively 
activated in several human cancers (Li et al., 2005; Karin, 2006), including cancer of the 
cervix (Nair et al., 2003; Prusty et al., 2005; Branca et al., 2006). Other studies have also 
shown that NFκB activation is a frequent occurrence in squamous cell carcinomas and there 
is strong evidence that it is important for transformation of epithelial cells (Huber et al., 
2004).  
From the network of genes regulating the NFκB pathway in the current study, the expression 
of HPV18E6 had more genes being up-regulated while the expression of HPV11E6 had more 
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genes being down-regulated, though they both shared genes that had more up- than down- 
regulated genes. These results highlighted the differences between the expression of HPVE6 
and indicated that NFkB activity is increased immediately upon infection by HPVE6, serving 
as a mechanism to alert the immune system to the presence of an infection. It is tempting to 
speculate that the expression of both the low risk HPV11E6 and the high risk HPV18E6 
exploited the NFκB signalling pathway in achieving cellular transformation, although to a 
lesser extent with the low risk HPV11E6. A more indepth analysis of structural variants and 
other viruses apart from HPV that maybe involved in the progression of OSCC is presented 
in chapter 4. 
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CHAPTER FOUR  
Genomic Alterations in OSCC  
 
4.1 Introduction 
 
Cancer involves many genome alterations such as DNA sequence changes, copy number 
aberrations, chromosomal rearrangements and modification in DNA methylation that together 
drive the development and progression of malignancies (McLendon et al., 2008). Single 
nucleotide polymorphisms (SNPs) were initially believed to be the main contributing factor 
to genetic variation (International HapMap Consortium, 2005). However, there has been 
growing appreciation for the effect of larger-scale rearrangements, such as structural variants 
(SVs) (Sharp et al., 2006; Scherer et al., 2007; Xi et al., 2010). 
Structural variants (SVs) include large deletions, insertions, inversions, duplications and 
translocations that can lead to abnormal cell growth and proliferation. These are important 
hallmarks of cancer responsible for the creation of regulatory changes leading to activation or 
over-expression of oncogenes and inactivation of tumour suppressor genes (Albertson et al., 
2003; Mijušković et al., 2012). With the sequencing of human genomes being routine (1000 
Genomes Project Consortium, 2010) this has widened the spectrum of structural variants 
(SVs) and copy number variants (CNVs) from originally being defined as greater than 1 kb in 
size (Feuk et al., 2006) to also include much smaller events of >50 bp in length. The only 
challenge being to discover the full extent of structural variation in order to genotype it 
routinely so as to understand its effects on human disease, complex traits and evolution 
(Alkan et al., 2011). Rapidly accumulating evidence indicates that structural variants can 
comprise millions of nucleotides of heterogeneity within every genome and are likely to 
make an important contribution to human diversity and disease susceptibility (Feuk et al., 
2006). 
Viruses have also been instrumental in the evolution of cancer (Butel, 2000). The link 
between human cancers with viral origin was made nearly half a century ago with the 
discovery of the association between Epstein-Barr virus (EBV) and Burkitts Lymphoma 
(Javier & Butel, 2008). Since then it has become apparent that a number of viruses e.g. 
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Merkel cell polyomavirus (MCPyV) (Nishizawa et al., 1997; Gifford & Tristem, 2003; 
Burmeister et al., 2004; Holland & Pogo, 2004; Kremsdorf et al., 2006; Park et al., 2006; Lee 
& Lee, 2007; Houben et al., 2010; Kofman et al., 2011; Banks et al., 2012; Zwolińska et al., 
2013; Hampras et al., 2014; Miner et al., 2014) play significant roles in the multistage 
development of human cancers.   
Six human viruses have been considered by the International Agency for Research on Cancer 
(IARC) as being carcinogenic based on sufficient evidence supporting their aetiologic 
association with human cancers: they are Epstein-Barr virus, Hepatitis B Virus(HBV), 
several types of human papilloma viruses (HPV), human T-cell lymphotropic virus type 1, 
Hepatitis C Virus (HCV), and Kaposi’s sarcoma-associated herpesvirus (Parkin, 2006). 
However, even though these infectious agents are widespread in the general population, only 
a very small fraction of infected people develop neoplastic disease, indicating the crucial role 
of some presently unknown, genetic factors (Mazzaro et al., 2005). Other infectious agents 
other than viruses e.g. Helicobacter pylori and liver flukes have also been known to be 
carcinogenic (Sripa et al., 2007; Selgrad et al., 2008). 
Approximately 15-20% of cancers are associated with viral infections (zur Hausen, 2001; 
Parkin, 2006). Oncogenic viruses can contribute to different steps of the carcinogenic 
process, and the association of a virus with a given cancer can range anywhere from 15 to 
100% (Parkin, 2006). Furthermore, many other viral agents have been classified as possibly 
carcinogenic to humans and others have been occasionally found in human tumours 
suggesting that this figure may be an underestimation of virus involvement in the aetiology of 
human cancer. Thus, defining the architecture of a specific cancer genome is therefore 
essential not only as a first step towards understanding the biology of the tumour and 
mechanisms of oncogenesis, but also clinically towards designing effective personalised 
therapies (Druker et al., 2001a; Druker et al., 2001b). 
With the completed sequence of the human genome and continuing improvement of high-
throughput genomic technologies, it is now feasible to contemplate comprehensive surveys of 
human cancer genomes (McLendon et al., 2008). Recent advances in high throughput 
sequencing technology have made it possible to study whole genomes at unprecedented high 
resolution and relatively low cost (Bentley et al., 2008; Mardis, 2008b). Next-generation 
sequencing (NGS) technology has made whole genome sequencing (WGS) possible at an 
individual level (Mardis, 2008b; Rusk & Kiermer, 2008; Metzker, 2010). WGS has revealed 
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numerous single nucleotide variations (SNVs), de novo mutations and somatic mutations in 
cancer genomes that had not been previously reported (Beroukhim et al., 2010; Lee et al., 
2010; Pleasance et al., 2010; Roach et al., 2010; Fujimoto et al., 2012; Shigemizu et al., 
2013). 
Some of the applications of NGS include analysis of gene expression and alternative splicing 
(RNA-seq), DNA–protein interactions, de novo genome sequencing, metagenomics and 
identification of genetic variants within and across populations (Alkan et al., 2009; Schmidt 
et al., 2009; Wang et al., 2009; Li et al., 2010). Many computational methods are also 
available for analysing genetic variants using NGS data. These variants include single-
nucleotide polymorphisms (SNPs) and structural variants such as copy numbers, insertions, 
deletions, tandem duplications, inversions and translocations (Ruffalo et al., 2012). 
Characterization of such variants is useful in many applications, including genome-wide 
association studies, identification of driver mutations in cancer and comparative genomics 
(Hudson, 2008; Mardis, 2008a; Meyerson et al., 2010). 
This chapter aims to identify structural variants, primarily large insertions and deletions and 
viral sequence integration that may be associated with the aetiology of oesophageal squamous 
cell carcinoma (OSCC) in the South African population. 
4.2 Results 
4.2.1 WGS Quality Control 
This was a pilot study aimed at identifying structural variants and viral sequences associated 
with OSCC. The whole genome of four patients with oesophageal squamous cell carcinoma 
(OSCC) was sequenced and compared to the human reference genome (NCBI37), to do a 
preliminary screen for insertions and deletions. The samples were taken from the black and 
mixed ancestry population groups since these are the populations most affected by OSCC in 
South Africa. Quality control (QC) measures were carried out to validate the integrity of the 
samples for whole genome sequencing (WGS) using the NanoDrop 2000/2000c 
Spectrophotometer (Thermo Scientific, IL, USA). All samples passed the QC for DNA 
concentration and quality and conformed to the requirements for the downstream application 
of WGS as shown in Table. 4.1. 
 
 
 
75 
 
Table 4.1: QC for the four patient samples submitted for WGS 
    
 
 
 
 
DNA concentration and the optical density 260/280 of the samples was quantified using the NanoDrop 
2000/2000c Spectrophotometer (Thermo Scientific, IL, USA), values of 1.8–2.0 are considered indicative of 
relatively good quality DNA as described in section 6.23.3. 
4.2.2 Structural Variants in OSCC 
 
Paired-end sequencing was performed on the Illumina HiSeq2000 (Wang et al., 2010). This 
generated 4.27 billion reads of 100 bp covering at least 95% of the human reference genome. 
Quality control indicators such as the duplication rate, coverage and mean depth of coverage 
indicated that the experiments were successful in acquiring high-quality sequence reads 
(Table 4.2). The minimum depth of coverage was 33.7, and the library preparation was 
successful across all samples without being compromised by PCR amplification bias (Aird et 
al., 2011) after having obtained a 98% unique read proportion (Non-N reference) to the 
human reference genome (NCBI37). 
 
 
All the four samples were aligned onto the human reference genome (NCBI37) using ELAND and CASAVA 
software. Duplication rate of the reads was only 2% while 98% were unique reads allowing for a greater 
confidence in variant calling. Following paired end sequencing, all the sample achieved a median targeted 
fragment length of > 300bp and fragment length standard deviation around the median of >60bp. 
 
The samples were genotyped on an Illumina HumanOmni2.5-8 array (Soorya et al., 2013), 
and had a high quality score with a percentage base calling of > Q30 indicating a smaller 
probability of error. Fig. 4.1A, shows that sample B381 had 89.0% of filtered and aligned 
reads with a mean depth of coverage of 40.7. While Fig 4.1B, shows that sample B450 had 
90.7% of filtered and aligned reads with a mean depth of coverage of 35.0.  In Fig. 4.2A, 
sample M456 had 89.3% of filtered and aligned reads with a mean depth of coverage of 33.6. 
Sample ID       Sample Description Concentration      
(ng/μl) 
A260/280 
B381 Black population 42.23 1.92 
B450 Black population 47.26 1.85 
M456 Mixed ancestry 76.46 1.89 
M478 Mixed ancestry 89.09 1.91 
Sequence coverage/quality 
measures 
B381 B450 M456 M478 
Reference genome length 3,095,693,981 3,095,693,981 3,095,693,981 3,095,693,981 
Proportion duplicate reads 0.02 0.02 0.02 0.02 
Proportion unique reads 0.98 0.98 0.98 0.98 
Mean depth of coverage 40.7 35.0 33.7 34.2 
Median fragment length (bp) 320 301 311 314 
Fragment length standard 
deviation (bp) 
63 62 62 65 
Table 4.2: Sequence coverage and quality indicators for whole genome sequencing of four 
      tumour samples 
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While in Fig 4.2B sample M478 had 88.3% of filtered and aligned reads with a mean depth 
of coverage of 34.2. Additionally, at least 96% of genes (including introns and untranslated 
regions) were covered at 10X coverage. Thus the sequencing phase of this experiment 
achieved high quality reads that allowed for greater confidence in the variant calling 
procedure and results. 
 
 
 
 
Fig. 4.1: Data volume and coverage summaries. The samples had a high quality score with a percentage base 
calling of > Q30 indicating a smaller probability of error following alignment to the human reference genome 
(NCBI37). The passing filters gave the yield in Gigabases of data from the samples input into the NCBI37 
reference genome, while the passing filter and aligned reported only the subset of data in Gigabases that aligned 
to the NCBI37 reference genome. A:  Sample B381 had 89.0% of filtered and aligned reads with a mean depth 
of coverage of 40.7. B: Sample B450 had 90.7% of filtered and aligned reads with a mean depth of coverage of 
35.0 
A 
B 
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Fig. 4.2: Data volume and coverage summaries. The samples had a high quality score with a percentage base 
calling of > Q30 indicating a smaller probability of error following alignment to the human reference genome 
(NCBI37). The passing filters gave the yield in Gigabases of data from the samples input into the NCBI37 
reference genome, while the passing filter and aligned reported only the subset of data in Gigabases that aligned 
to the NCBI37 reference genome. A:  Sample M456 had 89.3% of filtered and aligned reads with a mean depth 
of coverage of 33.6. B: Sample M478 had 88.3% of filtered and aligned reads with a mean depth of coverage of 
34.2. 
A 
B 
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4.2.2.1 Alignment and Variant Calling 
Illumina’s proprietary alignment algorithm ELAND and CASAVA software were used to 
align the reads to the NCBI37 human reference genome (Kidd et al., 2010). Because we did 
not include matched normal samples, variants with global allele frequency >10% in either 
exome variant server (EVS) or thousand genomes (TGP) were filtered out to reduce 
background noise (Bailey et al., 2001; Bailey et al., 2002). Structural variants (SV) reported 
from the alignment were collated with gene loci (upstream, downstream and overlapping) 
using the variant effect predictor of Ensembl (McLaren et al., 2010). A large number of SNP 
effects from all the four samples was observed (Table 4.3), having 98% mean array 
agreement between the samples and the reference genome NCBI37 of which 38% were 
associated with Genes. 
 
Table 4.3: Summary of SNP consequences across all four tumour samples 
 
 
 
 
 
 
Samples were aligned to the NCBI37 Homo sapiens reference genome using ELAND and CASAVA, and the 
SNP consequences reported from the alignment were collated with gene loci using the variant effect predictor of 
Ensembl. In all 4 samples there was a 98% mean array agreement between the genotyping and sequencing SNPs 
to the reference genome NCBI37 of which 38% were associated with Genes. The affected genes were 
subsequently cross-checked against the genetic association database for disease and cancer associations. 
 
The transition/transversion (Ti/Tv) ratio has been used in multiple studies for assessing the 
specificity of SNP calls, and has an empirical Ti/Tv ratio of ~2.1 for genome-wide variants 
(Li & Durbin, 2010; DePristo et al., 2011; Liu et al., 2012; Guo et al., 2013a; Guo et al., 
2014). Ti/Tv ratio is computed as the number of transition SNPs divided by the number of 
transversion SNPs (Guo et al., 2014). Typically, the Ti/Tv ratio is lower in novel SNPs than 
in known SNPs because of residual false positives and a relative deficit of transitions due to 
sequencing context bias (DePristo et al., 2011; Zhang et al., 2014). 
Variant Effects B381 B450 M456 M478 
% Array Agreement 98.47 99.24 97.61 99.22 
SNP  Total 4,919,446 5,334,173 4,185,808 5,018,129 
% in Genes 38.9 38.9 38.8 39.1 
% in Exons 1.6 1.6 1.6 1.6 
Ti/Tv 2.1 2.1 2.1 2.1 
Novel 591,283 617,474 476,394 656,181 
Ti/Tv novel 1.5 1.6 1.4 1.7 
Synonymous 14,266 15,310 11,750 14,562 
Missense 13,349 14,556 11,243 13,660 
Nonsense 140 144 118 135 
Indel Total 1,308,522 1,358,218 1,153,901 1,303,928 
Frameshift indel 417 431 378 446 
Splice Region (<=5b From 
Splice Site) 
1,819 1,892 1,450 1,857 
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In all the samples the Ti/Tv ratio was 2.1, further validating the accuracy of SNP calling.  The 
SNP sequence variation in the chromosome showed 90% call accuracy to the reference 
genome (NCBI37) across all the four samples, which was replicated with the autosomal, 
mitochondrial and the X-specific sites (Table 4.4). 
 
Table 4.4: Summary of the chromosomal origin of SNP calls across all four tumour  
      samples 
 
 
Samples were aligned to the NCBI37 Homo sapiens reference genome using ELAND and CASAVA, and the 
chromosomal origin of SNP reported using the variant effect predictor of Ensembl. The samples showed an 
excellent agreement with the sequence-based SNP calls at (>90%) in all the sites generating high-quality and 
reliable sequencing data as described in section 6.23.3. 
 
 
The most prevalent structural variants were insertions, deletions and copy number variation 
(Table 4.5). Very few insertions were observed in all the four samples compared to deletions 
and copy number variations. This study concentrated on identifying large structural variants 
(>300bp) and the role that they could play in OSCC. 
 
 
Sequence variation  B381 B450 M456 M478 
Total sites called (out of 
3,095,693,981) 
2,803,227,246 2,786,676,594 2,797,772,217 2,787,310,210 
Autosomal sites 
Total sites called (out of 
2,881,033,286) 
2,641,282,521 2,639,594,675 2,638,753,835 2,640,156,272 
Proportion called 0.91 0.91 0.91 0.91 
Called heterozygous 4,071,708 4,374,861 2,991,031 4,136,946 
Proportion heterozygous 0.0015 0.0016 0.0011 0.0015 
X-specific sites 
Total sites called (out of 
152,301,523) 
143,955,244 144,539,991 143,955,546 144,602,308 
Proportion called 0.94 0.94 0.94 0.94 
Called heterozygous 17,022 163,845 15,722 176,523 
Proportion heterozygous 0.00011 0.0011 0.00011 0.0012 
Y-specific sites 
Total sites called (out of 
56,404,529) 
15,449,993 0 12,538,545 0 
Proportion called 0.27 0 0.22 0 
Called heterozygous 11,860 0 9,117 0 
Proportion heterozygous 0.00076 0 0.00072 0 
Mitochondrial sites 
Total sites called (out of 
16,569) 
16,566 16,567 16,565 16,565 
Proportion called 0.99 0.99 0.99 0.99 
Called heterozygous 1 1 0 0 
Proportion heterozygous 0.00006 0.00006 0 0 
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Table 4.5: Summary of structural variants detected in all four tumour samples 
 
    
 
.  
 
Only structural variants which were >300bp following alignment to the human reference genome (NCBI37) 
using ELAND and CASAVA were collated and called with gene loci, (upstream, downstream and overlapping) 
using the Variant Effect Predictor of Ensembl as described in section 6.23.3. 
 
4.2.2.2 Effects associated with insertions  
 
No common insertions were identified in all four samples. Five insertions were associated 
with genes (Table 4.6), but they lacked adequate evidence to justify an association with 
OSCC. The evaluation of insertions was not explored further since these insertions were 
identified as intronic variants that were associated with diseases such as sinusitis, Diabetes 
Mellitus, Type 1, congenital diaphragmatic hernia, Alpers syndrome and Coronary Artery 
disease while none was associated with the progression of OSCC. 
 
Table 4.6: Description of Genes associated with insertions common to all four tumours,  
                  showing five genes that were not associated with OSCC 
 
 
 
 
 
 
 
 
Insertions associated with genes were cross-checked against the genetic association database for disease and 
cancer associations as described in section 6.23.3. 
 
4.2.2.3 Effects associated with deletions 
 
A total of 697 deletions were observed in all the four samples of which 349 were associated 
with genes and 127 were associated with different types of cancer (Table 4.7). Only twelve 
genes were shown to have deletions in the coding region or were associated with oesophageal 
cancer (Table 4.8). Among the twelve genes; ADH4, EGFR, MSH3 and BCLAF1 have 
previously been associated with cancer (Kuwano et al., 2005; Ungerback et al., 2012; Kato et 
al., 2013; Lawrence et al., 2014; Vogelsang et al., 2014), but only the BCLAF1 deletion was 
identified as a possible interesting structural variant in OSCC.  
Structural Variants  B381 B450 M456 M478 
Insertions  8 3 4 3 
Deletions  2,876 2,558 2,478 2,556 
Copy number variations  1,748 992 1,465 1,165 
Genes  
(HGNC)  
Location Variant  
Consequence 
Disease Associated 
IQGAP2 Chr.5 intron_variant Intellectual disability and sinusitis 
LRRC7 Chr.1 intron_variant Diabetes Mellitus, Type 1 
CCDC102B Chr.18 intron_variant Congenital diaphragmatic hernia  
FARS2 Chr.6 intron_variant Alpers syndrome 
ZNF385D Chr.3 intron_variant Coronary Artery Disease 
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The BCLAF1 deletion had previously been shown to be associated with Non-Hodgkin's 
lymphoma (Kasof et al., 1999) and recently with colorectal cancer (Lawrence et al., 2014). In 
this study the BCLAF1 deletion spanned 53.20% of the protein coding region as opposed to 
the other structural variants and was thought to have significant implications for the 
progression of OSCC. 
 
Table 4.7: Summary of deletions common to all four tumour samples, showing the  
                  breakdown of the total number of deletions described in the samples 
 
 
 
 
 
Deletions associated with genes were cross-checked against the genetic association database for disease and 
cancer associations as described in section 6.23.3. 
 
 
Table 4.8: Description of Gene deletions common to all four tumour samples 
 
Percentage overlap of the protein coding region was reported from the alignment to the human reference 
genome (NCBI37), and collated with gene loci using the Variant Effect Predictor of Ensembl as described in 
section 6.23.3.        
 
Deletions  Common in all four samples 
Number of common deletions  697 
Deletions associated with genes  349 
Deletions associated with cancer  127 
Genes  
(HGNC)  
Location Variant  Consequence MeSH Disease Terms Percentage 
Protein Coding 
overlap 
NXPE1 Chr.11 non-coding exon variant Ulcerative colitis and Inflammatory 
bowel disease 
0.66 
DLEU1 Chr.13 non-coding exon variant Chronic lymphocytic leukemia 0.32 
TMBIM4 Chr.12 3’UTR variant Venezuelan hemorrhagic fever and 
Bolivian hemorrhagic fever 
0.73 
ADH4 Chr.4 upstream_gene_variant Adenocarcinoma, Oesophageal 
neoplasm and Parkinson Disease 
0.12 
HYDIN Chr.16 coding sequence variant Primary ciliary dyskinesia 5 and 
Hydin-related primary ciliary 
dyskinesia  
0.49 
KCNJ12 Chr.17 Frameshift  variant 
3’UTR 
Hypokalemic periodic paralysis 3.53 
BCLAF1 Chr.6 coding sequence variant Non-Hodgkin's Lymphoma 
Colorectal cancer 
53.20 
CACNA1B Chr.9 coding sequence variant Pulmonary aspergilloma 
 
0.34 
EGFR Chr.7 intron_variant Oesophageal neoplasms, colonic 
neoplasms and cervical squamous 
cell carcinoma. 
0.24 
FAM118A Chr.22 coding sequence variant Cardiovascular Diseases and 
Diabetes Mellitus, Type 2 
1.70 
OR6K5P Chr.1 Noncoding     exon 
variant 
Neuronitis 25.35 
MSH3 Chr.5 intron_variant Adenocarcinoma, Oesophageal 
neoplasm and Colonic Neoplasms 
0.31 
82 
 
4.2.2.4 BCLAF1 Validation 
 
In order to ascertain the role of BCLAF1 deletion on the progression of OSCC we checked 
the frequency of BCLAF1 deletion by PCR of thirty DNA tissue biopsies from OSCC patients 
and their normal blood DNA samples (Fig. 4.3). The PCR reaction was optimized and gave 
rise to PCR products of 2045 bp and 690 bp for non-deletion and deletion alleles respectively, 
while the presence of both fragments defined the heterozygous deletion (Figure 4.4). The 
frequency of the BCLAF1 deletion in OSCC samples was 40% with 33% (10/30) being 
homozygous deletions and 7% (2/30) heterozygous deletions, while 60% had no deletions. 
There were no deletions observed in the respective patient’s blood samples used as control 
(Figure 4.5). 
 
 
 
 
         
 
 
 
 
Figure 4.3 PCR assay for BCLAF1 deletion. A two primer set was used to show the presence of BCLAF1 
deletion. Primers AF and AR amplify two distinct fragments: a 2045 bp fragment detecting the presence of the 
BCLAF1 gene and a 690 bp fragment generated by the deletion of BCLAF1 gene. According to the presence or 
absence of these fragments, three results could be inferred. The sole presence of the 2045 bp or 690 bp fragment 
showed no deletion or homozygous deletion, while the contemporary presence of both fragments showed 
heterozygous deletion. Solid lines represent genomic sequences; the black bar represents the size of BCLAF1 
deletion (1355bp) while the red arrows indicate forward (F) and reverse (R) primers. Expected PCR products are 
drawn as small blue bars. Results from the two PCR assays for BCLAF1deletion are shown in Fig. 4.4 & 4.5. 
 
 
 
              
 
Figure 4.4 Deletion of the BCLAF1 gene. PCR amplification of tumour biopsy DNA samples using the 
primers described in appendix A resulted in three possible outcomes: the sole presence of either a 2045 bp band 
(lanes 1–3) or a 690 bp band (lanes 6-8) defined no deletion and homozygous deletion, respectively, while the 
presence of both fragments defined the heterozygous deletion (lanes 4&5) with lane 9 being the water blank. 
MW: Molecular weight marker (Fermentas).  
2045bp 
     MW         1           2            3             4           5          6            7            8           9 
690bp 
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Figure 4.5 No Deletion of the BCLAF1 gene. PCR amplification of blood DNA samples using the primers 
described in appendix A, resulted in the sole presence of a 2045 bp band (lanes 1–8) defining the absence of 
deletion with lane 9 being the water blank. MW: Molecular weight marker (Fermentas). 
 
4.2.3 Viral Integration in OSCC 
 
Having previously described on the role of HPVs in causing cellular transformation (chapter 
three), we also searched for the presence of other viruses that may be implicated in the 
aetiology of OSCC. Reads from the WGS that didn't map to the human reference genome 
were probed for viral association with OSCC. The program DeconSeq (Schmieder & 
Edwards, 2011) was used to align the unmapped reads against complete set of NCBI RefSeq 
Viral Genomes (build 64) using the Burrows Wheeler Aligner (BWA) (Li & Durbin, 2010). 
DeconSeq allows detecting of plausible matches based on a user specified match identity and 
sequence coverage. For our detection we set the identity match to a minimum of 95% and 
sequence coverage to a minimum of 90%. Based on the detection criteria Table 4.9 shows the 
number of reads per sample that has viral origin. From the DeconSeq results a list of the most 
to least frequent viral hits was built. The BWA database indexing, alignment and filtering 
were done on the UCT HPC cluster (http://hex.uct.ac.za).  
Table 4.9: Total number of unmapped reads for each sample that has viral origin. Based on a  
                   minimum of 95% identity match and a minimum of 90% sequence coverage on  
                   BWA alignments against NCBI's RefSeq Viral Genomes (build 64). 
 
Sample Viral Reads (100bp) 
B381 1236585 
B450 912766 
M456 961224 
M478 1079614 
 
  MW        1             2            3            4            5           6            7            8          9 
2045bp 
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4.2.4 Detection of viral integration in OSCC 
 
From the list of viral sequences identified in all the four samples, 22 viral sequences were 
selected which were common and of human origin in all the four samples (Table 4.10). In 
order to detect the viral integration sites we used BWA to align all the reads from the WGS to 
the human reference genome (hg19, UCSC) and the 22 viral genomes. 
 
Table 4.10: Selected human viral sequences used in building a BWA database to detect  
                    human viral integration 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the discordant reads were extracted from the complete mapping and only those matches 
where one of the read pairs mapped to the human genome and the other read pair mapped to 
any of the viral genome were selected (Jiang et al., 2012). In order to achieve a high 
confidence in viral integration, we further filtered the selected viral reads to only those that 
had 100% match in both the BWA alignment score and CIGAR string to the reference human 
genome and human viral sequence. Following this further filtering only 2 viral sequences that 
had varying integration sites between the four samples were observed; sample B381 had one 
integration site observed for Human Endogenous Retrovirus K113 (HERV-K113) and 
another for two Human herpesvirus 6A (HHV-6A); sample B450 had one integration site 
NCBI_RefSeq Virus Name 
GI:9626597/NC_001457.1 Human papillomavirus type 4, complete genome 
GI:962739/NC_001596.1 Human papillomavirus type 9, complete genome 
GI:9626069/NC_001357.1 Human papillomavirus 18, complete genome 
GI:9628574/NC_001694.1 Human papillomavirus  61, complete genome 
GI:310698439/NC_001526.2 Human papillomavirus type 16 
GI:9629378/NC_001806.1 Human herpesvirus type  1 
GI:9629267/NC_001798.1 Human herpesvirus 2 
GI:9625875/NC_001348.1 Human herpesvirus 3 
GI:139424470/NC_009334.1 Human herpesvirus 4 
GI:82503188/NC_007605.1 Human herpesvirus 4 type 1, complete genome 
GI:224020395/NC_001664.2 Human herpesvirus 6A 
GI:51874225/NC_001716.2 Human herpesvirus 7 
GI:139472801/NC_009333.1 Human herpesvirus 8 
GI:157781212/NC_009823.1 Hepatitis C virus genotype 2 
GI:157781216/NC_009824.1 Hepatitis C virus genotype 3 
GI:157781214/NC_009827.1 Hepatitis C virus genotype 6 
GI:155573622/NC_006273.2 Human herpesvirus 5 strain Merlin 
GI:56160839/AC_000017.1 Human adenovirus type 1 
GI:56160492/AC_000007.1 Human adenovirus 2 
GI:12175745/NC_002645.1 Human coronavirus 2 
GI:9630376/NC_001897.1 Human parechovirus 1 
GI:548558394/NC_022518.1 Human endogenous retrovirus K113 complete genome 
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observed for HERV-K113 and two integration sites observed for HHV-6A; sample M456 had 
four integration sites observed for HERV-K113 and seven integration sites observed for eight 
HHV-6A; sample M478 had seven integration sites observed for nine HERV-K113 and one 
integration site observed for HHV-6A (Table 4.11).  A Circster figure showing the 
chromosomal integration sites of the filtered viral sequences for the four patient samples was 
generated on Galaxy (Giardine et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010) as 
shown on Fig 4.6.    
 
Table 4.11: Chromosomal integration sites of filtered viral sequences identified in all four    
                     samples 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Multiple viruses integrated at the same site 
 
 
 
 
 
Samples Viral Sequences Integration 
Sites 
B381 Human endogenous retrovirus K113 complete genome 4p16.1 
Human herpesvirus 6A 13q12.12* 
Human herpesvirus 6A 13q12.12* 
B450 Human herpesvirus 6A 7p22.1 
Human herpesvirus 6A 11q22.1 
Human endogenous retrovirus K113 complete genome 19p13.11 
M456 Human herpesvirus 6A 1q24.1 
Human herpesvirus 6A 1q32.1 
Human herpesvirus 6A 2p16.3 
Human herpesvirus 6A 2q31.1 
Human endogenous retrovirus K113 complete genome 3q28 
Human herpesvirus 6A 3q28 
Human endogenous retrovirus K113 complete genome 8p23.1 
Human herpesvirus 6A 9q22.31 
Human herpesvirus 6A 9q34.3 
Human endogenous retrovirus K113 complete genome 19p13.11 
Human endogenous retrovirus K113 complete genome 20p12.1 
Human herpesvirus 6A 21p11.1 
M478 Human herpesvirus 6A 1p31.1 
Human endogenous retrovirus K113 complete genome 3q28* 
Human endogenous retrovirus K113 complete genome 3q28* 
Human endogenous retrovirus K113 complete genome 4p16.1 
Human endogenous retrovirus K113 complete genome 6q14.2 
Human endogenous retrovirus K113 complete genome 8p23.3 
Human endogenous retrovirus K113 complete genome 15q21.3* 
Human endogenous retrovirus K113 complete genome 15q21.3* 
Human endogenous retrovirus K113 complete genome 19p13.11 
Human endogenous retrovirus K113 complete genome Xq13.2 
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Fig.4.6: Circster plot showing chromosomal integration sites of the filtered viral sequences from the four patient 
samples. Red spike (B381): Shows the presence of 3 viral integration sites, Green spike (B450): Shows the 
presence of 3 viral integration sites, Blue spike (M456): Shows the presence of 12 viral integration sites and 
Orange spike (M478): Shows the presence of 10 viral integration sites 
 
4.3 Discussion 
 
Cancer represents a special opportunity not only to study disease genesis and progression but 
also to study mechanisms of cellular regulation, as specific genomic alterations can be 
identified in cancer compared to normal cells (Strausberg & Simpson, 2009). Many genetic 
alterations that disrupt the normal balance during cell proliferation, survival and 
differentiation are associated with chromosomal abnormalities (Mitelman et al., 2007). 
In this pilot study, four DNA samples from patients with OSCC were sequenced primarily to 
identify large structural variants (insertions and deletions) and viral sequences that may be 
associated with the progression of OSCC in the South African population. A total of 4.27 
billion reads of 100 bp were generated covering 95% of the human reference genome 
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(NCBI37) at a mean read depth of 33.7. This allowed for reliable calling of SNPs and 
structural variants across  the human reference  genome (NCBI37), and corresponded with 
previous studies that also showed that an average read depth that exceeded 30× was the de 
facto standard for achieving reliable variant calling across 95% of the reference genome 
(Bentley et al., 2008; Wang et al., 2008; Ahn et al., 2009; Yoon et al., 2009; Sims et al., 
2014). 
The transition/transversion ratio is also a critical metric for assessing the specificity of SNP 
calling (DePristo et al., 2011) and has been used as a quality control parameter for assessing 
the overall SNP quality by multiple studies with the expected Ti/Tv ratios in whole-genome 
sequencing being 2.1 thus, the higher Ti/Tv ratio generally indicated higher accuracy in 
variant calling (DePristo et al., 2011; Liu et al., 2012; Guo et al., 2013a; Guo et al., 2013b). 
This corresponded with our results having a Ti/Tv ratio of 2.1 across all four samples, further 
confirming the reliability of our SNPs and structural variant calling. 
Structural variants (SVs) in the human genome play an important role in the genetics of 
complex diseases (Iafrate et al., 2004; Sebat et al., 2004; Feuk et al., 2006). Although our 
analysis reduced the number of variants of specific interest from the pool of structural 
variants in this study to a select few, large numbers of potentially functional alterations that 
could contribute to OSCC susceptibility were not analysed further for functional 
consideration at this time with the potential role of CNV and insertional changes not being 
considered. From the twelve potential genes common in all four samples only three genes 
have been previously shown to be associated with OSCC; ADH4, EGFR, MSH3 and one 
novel gene BCLAF1 that has not been reported in OSCC.  
A reduction in ADH4 expression in poorly differentiated OSCC was shown to contribute to 
the maintenance of the tumour by inhibiting the retinoic acid signaling pathway (Han et al., 
1998; Chou et al., 2002; Yin et al., 2003; Matsumoto et al., 2005; Lee et al., 2006), while 
mutations in EGFR have also been shown to occur in primary OSCC (Guo et al., 2006; 
Hanawa et al., 2006; Mir et al., 2008). Other studies by (Vogelsang et al., 2012; Vogelsang et 
al., 2014) also showed that MSH3 polymorphism, together with exposure to tobacco smoke 
increased the risk of oesophageal carcinogenesis. Although these genes (ADH4, EGFR and 
MSH3) had previously been associated to OSCC, we did not analyze them further for 
functional significance in this study due to the low protein coding overlapping regions.  
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The BCLAF1 deletion on the other hand, is an interesting structural variant (SV) candidate 
associated with OSCC, due to its identification as a coding variant with an overlap of 53.20% 
in the protein coding region. Although the exact molecular role of BCLAF1 remains to be 
defined, BCLAF1 has been shown to have functional connections and mutation patterns 
consistent with the known hallmarks of cancer (Hanahan & Weinberg, 2011; Imielinski et al., 
2012) including cell proliferation, apoptosis, genome stability, chromatin regulation, immune 
evasion, RNA processing and protein homeostasis (Lawrence et al., 2014) which suggested 
BCLAF1 contribution to the progression of OSCC.  
BCLAF1 has also been shown to directly interact with and activate TP53 gene transcription 
and the silencing of BCLAF1 gene reduces TP53 dependent apoptosis thus, providing 
evidence that TP53 is a downstream target of BCLAF1 (Liu et al., 2007). This is also 
supported by other recent studies that identified TP53 as among the significantly mutated 
genes in OSCC (Lin et al., 2014; Song et al., 2014). These studies were thus confirming the 
DNA microarray gene expression results in chapter two of this thesis which showed the 
down-regulation of TP53 gene by the high risk HPV18E6.  
In order to ascertain the presence of BCLAF1 deletion in OSCC, a PCR assay was done on a 
larger sample size of tumour DNA and their respective normal blood samples. Deletions were 
specific for the tumour DNA as there were no deletions observed in their respective patient’s 
blood samples used as control. These results demonstrated that BCLAF1 deletion may be an 
important determinant for the progression of OSCC.  According to our knowledge this is the 
first study linking BCLAF1 deletion in OSCC. It is possible that the link between BCLAF1 
deletion and the progression of OSCC is through the down-regulation of TP53 and the 
deregulation of cellular processes involved in carcinogenesis. This hypothesis was also 
supported by studies that showed the role of BCLAF1 as a tumour suppressor and to promote 
the stability of genes required for DNA repair and maintenance of genomic stability (Savage 
et al., 2014).  
Viruses have been known to cause cellular transformation by the expression of viral 
oncogenes, by genomic integration to alter the activity of cellular proto-oncogenes or tumour 
suppressors and by inducing inflammation that promotes oncogenesis (Tang et al., 2013). 
Thus, the study of oncogenic viruses has been invaluable to the discovery and analysis of key 
cellular pathways that are commonly rendered dysfunctional during carcinogenesis 
(McLaughlin-Drubin & Munger, 2008). This study utilised a discovery approach of analysing 
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unmapped reads, generated from WGS of the four samples to detect viral integration within 
the host genome and their association with OSCC (Cimino et al., 2014).  
This study showed the Human Herpes virus 6A (HHV6A) and Human endogenous retrovirus 
K113 (HERV-K113) as the two viral sequences to be integrated into the chromosomes of all 
the four sequenced human genomes, these ﬁndings are not contradictory to others since both 
have previously been shown to be integrated in the human genome in cases of autoimmune 
diseases (Moyes et al., 2005; Amirian et al., 2014).  
HHV6A has been shown to persist in latent state by naturally integrating into the human 
genome, where it has been reported to escape immune surveillance by expressing a number 
of proteins that counteract the host’s immune system (Arena et al., 1999; Lusso, 2006; Hall et 
al., 2008; Nacheva et al., 2008; Flamand et al., 2010). The reactivation of HHV6A has been 
observed in AIDS and cancer patients (Lusso & Gallo, 1995; Michalek et al., 1999). In this 
study HHV6A is integrated in several chromosome specific sites with some of these sites 
being consistent with other studies that also identified 9q34.3 as a HHV6A chromosome 
specific integration site (Nacheva et al., 2008; Morissette & Flamand, 2010). Previous studies 
have also reported on the role of HHV6A specifically its ORF-1 gene in its ability to bind and 
inactivate p53, while its other gene product U95 has been postulated to contribute to cancer 
by binding and deregulating the nuclear factor-kappa B (NFkB) (Doniger et al., 1999; Ablashi 
et al., 2010; Kofman et al., 2011). We thus hypothesise that the integration of HHV6A could 
have oncogenic properties that modify the expression of host cell proteins that are involved in 
apoptotic signaling and cell growth leading to OSCC.  
The human genome harbours about 8% of endogenous retroviral sequences known to 
originate from germ cell infections by exogenous retroviruses during evolution (Zwolińska et 
al., 2013). While most of those sequences have been shown to be inactive because of 
accumulation of mutations, HERV-K113 is capable of being transcribed and translated 
leading to malignant transformation of cells (Hanke et al., 2013; Downey et al., 2014). 
Previous studies have reported chromosomal integration sites 8p23.1 and 19p13.11for 
HERV-K113 (Turner et al., 2001; Kurth & Bannert, 2010; Zwolińska et al., 2013). This study 
also showed several chromosomal integration sites of HERV-K113 including 8p23.1 and 
19p13.11. HERV-K113 is known to inhibit tumor suppressor genes and promote cell growth 
in lymphoma, breast, and skin cancer (Burmeister et al., 2004; Contreras-Galindo et al., 2008; 
Golan et al., 2008; Wang-Johanning et al., 2008; Kurth & Bannert, 2010).We hypothesise 
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that the integration of HERV-K113 may be responsible for modifying the expression of 
tumour suppressor genes involved in cell growth regulation and tumourigenesis leading to 
oncogenic transformation of the host cells.  
These results highlight the role played by BCLAF1 deletion, HHV6A and HERV-K113 in 
enabling genomic instability of the host cell and support a model wherein the frequent assault 
of the human genome by widespread genomic alterations significantly widens oncogenic 
opportunities in patients with OSCC. 
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CHAPTER FIVE  
FINAL CONCLUSION 
 
5.1 Conclusion 
 
In this study, a normal human keratinocyte (HaCaT) cell line was used as a model to further 
our understanding on the early stages of HPVE6 expression through global gene expression 
profiling and also to identify structural variants and viral sequence integration associated with 
the initiation and progression of OSCC. 
The first objective was aimed at constructing a recombinant adenovirus capable of high level 
transient expression of the biologically active HPV E6 from the low risk HPV11 and high 
risk HPV18 and to ascertain their roles in inducing cellular transformation. HPVE6 appeared 
to serve as an initiation event capable of inducing cellular transformation by both HPV11E6 
and HPV18E6 although HPV11E6 achieved this at a much lower rate compared to 
HPV18E6, this may have been attributed to the differential ability of HPVE6 proteins to bind 
to and degrade p53. Thus, although HPVE6 infection alone may not be sufficient for the 
process of cellular transformation, expression of the HPVE6 may facilitate cellular 
transformation by the activation or inactivation of other cellular processes apart from the 
binding and inhibition of p53. 
The second objective was aimed at explaining the biological changes observed in HaCaT 
cells infected with HPVE6, and to assess the global effects of HPVE6 expression. This 
enabled us to gain a broader view of the overall effects that the E6 gene has on gene 
expression and to provide a first step towards elucidating the pathways and networks 
involved in HPV-induced oesophageal carcinogenesis. Gene ontology analysis revealed that 
most of the DEGs were part of the metabolic pathways and further inspection of this process 
showed that these DEGs were also involved in the deregulation of cell shape, cell 
proliferation, transport and cytoskeletal re-organization all of which are well known features 
of cancer cells. The up-regulation of metabolic pathway in this study may therefore be an 
early indication of cellular transformation since tumour cells are known to be metabolically 
active and thus metabolic pathways could be potential sources of therapeutic targets. 
92 
 
It was evident that HPV18E6 was capable of dysregulating more cancer signalling pathways 
compared to HPV11E6 thus, highlighting the differences between the expressions of HPVE6. 
This can be attributed to the ability of HPV18E6 being able to bind to more cellular proteins 
that are involved in cellular transformation. From the network of genes the expression of both 
the low risk HPV11E6 and the high risk HPV18E6 exploited the NFκB signalling pathway in 
predisposing normal cells toward malignancy, although to a lesser extent with the low risk 
HPV11E6.  
The third objective was aimed at identifying structural variants, primarily large insertions and 
deletions and viral sequence integration sites that may be associated with the aetiology of 
OSCC. From the results the BCLAF1 deletion and the integration of both HHV6A and 
HERV-K113 in the tumour tissue were implicated as aetiological agents associated with 
OSCC pathogenesis. This could be due to their involvement in the down-regulation of p53 
leading to the deregulation of cellular processes involved in cell proliferation and genomic 
instability, which are known hallmarks of cancer.  
Although it is unlikely that the role played by viruses and structural variants alone may be 
sufficient for the process of malignant transformation, this study contributes towards the 
understanding of the mechanisms involved in genomic alterations. It also provides for a better 
understanding of the underlying mechanisms in tumourigenesis which may ultimately lead to 
the development of more effective therapeutic interventions for OSCC. 
5.2 Future Work 
 
Future plans include examining the effect of inhibiting some of the dysregulated signalling 
pathways in order to understand the roles being played by the respective DEGs by HPVE6. It 
would also be interesting to investigate the action of the NFκB signaling pathway and to 
evaluate its potential role as a specific target for therapeutic strategies in OSCC with high 
NFκB activity. 
Sequence large numbers of tumour and normal DNA from patients to get more detailed 
information on integration sites and use PCR and other techniques to validate data and 
improve the precision of mapping so as to achieve high quality reads allowing for a greater 
confidence in variant calling. 
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Having identified BCLAF1 deletion as novel structural variants implicated in OSCC it is 
important to look at the downstream effects of BCLAF1 deletion following BCLAF1 
knockout studies in cells using siRNA. PCR and Sanger sequencing will also be done to 
validate the HHV6A and HERV-K113 integrated viral sequences sites in both tumour and 
normal samples. 
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CHAPTER SIX  
MATERIALS AND METHODS 
 
6.1 Preparation of ultracompetent Escherichia coli DH5α 
 
The method of Inoue et al., (1990) was used for the preparation of ultracompetent 
Escherichia coli DH5α, with a slight modification of the Hanahan, (1983) technique. 
Glycerol stocks of E.coli DH5α were streaked on a Luria Bertani (LB) plate and incubated 
overnight at 37°C, in a humidified atmosphere of 5% CO2. Prepared a starter culture by 
inoculating 25ml of Luria Bertani (LB) broth with a single colony of E.coli DH5α  in a 250-
ml flask the starter culture was then incubated for 6-8 hours at 37ºC with vigorous shaking 
(250-300 rpm) in a controlled environment incubator shaker (New Brunswick Scientific, Inc. 
G25; Edison, NJ, USA). 10 ml of the starter culture was then inoculated in 1-liter flask, 
containing 250 ml of LB and incubated overnight at 18-22ºC with moderate shaking. The 
OD600 was then read on a spectrophotometer and monitored every 45 minutes until the OD600 
reached 0.55.The culture vessel was then transferred to an ice water bath for 10 minutes and 
harvested by centrifugation at 2500g for 10 minutes at 4ºC. The medium was decanted and 
the centrifuge tube placed upside down on a stack of paper towels for 2 minutes after which a 
pipette was used to remove any drops of remaining medium adhering to walls of the 
centrifuge bottle or trapped in its neck. The cells were then gently re-suspended by swirling 
in 20 ml of ice-cold Inoue transformation buffer (section 6.23) with 1.5 ml of DMSO added, 
the cells were mixed by swirling and stored in ice for 10 minutes. Aliquots of the 
suspensions were quickly dispensed into chilled, sterile 1.5 ml microfuge tubes which were 
tightly closed and immediately snap-frozen by being immersed in a bath of liquid nitrogen. 
The tubes with the competent cells were then stored at -80ºC until needed. 
6.2 Large scale production of recombinant pShuttle2 vector 
 
Competent cells (50 μl) were transformed by adding 50 ng of the empty pShuttle2 vector, 
pShuttle2-11E6 or pShuttle2-18E6 to the cells, mixing gently, and incubating on ice for 30 
minutes. The cells were heat shocked for 50 seconds at 42°C, and placed on ice for 5 
minutes. 1 ml of LB broth was added to the cells, which were incubated at 37°C for 1 hour 
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with shaking. Thereafter, 50 μl of the transformed bacteria was plated onto LB agar 
containing 50 μg/ml kanamycin (Sigma-Aldrich, Steinheim, Germany) and incubated 37°C 
for 12 to 15 hours. Bacterial colonies containing the transformed plasmid were then picked 
into 5ml of LB broth containing 50 μg/ml of kanamycin, and incubated for 10 to 12 hours at 
37°C with shaking. A 100 μl aliquot of the overnight culture was used to inoculate 100 ml of 
LB containing 50 μg/ml kanamycin, and incubated overnight at 37°C with shaking. Large-
scale preparation of plasmid DNA was performed using the QIAGEN Endofree Plasmid 
Maxi Kit (QIAGEN, Hilden, Germany). This kit employed a modified alkaline lysis 
procedure followed by binding of plasmid DNA to QIAGEN Anion-Exchange Resin under 
appropriate low-salt and pH conditions. RNA, proteins, dyes, and low-molecular weight 
impurities were removed by a medium-salt wash and the plasmid DNA was eluted in a high 
salt buffer and then concentrated and desalted by isopropanol precipitation 
6.3 Construction of Recombinant Adenoviral DNA 
 
The recombinant pShuttle2 plasmid DNA with inserts of either HPV11E6 or HPV18E6 were 
excised with unique restriction endonucleases PI-SceI and I-CeuI and then “shuttled” into 
Adeno-X Viral DNA by means of an invitro ligation (Clontech Expression, 2012). Once the 
ligation was completed the products were treated with SwaI to linearize non-recombinant 
pAdeno-X DNA. 
6.4 Transformation of DH5α E.coli with recombinant Adeno-XTM DNA 
 
DH5α E.coli (50 μl) were transformed by adding 50 ng of the ligated product this was mixed 
gently and incubated on ice for 30 minutes. The cells were heat shocked for 50 seconds at 
42°C, and placed on ice for 5 minutes. 1 ml of Luria broth (LB) was added to the cells, which 
were incubated at 37°C for 1 hour with shaking. Thereafter, 50 μl of the transformed bacteria 
was plated onto LB agar plate (100 μg/ml ampicillin) and incubated 37°C overnight. The 
colonies were checked for recombinant pAdeno-X DNA by PCR using the Adeno-X forward 
and reverse PCR Primers (Appendix A). Bacterial colonies containing the transformed 
plasmid were then picked into 5ml of LB broth containing 100 μg/ml of ampicillin, and 
incubated at 37°C overnight with continous shaking. A 100 μl aliquot of the overnight culture 
was used to inoculate 100 ml of LB containing 100 μg/ml ampicillin, and incubated overnight 
at 37°C with continous shaking. Large-scale preparation of plasmid DNA was performed 
using the Endofree Plasmid Maxi Kit (QIAGEN, Hilden, Germany) as described earlier. 
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6.5 Analyzing Recombinant Adeno-XTM DNA 
 
Following purification the identity and integrity of the respective recombinant Adeno-X 
plasmids were confirmed through PCR analysis, by screening the pAdeno-X DNA for the 
presence of pShuttle2-derived expression cassettes using the Adeno-X Forward PCR Primer 
and Reverse PCR Primer. Since these primers specifically amplified the 287-bp sequence that 
spanned the I-CeuI ligation site in pAdeno-X, only the recombinant pAdeno-X templates 
were amplified as the non-recombinants lacked the Shuttle sequence needed for annealing 
with the reverse primer. Presence of the pAdeno-X DNA was also verified by digestion with 
XhoI. 
6.6 Transfecting HEK 293 Cells with PacI-Digested Adeno-X DNA 
 
Before Adeno-X E6 constructs could be packaged, the recombinant plasmids were digested 
with PacI to expose the inverted terminal repeats (ITRs) located at either end of the genome. 
The ITRs contained the origins of adenovirus DNA replication that had to be positioned at 
the termini of the linear Adenovirus DNA molecule to support the formation of the 
replication complex (Tamanoi & Stillman, 1982). HEK293 cells were plated at 50-70% 
confluence, approximately 1 x 106 cells, in a 100 mm cell culture dish, and incubated 
overnight at 37°C, in a humidified atmosphere of 5 % CO2. The cells were then washed twice 
with 1x sterile PBS and then transfected using Lipofectamine LTX and PLUS reagents 
(Invitrogen, CA, USA). Plasmid DNA from the large scale preparation; 10 μg from Adeno-
11E6 and Adeno -18E6 respectively, was added to 750 μl of MEM, together with 15 μl of 
PLUS reagent, and incubated for 10 minutes at room temperature. To 720 μl serum free 
MEM, 30 μl of Lipofectamine LTX was added, and this was added to the DNA mixture, and 
incubated for 30 minutes at room temperature. The entire transfection mixture was added 
drop wise to the cells and the plates were incubated at 37°C, in a humidified CO2 (5%) 
incubator for 6 hours, after which the medium was removed and replaced with fresh 10ml  
complete MEM. 
6.7 End-point dilution assay 
 
HEK293 cells were plated in four 96-well plates carefully seeded at the same density (~104 
cells per well) in 100 μl of growth medium and incubated overnight. Serial dilutions of the 
respective HPVE6 virus were prepared by first making a 1:100 dilution i.e (10 μl virus stock 
to 990 μl sterile growth medium) then 1:10 serial dilutions were prepared from the 1:100 
dilution by transferring 100 μl diluted HPVE6 virus to 900 μl sterile growth medium. The 96-
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well culture plates were then removed from the incubator and the wells inspected to ensure 
that the cells had attached to form an even monolayer. Respective 100 μl diluted HPVE6 
virus was then added to each well in columns 1–10 (Fig. 2.4), and 100 μl of virus free growth 
medium was also added to wells in columns 11–12 which served as controls for the viability 
of non-infected cells this was done in duplicate for each virus. The plates were then covered 
and incubated in a humidified CO2 (5%) incubator for 10 days at 37°C. Using a microscope 
each well was then checked for cytopathic effect (CPE) while comparing the duplicate plates 
for similar results. Finally only one plate for each of the respective HPVE6 viruses was used 
to determine the viral titer by calculating the fraction of CPE-positive wells in each row (Fig. 
2.4). 
6.8 Amplifying Recombinant Adenovirus (Preparing High-Titer Stocks) 
 
Following the determination of adenoviral titre using the End-point dilution assay (Clontech 
Expression, 2012), a multiplicity of infection (M.O.I.) of 1 was determined. This was used to 
quantify the optimal amount of virus required to seed seven 150 mm HEK 293 cell culture 
dishes in order to produce a greater quantity of high titer adenovirus. Each dish was seeded 
with 1.46x107 cells with the calculated quantity of adenoviral E6 constructs until a 50% 
cytopathic effect (CPE) was observed and harvested by lysing with three consecutive freeze 
thaw cycles. This was then purified using the Adeno-X Maxi purification kit (Clontech 
Purification, 2013). 
6.9 Evaluation of the Recombinant Virus (Confirmation of Constructs) 
 
PCR analysis was done to verify that the encapsidated adenoviral genome contained a 
functional copy of the HPV E6 constructs, using the Adeno-X forward and reverse PCR 
primers and also by using the HPV11E6 and HPV18E6 specific primers. PCR as carried out 
in a 2720 Thermal cycler (Applied Biosciences, CA, USA) using primers specific to the 
HPV11E6 and HPV18E6 genes. PCR reactions were carried out using 1 x PCR buffer 
(KAPA Biosystems, Cape Town, South Africa), 1.5 mM MgCl2, 0.4 uM dNTPs, 0.5 uM of 
each primer, 1U KAPA Taq DNA Polymerase and 5 ng plasmid DNA. Primers sequences 
and melting temperatures are described in Appendix A. Sequencing reactions and 
electrophoresis were performed by Macrogen Inc. (Seoul, South-Korea) using universal T7 
primers and a BLASTn search was conducted against the database of nucleotide sequences 
provided by the National Centre for Biotechnology Information (NCBI) internet site 
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(http://ncbi.blast.nlm.nih.gov/BLAST/) to confirm sequence identity. The sequences were 
interpreted using the Chromas software version 2.01 (McCarthy, 2004)     
6.10 Preparation of agarose gel for electrophoresis 
 
For the separation of the amplified PCR products we used a 1% agarose gel containing 0.5 μg 
of Ethidium Bromide (EthBr)/ ml of gel solution from stock solution (10 mg/ml). Thus, we 
added 5 μl of stock solution for every 100 ml of gel solution. First a running buffer was made 
by adding 25 μl (10 mg/ml) of EthBr into 500 ml of 1X TBE (Tris-Borate-EDTA) solution. 
Then  to make 500ml of 1% agarose gel we added 5 g of agarose powder to 500 ml of 1X 
TBE and the solution was dissolved by warming it up in a microwave for 5-10 min. When the 
agarose was completely dissolved it was allowed to cool down to 40-50°C and 25 μl of EthBr 
was added and mixed properly. The gel was poured into the gel tank, combs were inserted 
and allowed to set, being careful to remove all the bubbles present on the gel surface. When 
the gel had set the comb was removed and the gel placed into the electrophoresis tank filled 
with 500 ml of running buffer. The total volume of each PCR product (10 μl) was then mixed 
with 2 μl of 6X DNA loading dye and then loaded into the wells of the gel. As marker, we 
used GeneRuler DNA Ladder Mix from Fermentas. The electrophoresis chamber was then 
connected to the battery by the +/– conductors and the running was carried out for 1 hour at 
100volts. The gels were then digitally photographed using a UV transilluminator 
(BioSpectrumTM 500 Imaging System, Upland, CA, USA) with VisionWorks LS Image 
Acquisition and Analysis Software (Version 6.8). 
6.11 Maintenance of cells in culture 
 
HaCaT Cells were cultured at 37°C in  a humidified atmosphere of 5 % CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % heat inactivated fetal calf serum 
(FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. The medium for 
HaCaT cells was changed every 2 to 3 days, and the cells were sub-cultured every 5 to 7 
days, or when 70% confluent, by discarding the used medium and washing the cells with 
Phosphate Buffered Saline (PBS). Cells were trypsinized with 0.05% trypsin-EDTA and once 
they had detached, the trypsin-EDTA was inactivated by adding 5 ml of complete DMEM. 
Cells were collected by centrifugation at 4000 rpm for 5 minutes, resuspended in DMEM and 
replated at a dilution of 1:3. Preparation of frozen stocks involved the steps described above, 
however, instead of replating the cells, they were resuspended in cell freezing medium (70 % 
DMEM, 20 % FCS and 10 % DMSO) by gently pippetting twice. The cells were aliqouted 
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into 2 ml ampoules at about 1 x 106 cells/ml and stored at -800C for 48 hours before being 
transferred to a liquid nitrogen tank. Every two months the cells were checked for 
mycoplasma contamination. When required, frozen stocks were thawed at 37°C in a water 
bath, and directly plated into 10 ml of supplemented DMEM. The cells were incubated 
overnight at 37°C, in a humidified atmosphere of CO2 (5%) after which the medium was 
replaced with fresh DMEM. The techinique for maintaining the Minimum essential medium 
for HEK293 cells was also the same as DMEM. 
6.12 Infection of HaCaT with Adenovirus-E6 Constructs 
 
Using a 6 well plate 2.0x105 HaCaT cells were plated into each well and incubated overnight, 
until 70% confluent. The media was removed and the cells washed once with 1x PBS. 1ml of 
DMEM media was mixed with respective E6 construct (MOI 100) and1µL DEAE-dextran 
(7.5µg/ml) and was added gently drop-wise onto each well. The plate was then sealed with 
parafilm and incubated at 37°c in a humidified atmosphere of CO2 (5%) for 1 hour; the plates 
were then centrifuged for 1 hour at 2000rpm set at 37°c.  A fresh 1ml of DMEM media 
mixed with respective E6 construct (MOI 100) and1µL DEAE-dextran (7.5µg/ml) and was 
added gently drop-wise onto each well making the a total final volume of 2 ml. The plate was 
then sealed with parafilm and incubated at 37°c in a humidified atmosphere of 5 % CO2 for 1 
hour; the plates were then again centrifuged for 1 hour at 2000rpm set at 37°c. The plates 
were then incubated at 37°c in a humidified atmosphere of CO2 (5%) for 48 hours. Finally, 
DNA, RNA and Protein extraction was done to enable the confirmation of the expression of 
HPV11E6 and HPV18E6 at both an mRNA level through qRT-PCR and at a protein level 
through western blotting and confocal microscopy. 
6.13 Determination of Multiplicity of infection (MOI) and Time point. 
 
Using a 6 well plate 2.0x105 HaCaT cells were plated into each well as three biological 
replicates for each time point and incubated overnight, until 70% confluent. The cells were 
then infected with HPV11E6 and HPV18E6 and incubated at various time points i.e. 12 
hours, 24 hours, 48 hours and 72 hours at 37°C, CO2 (5%), in a humidified atmosphere a 
control uninfected plate was also included. After each time point cells were harvested, RNA 
extracted and cDNA prepared which was used for qRT-PCR (section 6.16). The MOI and 
time point which gave the highest viral infectivity based on mRNA levels was selected. 
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6.14 DNA Extraction 
6.14.1 DNA Extraction from Agarose Gel 
 
A known amount of plasmid DNA was digested with the required restriction enzymes for at 
least 1 hr, depending on the enzyme being used, and the digested material resolved on 1% 
agarose gels containing 0.5 µg/ml ethidium bromide. DNA molecular weight markers were 
routinely included in all agarose gels to determine the approximate sizes of the DNA bands. 
The DNA fragment of interest was excised from the gel, excess agarose was removed and gel 
pieces transferred to a microfuge tube containing 500 μl of Promega DNA binding solution. 
The DNA was extracted using the Promega gel extraction kit (Promega, 2010). Following 
electrophoresis, the DNA band was excised from gel and placed in a 1.5ml microcentrifuge 
tube. 10μl Membrane Binding Solution per 10mg of gel slice was added vortexed and 
incubated at 50–65°C until gel slice was completely dissolved. An equal volume of 
membrane binding solution was added to the dissolved gel slice and transferred to a 
minicolumn assembly. The mixture was then centrifuged at 16,000 ×g for 1 minute and the 
flow through discarded. The preparation was washed by adding 700μl Membrane Wash 
Solution (ethanol added) and centrifuged at 16,000 ×g for 1 minute and discarded the flow 
through, this step was reapeated by 500μl Membrane Wash Solution and centrifuge at 16,000 
×g for 5 minutes and the flow through discarded. The minicoloumn was then recentrifuged 
for 1 minute to allow evaporation of any residual ethanol.The Minicolumn was then carefully 
transferred to a clean 1.5ml microcentrifuge tube. 50μl of Nuclease-Free Water was then 
added to the minicolumn and incubated at room temperature for 1 minute, then centrifuged at 
16,000 ×g for 1 minute. The minicolumn was then discarded and DNA stored at –20°C. 
6.15 RNA Extraction 
 
RNA extraction from cell cultures was performed using Qiazol Lysis Reagent (QIAGEN, 
Hilden, Germany). Three clones each from the three cell lines, HaCaT control, HPV11E6 and 
HPV18E6 were harvested using trypsin-EDTA as described above. The cells were collected 
by centrifugation at 4000 rpm for 5 minutes, resuspended in 1 ml PBS and transferred to a 1.5 
ml microcentrifuge tube. Cells were collected by centrifugation at 4000 rpm for 5 minutes. 
The supernatant was discarded, and the cell pellet resuspended in 1 ml Qiazol. The cells were 
lysed by aspirating with a pipette, and incubated for 5 minutes at room temperature. 
Chloroform, 200µl per 1ml of Qiazol, was added shaken vigorously (not vortexed) for 15 
seconds to mix well and incubated for 3 minutes at room temperature. The samples were then 
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centrifuged at 14000 rpm for 15 minutes at 4°c. The upper (clear) aqueous layer was 
transferred to a fresh tube and 0.5 ml of isopropanol was added and mixed thoroughly by 
shaking for 15 seconds this was then incubated at room temperature for 10 minutes. The 
samples were then centrifuged at 14000rpm for 20 minutes at 4°c to pellet the RNA. The 
supernatant was carefully removed. 1ml 75% DEPC-ethanol was added and vortexed on low 
for 5-10 seconds to wash the pellet thoroughly, this was then centrifuged at 12000 rpm for 5 
minutes at 4°c to re-pellet the RNA. The supernatant was carefully removed and the pellet air 
dried at room temperature for 10 minutes. The pellet was then dissolved in 30µl DEPC-water 
by gentle pipetting and incubated at 55°c for 5 minutes. RNA was quantitated on a NanoDrop 
2000/2000c Spectrophotometer (Thermo Scientific, IL, USA) and the integrity checked by 
electrophoresis on 1% agarose formaldehyde gels containing 0.5 μg/ml ethidium bromide and 
stored at -80°C until needed.  
6.15.1 Preparation of a 1% formaldehyde agarose gel 
 
Agarose formaldehyde mini gels were prepared by boiling 0.5 g high-gelling agarose in 45 
ml distilled water mixed with 5 ml of 10 x MOPS. After the solution had cooled down to 
approximately 65oC, 2.7 ml of 27 % formaldehyde was added. After cooling further to 50oC, 
ethidium bromide was added to the solution and mixed properly. The gel was poured into the 
gel tank, combs were inserted and allowed to set in the fume hood. MOPS (1x) was added to 
the tank and used as the running buffer.  
6.15.2 RNA Visualization 
 
1 μg of RNA was mixed with RNA loading buffer and the mixture added to the formaldehyde 
agarose gel wells. Running standards were loaded beside the samples. Electrophoresis was 
done at 60V for 45 minutes. The gels were then digitally photographed using a UV 
transilluminator (BioSpectrumTM 500 Imaging System, Upland, CA, USA) with 
VisionWorks LS Image Acquisition and Analysis Software (Version 6.8). 
6.16 cDNA synthesis 
 
Conversion of mRNA to cDNA was performed using the ImProm-II™ Reverse Transcription 
System (Promega, WI, USA), following manufacturer’s instructions. Briefly, 2 μg template 
mRNA, oligo dT and dH2O up to 10 μl, were added together and incubated for 5 minutes at 
room temperature, 10 minutes at 70°C and 5 minutes at 4°C. MgCl2, buffer, dNTPs, RNAsin 
and reverse transcriptase were added and incubated for 90 minutes at 42°C, followed by 10 
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minutes at 70°C to inactivate the reverse transcriptase. The cDNA was stored at -20°C until 
needed. 
6.17 Quantitative Real-Time PCR (qRT-PCR) 
 
Quantitative real-time PCR was performed on a Roche Lightcycler 480 II. To a mixture of 
SYBR Green PCR Master Mix (KAPA SYBR Fast qPCR Kit, KAPA Biosystems), 20 uM of 
forward and reverse primers, as well as 2 μl of cDNA was added, in a total volume of 20 μl. 
GAPDH was used as a housekeeping gene. Primers and melting temperatures are shown in 
Appendix A. 
6.18 Western Blotting 
 
HaCaT cells were infected as explained earlier with HPV11E6 and HPV18E6, a control 
uninfected plate was also included. The cells incubated for 48 hours at 37°C, CO2 (5%) in a 
humidified atmosphere. Before harvesting, the spent media was aspirated, and the cells rinsed 
twice with ice cold PBS. Cold cell lysis buffer (Cell Signalling, MA, USA), approximately 
100 μl for a 100 mm cell culture dish and 50 μl for a 6-well dish, was added, and incubated 
with the cells for 5 minutes on ice. A cell scraper was used to harvest the cells, which were 
transferred to a 1.5 ml microcentrifuge tube and sonicated for 10 seconds (Heat System-
Ultrasonics, Inc, Plainview, New York). The lysate was centrifuged for 15 minutes at 14000 
rpm, at 4°C. The supernatant was transferred to a fresh tube, leaving behind the pellet of 
insoluble material and cell debris. Protein was quantitated using the Pierce BCA 
(Bicinchoninic Acid) Protein Assay (Thermo Scientific, IL, USA) according to 
manufacturer’s instruction. Briefly, a standard curve was constructed using Bovine Serum 
Albumin (BSA) diluted in dH2O to concentrations between 0 and 2000 μg/ml. Protein 
samples were diluted 10x in 25 μl dH2O. The assay was conducted in a 96-well plate, where 
200 μl working solution, prepared by adding reagent A (sodium carbonate, sodium 
bicarbonate, BCA detection reagent, sodium tartrate in 0.1 M NaOH) and reagent B (4% 
CuSO4.5H20) together in a ratio of 50:1. The standards and samples were added to the 
reaction mix, and incubated at 37°C for 30 minutes, where after the absorbance was 
measured at 595 nm. The equation of the slope of the standard curve was used to determine 
the concentration of the protein samples. Equal protein concentrations (100μg/μl) were 
separated electrophoretically on a 12% SDS-PAGE (Laemmli, 1970) at 180 V. A PageRuler 
™ Plus Prestained Protein Ladder (Fermentas, MD, USA) was also loaded in order to 
visualize the size of the protein of interest. The proteins were then transferred 
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electrophoretically onto nitrocellulose membrane in a transfer tank (Biorad, CA, USA) for 
1.5 hours at 100 V, according to a standard protocol (Towbin et al., 1979). Gels were stained 
using coomassie blue staining solution (50% methanol, 10% glacial acetic acid, 0.25% 
coomassie blue). Nitrocellulose membranes were rinsed three times in TBS (50mM Tris 
pH7.5, 150mM NaCl) containing 0.1% Tween-20 (TBST) and blocked in 5% non-fat milk in 
TBST for 1 hour with shaking at room temperature to reduce non-specific binding. Primary 
antibodies against HPV18E6, p53, p21 and GAPDH were diluted 1:1000 in blocking 
solution. Membranes were incubated with the indicated primary antibody (Table 6.1) at 4°C 
overnight with shaking. Membranes were washed 3 times for 15 min in TBST and then 
incubated for 1 hour in 5% non-fat milk blocking solution. Horseradish peroxidase-
conjugated secondary antibodies were diluted 1:5000 in 5% blocking solution. Membranes 
were incubated with secondary antibody for 1 hour at room temperature with shaking. Protein 
bands were detected using the Lumiglo Reserve chemiluminescent substrate system detection 
kit (KPL, Gaithersburg, MD, USA) and the UVP BioSpectrum chemiluminescent detection 
system (BioSpectrumTM 500 Imaging System, Upland, CA, USA) with VisionWorks LS 
Image Acquisition and Analysis Software (Version 6.8). Membranes were then stripped of 
primary and secondary antibodies by washing with 1M glycine pH 2.5 for 10 min with 
shaking, after which 1ml Tris pH 7.5 was added and membranes were washed three times for 
10 min in TBST. Membranes were incubated with blocking solution for 1 hour before being 
re-probed with a different primary antibody. 
 
Table 6.1: Antibody conditions for western blotting 
 
Protein detected  Primary Antibody  Secondary Antibody 
GAPDH Rabbit anti-GAPDH (Santa Cruz) 1:1000 
dilution 
5 % non-fat dried milk powder in 0.1% 
TBST 
Goat anti- rabbit HRP-conjugate (Bio 
rad) 1:5000 dilution 
5% non-fat dried milk powder in 0.1% 
TBST 
HPV18E6 Mouse anti-HPV E6 type 18 (Arbovita) 
1:1000 dilution 
5 % non-fat dried milk powder in 0.1% 
TBST 
Goat anti-mouse HRP-conjugate (Bio 
rad) 1:5000 dilution 
5% non-fat dried milk powder in 0.1% 
TBST 
P53 Mouse anti-P53 (Santa Cruz) 
1:1000 dilution 
5 % non-fat dried milk powder in 0.1% 
TBST 
Goat anti-mouse HRP-conjugate (Bio 
rad) 1:5000 dilution 
5% non-fat dried milk powder in 0.1% 
TBST 
P21 Rabbit anti-P21 (Santa Cruz) 
1:1000 dilution 
5 % non-fat dried milk powder in 0.1% 
TBST 
Goat anti- rabbit HRP-conjugate 
(Bio rad) 1:5000 dilution 
5% non-fat dried milk powder in 0.1% 
TBST 
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6.19 Double Immunofluorescence for Confocal Microscopy 
 
A microscope cover slip was placed inside a 6-well cell culture dish, and 1.0 x 105 HaCaT 
cells were seeded onto the cover-slips in triplicate. The cells were infected as explained 
earlier with HPV11E6 and HPV18E6 with some being left uninfected to act as controls. The 
plates were incubated for 48hours at 37°C, 5% CO2, in a humidified atmosphere. After 
incubation, media was removed and the cells rinsed twice in pre-warmed 1x PBS. The cover-
slips with cells were then fixed by being immersed in absolute ethanol and incubated at -20°c 
for 5 minutes. The cells were then fixed in 4% Paraformaldehyde in PBS for 5 minutes at 
room temperature and washed in PBS, 3 times for 10 minutes. Cells were then incubated in 
Blocking Solution (1% bovine serum albumin (BSA) and 0.1% Triton X-100 in PBS) for 1 
hour at room temperature to reduce non-specific staining. The cells were then incubated with 
the appropriate pair of primary antibodies (Table 6.2) diluted 1:100 in blocking solution, this 
was then sealed in a humidified chamber and incubated overnight at 4oC. The cells were then 
washed in PBS, 3 times for 10 minutes and incubated in secondary antibodies diluted 1:500 
in blocking solution. After which the cells were incubated for 90 minutes in a humidified 
chamber in the dark and then washed in PBS, 3 times for 10 minutes at room temperature. 
Counterstaining was done with a DAPI Nuclear Stain (0.5 µg/ml in PBS) diluted 1:100 in 
blocking solution for 10mins and the cells washed again in PBS, 3 times for 10 minutes at 
room temperature. The cells were then mounted onto microscope slides with mowiol (Sigma-
Aldrich, Steinheim, Germany) containing n-propylgallate as anti-fading agent. The slides 
were then stored in the dark at room temperature for the mowiol to set and then stored in the 
dark at 4°C until viewing. The slides were finally analysed using a confocal microscope 
(Zeiss LSM 510 Meta with NLO). 
 
Table 6.2: Antibody conditions for Double Immunofluorescence 
 
Protein Primary Antibody  Secondary Antibody 
HPV18E6 Mouse anti-HPV E6 type 18 
(Arbovita) 
1:100 dilution 
1 % BSA 
Sheep anti-Mouse cy3 (sigma) 
1:500 dilution 
1 % BSA 
P53 Mouse anti-P53 (santa cruz) 
1:100 dilution 
1 % BSA 
Goat anti-Mouse cy3 (sigma) 
1:500 dilution 
1 % BSA  
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6.20 Flow cytometry 
 
HaCaT cells were infected as explained earlier with HPV11E6 and HPV18E6, a control 
uninfected plate was also included. The cells incubated for 48 hours at 37°C, CO2 (5%) in a 
humidified atmosphere. After incubation, the cells were harvested as described previously. 
The cell pellet was resuspended in PBS, and washed by centrifugation at 4000 rpm for 5 
minutes and resuspended in 1 ml of 70% ethanol. Before analysis, samples were centrifuged 
at 4000 x g for 5 minutes. The pellet was washed twice in PBS by centrifugation at 4000 x g 
for 5 minutes. The pellet was resuspended in 100 μl PBS containing 100 μg/ml Ribonuclease-
A (RNase), and left at room temperature for 5 minutes. Finally, 500 μl of propidium iodide 
(50 μg/ml in PBS) was added to the cells, which were stored in the dark at 4°C until flow 
cytometric analysis was performed (1 – 2 hours). The experiment was performed in triplicate 
on three clones from each HPVE6 virus. Flow cytometric cell cycle analysis was carried out 
using a BD FACS ™ Calibur flow cytometer (BD Biosciences, CA, USA). For each sample, 
at least 20 000 cells were measured for DNA content. Analysis of the results was performed 
using ModFit LT software (Verity Software House) to calculate the percentage of cells in 
each stage of the cell cycle. 
6.21 Soft agar assay 
 
HaCaT cells were infected as explained earlier with HPV11E6 and HPV18E6, a control 
uninfected plate was also included. The cells incubated for 48 hours at 37°C, CO2 (5%) in a 
humidified atmosphere. The used media was then discarded and the cells washed with 
Phosphate Buffered Saline (PBS), trypsinized with 0.05% trypsin-EDTA and once detached, 
the trypsin-EDTA was inactivated by adding 5 ml of complete DMEM. Cells were collected 
by centrifugation at 4000 rpm for 5 minutes and resuspended in 3ml DMEM. A base agar 
was prepared by mixing 1% agarose gel (40°c) with 2x DMEM (20% FCS and 2% P/S). 1ml 
of the mixture was added to each well of a 6 well plate and swirled to cover the whole 
surface. The plates were then stored at 4°c for upto one week sealed in a parafilm or let to set 
at room temperature for 30 minutes before using them. Once the base agar had set a top agar 
base was prepared by melting 0.7% DNA agarose in microwave and cooling it to 40°c. The 
HPVE6 infected and HaCaT control cells were counted to 2,500 cells/plate. By using 
15,000/tube, there was enough to plate a six well agar plate from each original tissue culture 
plate, the volume was adjusted so that the cell count = 150,000 cells/ml. A mixture of 0.1ml 
cell suspension, 3ml of 2x DMEM (20% FCS and 2% P/S) and 3ml of 0.7% DNA agar was 
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added into a 10ml tube and mixed gently. Then 1ml of the mixture was added gently onto the 
warmed base agar in triplicate and incubated at 37°C in 5% CO2 humidified incubator for 10 
to 30 days with feeding of the cells with 1ml DMEM 1-2 times per week. After 21 days the 
cells were stained with 0.5 ml of 0.005% crystal violet for more than 1 hour and the pink 
colonies were counted using an Olympus CKY41 light microscope set at 10 x magnification. 
6.22 Microarray analysis 
 
RNA samples extracted from HaCaT cells infected as explained earlier with HPV11E6 and 
HPV18E6 with a control uninfected plate in triplicate were analysed on the agilent 
bioanalyzer using the total RNA Nano Assay. An internal quality control sample control 
RNA-50ng/μl was included as internal reference. The NanoDrop 2000/2000c 
Spectrophotometer (Thermo Scientific, IL, USA) was used to determine sample 
concentration and the presence of possible contaminants followed by the Agilent Bioanalyzer 
Nano Assay to assess the integrity of the samples prior to downstream application(Agilent, 
2014). The prepared samples were then hybridized overnight to the Affymetrix Human Gene 
ST 2.0 arrays. Following hybridization, the arrays were washed and stained using the 
GeneChip Fluidics Station 450 and scanned using the GeneChip® Scanner 3000 7G. An 
initial analysis was carried out to determine the quality of the data using expression console, 
which included a range of quality assessment metrics with this software being used primarily 
in determining the quality of the data and the identification of any possible outliers. Raw 
intensity files were normalised using the Robust Multichip Average (RMA) method for 
affymetrix microarray chips (Affymetrix, 1999). Analysis of Variance (ANOVA) was used in 
identifying the differentially expressed genes having a cut-off  fold change of between –2.0 to 
2.0 and significance FDR of ≤ 0.05, this was achieved through the use of the Partek® 
Genomics Suite™ 6.6 software(Partek Inc., 2014). 
6.22.1 Venn diagram 
 
A web-based Venn diagram (Pirooznia et al., 2007) was used to calculate and identify genes 
that were uniquely induced by either HPV11E6 or HPV18E6 and genes that were shared 
between the two datasets.  
6.22.2 Gene Ontology (GO) analysis 
 
A web-based GOTree Machine (GOTM) (Zhang et al., 2004) that identifies enriched GO 
terms in ranked lists of genes was used for GO analysis of the differentially expressed genes. 
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The output of the enrichment analysis was visualised as a bar graphs and acyclic graphs, 
providing a view of the relations between GO terms. 
6.22.3 Pathway analysis 
 
The Ingenuity™ Pathway Analysis (IPA) system (Ingenuity, 2014) was used to identify the 
top most significantly regulated pathways from Venn diagram list, and identified genes that 
were uniquely induced by either HPV11E6 or HPV18E6 and genes that were shared between 
the two datasets. The results were presented graphically based on scoring of the ratio of 
significant genes present in the canonical pathway to the total number of molecules in the 
canonical pathway. The threshold level was set at p = 0.05. The Kyoto Encyclopedia of 
Genes and Genomes (KEGG) software (Kanehisa et al., 2004) was also used due to its 
capability to integrated current knowledge on molecular interaction networks in biological 
processes.  
6.22.4 Network analysis 
 
The Ingenuity™ Pathway Analysis (IPA) system (Ingenuity, 2014) was also used to generate 
networks which were assembled based on gene connectivity with other genes based on the 
assumption that the more connected a gene, the more influence it had and the more important 
it was. Networks were assembled using decreasingly connected molecules from data set of 
respective HPVE6 DEGs. A maximum of 35 genes comprised a network which was 
annotated with high-level functional categories. Focus molecules with the most interactions 
to other focus molecules were connected together to form a network with non-focus 
molecules and dataset genes from the knowledge base were also added to fill areas lacking 
connectivity, the resulting networks were scored and then sorted based on the p-score. 
6.23 Whole genome sequencing (WGS) 
6.23.1 DNA Extraction from Blood 
 
Genomic DNA was extracted according to the protocol from (Gustafson et al., 1987), which 
consisted of the following steps; Whole blood samples were defrosted and transferred to a 
sterile polypropylene 50 ml tube and diluted with 40-45 ml of phosphate buffered saline 
(PBS) solution and then centrifuged at 7000 rpm for 15 min. The supernatant was then 
poured off and the pellet suspended in 25 ml of Sucrose Triton X-100 Lysing Buffer. The 
homogenized solution was spun for 5 min at 6000 rpm and the supernatant poured off. The 
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pellet was then resuspended in 3 ml of T20E5 solution, 200 μl of 10% Sodium dodecyl 
sulfate (SDS) to a final concentration of 1% and 100 μl of proteinase K, 10 mg/ml to a final 
concentration of 250 μg/ml. This solution was incubated at 45°C overnight. 4 ml of saturated 
NaCl was added and mixed vigorously for 15 sec. and the samples spun for 40 min at 7000 
rpm to allow for precipitation of proteins. The supernatant containing the DNA was 
transferred to a 12 ml tube and absolute ethanol was added in order to precipitate the DNA. A 
white isolated lump made of precipitated DNA was then transferred to a 2 ml tube and 
washed in 1 ml of 70% ethanol. The tubes were then finally centrifuged at 7000 rpm for 5 
min and pellets (DNA) were dissolved in 400 μl of 1X TE buffer. The DNA samples were 
then left at 4°C overnight or longer, until the pellet was completely dissolved in TE buffer. 
DNA was then quantitated on a NanoDrop 2000/2000c Spectrophotometer (Thermo 
Scientific, IL, USA) and the samples stored at –20°C until needed. 
 
6.23.2 DNA Extraction from Tissue Biopsy  
Frozen tissue was first thawed on ice and placed into a sterile microcentrifuge tube containing 
0.5 ml of QIAzol Lysis ReagentTM. The sample volume was not to exceed 10 % of the 
volume of the QIAzol Lysis ReagentTM. For efficient disruption of tissue samples, the size of 
the sample was not supposed to be greater than half the diameter of the homogeniser probe, 
and the sample was into smaller pieces if necessary. The tip of the tissue pestle disposable 
probe was then placed into the QIAzol Lysis ReagentTM and the pestle operated the pestle at 
full speed until the tissue lysate was uniformly homogeneous (1-5min). An additional 0.5 ml 
of QIAzol Lysis ReagentTM reagent was added and mixed by vortexing for 30 sec. The 
homogenized samples were then incubated for 5 minutes at room temperature (20°-25°C) to 
permit the complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform per 1ml 
of QIAzol Lysis ReagentTM was then added to the sample tubes, capped and shaken 
vigorously by hand for 15 sec. After which the samples were incubated at room temperature 
for 2 to 3 min. The samples were then centrifuged at 12 000 x g for 15 minutes at 4° C. 
Following centrifugation, the mixture separated into 3 phases: a colourless upper aqueous 
phase containing RNA, a white middle interphase containing DNA and a lower red organic 
phenol phase containing protein. The upper aqueous phase to a new tube and stored at 4°C 
for later RNA extraction.  0.3 ml of 100% ethanol was the added to the interphase and phenol 
phase, and carefully the samples were mixed by inversion and incubated at room temperature 
for 2–3 min. The samples were then centrifuged at 14000 x g for 5 min at 4° C to sediment 
DNA, and the phenol/ethanol supernatant was discarded. 1 ml sodium citrate solution was 
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then added to the DNA pellet and the samples Incubated at room temperature for 30 min, 
with mixing by inversion every 5 min. The samples were then centrifuged at 14,000 x g for 5 
min at 4°C, and the supernatant carefully removed. 1.5 ml of 75% ethanol was then added to 
the DNA pellet and Incubated at room temperature for 20 min, with mixing by inversion 
every 5 min. The samples were then centrifuged at 12,000 x g for 5 min at 4° C and ethanol 
supernatant was completely removed before the DNA pellet was air dried for 5-15 min. The 
DNA pellet was dissolved by adding 200 ul of 8 mM NaOH to the pellet and the solution 
vortexed for 15 sec and before being incubated for 30 min at 60°C.  The samples were then 
centrifuged at 14,000 x g for 10 min at room temperature to remove insoluble material, and 
the supernatant transferred to a new tube. The pH of 8 mM NaOH was approximately 9. For 
storage, the pH of the DNA sample solution was adjusted to pH 7–8 by addition of 23.4 ul of 
0.1 M HEPES and 2.2 μl 100 mM EDTA (final concentration 1 mM). DNA was then 
quantitated on a NanoDrop 2000/2000c Spectrophotometer (Thermo Scientific, IL, USA) and 
the samples stored at –20°C until needed. 
6.23.3 DNA concentration measurement 
DNA concentration was determined by NanoDrop 2000/2000c Spectrophotometer (Thermo 
Scientific, IL, USA). For each sample, 2 μl of dissolved DNA was loaded on the 
spectrophotometer, which provided the DNA concentration in ng/μl, the 260/230 ratio for 
organic chemicals and solvent contamination (important to have this ratio above 1.6 for 
PCR), and the 260/280 ratio for protein contamination (ratios above 1.8 were considered 
relatively good quality). The samples were then stored at 4°C prior PCR. 
6.23.4 Variant Calling 
Four oesophageal squamous cell carcinoma (OSCC) DNA biopsy samples were submitted to 
CPGR for whole genome sequencing. Quality control (QC) measures were carried out to 
validate the integrity of the samples for whole genome sequencing with the Quant-iT™ 
PicoGreen® dsDNA kit (Bhat et al., 2010).  Paired-end sequencing was performed on the 
Illumina HiSeq2000, with 2x100 bp reads (Wang et al., 2010). Reads were aligned to the 
NCBI37 Homo sapiens reference genome using ELAND and CASAVA (Kidd et al., 2010). 
Structural variants (SV) reported from the alignment were collated with gene loci, (upstream, 
downstream and overlapping) using the Variant Effect Predictor of Ensembl (McLaren et al., 
2010). The affected genes were subsequently cross-checked against the genetic association 
database for disease and cancer associations (Becker et al., 2004). 
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6.23.5 Determination of BCLAF1 deletion 
The BCLAF1 deletion was determined by PCR assay as previously described (Matejcic et al., 
2011). A two primer set (Table 6.1) was used to identify both the deletion and non-deletion in 
a single reaction. Briefly, 50 ng of genomic DNA was added to buffer containing 1.5 mM 
MgCl2, 2 mM dNTPs, 10 pmol of each oligonucleotide primer and 0.5 U of HotStart Taq 
polymerase (Roche). Fragments were amplified in a final volume of 25 μl. The PCR reaction 
was carried out in a Veriti Thermal Cycler (Applied Biosystems) and thermal cycling 
conditions consisted of an initial hot start of 10 min at 95°C followed by 30 cycles of 
denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 3 
min, with a final extension step at 72°C for 7 min. PCR products were separated by 
electrophoresis on 1% agarose gels in Tris-Borate-EDTA buffer. The gels were stained with 
ethidium bromide and digitally photographed using a UV transilluminator (BioSpectrumTM 
500 Imaging System, Upland, CA, USA) with VisionWorks LS Image Acquisition and 
Analysis Software (Version 6.8). The resulting bands in the gel were distinguished by 
comparing their position with that of standard bands from the GeneRuler DNA Ladder Mix 
marker (Fermentas). 
6.23.6 Determination of viral sequence integration sites 
Reads from the WGS that didn't map to the human reference genome were probed for viral 
association with OSCC. The program DeconSeq (Schmieder & Edwards, 2011) was used to 
align the unmapped reads against complete set of NCBI RefSeq Viral Genomes (build 64) 
using the Burrows Wheeler Aligner (BWA) (Li & Durbin, 2010). DeconSeq allows detecting 
of plausible matches based on a user specified match identity and sequence coverage. For our 
detection we set the identity match to a minimum of 95% and sequence coverage to a 
minimum of 90%. From the DeconSeq results a list of the most to least frequent viral hits 
were built. The BWA database indexing, alignment and filtering were done on the UCT HPC 
cluster (http://hex.uct.ac.za). From the list of viral sequences identified in all the four 
samples, 22 viral sequences were selected which were common and of human origin in all the 
four samples. In order to detect the viral integration sites we used BWA to align all the reads 
from the WGS to the human reference genome (hg19, UCSC) and the 22 viral genomes. All 
the discordant reads were extracted from the complete mapping and only those matches 
where one of the read pairs mapped to the human genome and the other read pair mapped to 
any of the viral genome were selected (Jiang et al., 2012). In order to achieve a high 
confidence in viral integration, we further filtered the selected viral reads to only those that 
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had 100% match in both the BWA alignment score and CIGAR string to the reference human 
genome and human viral sequence. A Circster image was then generated on Galaxy to 
visualize the chromosomal integration sites of the filtered viral sequences for the four patient 
samples (Giardine et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010).  
6.24 Solutions & Buffers 
 
Acrylamide/Bisacrylamide Solution (30%)  
29 g Acrylamide 
1 g Bisacrylamide 
Made to 100 ml with distilled water and stored in dark at 4°C 
 
7.5 M Ammonium acetate, pH 7.4 
Dissolve 57.81 g ammonium acetate in 60 ml of distilled water, adjust pH to 7.4 with 
ammonia solution, make up to 100 ml with distilled water and sterilise by filtration using a 
filter of 0.45 μm pore size 
 
2 M Ammonium acetate, pH 7.4 
Dissolve 15.416 g ammonium acetate in 60 ml of distilled water, adjust pH to 7.4 with 
ammonia solution, make up to 100 ml with distilled water and sterilise by filtration using a 
filter of 0.45 μm pore size 
 
10 % Ammonium persulfate (APS) 
Dissolve 100 mg of APS in 1 ml of distilled water, store at 4°C 
 
Ampicillin Stock Soln (10 mg/ml) 
Dissolve 500 mg Ampicillin in 50 ml of distilled water. Sterilise by filtration through a filter 
of pore size 0.22 μm and store at -80°C. Dilute to a working solution of 50 μg/ml. 
 
Coomassie blue staining solution 
0.5 g Coomassie BB 
500 ml methanol 
100 ml acetic acid  
400 ml distilled water 
DEPC-Treated water (0.01 %) 
Add 10 μl of DEPC to distilled water (100 ml) and stir at room temperature. Leave overnight 
and then autoclave 
 
DEAE-dextran (Stock); Sigma Aldrich (D9885-10G) 
Reconstitute 5 grams of DEAE-Dextran in one litre of distilled sterile water. 
Filter through a 0.45-micron filter and aliquot 10 ml in 15 ml conical tubes. 
Store tubes at - 80°C 
 
Destaining Solution (10 % Acetic acid (v/v)) 
100 ml acetic acid 
100 ml methanol 
800 ml distilled water 
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6X DNA loading dye 
Weigh 25 mg bromophenol blue, 25 mg xylene cyanol FF, and 4 gm Sucrose 
Dissolve them in 9 ml distilled water to make up 10 ml solution 
Store the solution in small aliquots (1 ml) at -20°C for long time. 
 
0.5 M EDTA, pH 8.0 
Add 37.22 g of Na2EDTA.2H2O to 140 ml of distilled water. Adjust the pH to 8.0 with 10 N 
NaOH then add distilled water to a final volume of 200 ml. Autoclave and store at room 
temperature. 
 
70 % Ethanol 
70 ml of absolute ethanol 
Add 30 ml of distilled water 
 
Ethidium Bromide 
Stock solution 10 mg/ml 
Final concentration 0.5 mg/ml 
Add 10 μl of stock solution (10 mg/ml) to 200 ml dH2O to get a final concentration of 0.5 
mg/ml 
Store the solution in a light-proof container at 4°C for long time. 
 
75 % DEPC- Ethanol 
75 ml absolute ethanol 
25 ml DEPC-treated water 
 
Fixing Solution  
100 ml acetic acid 
500 ml methanol 
400 ml distilled water 
 
Freezing down media 
70 % Fetal bovine serum 
20 % DMEM media 
10 % Dimethylsulphoxide (DMSO) 
Store at 40C 
 
Inoue transformation buffer 
The Inoue transformation buffer was prepared by dissolving all the solutes listed below in 
800 ml of distilled H2O and then 20 ml of 0.5 M PIPES (pH 6.7) was added. Adjust the 
volume of the Inoue transformation buffer to 1 litre with distilled H2O 
 
 
 
 
 
 
 
 
The Inoue transformation buffer was then sterilized by filtration through a pre-rinsed 0.45-
mm Nalgene filter. Divide into aliquots (10 ml) and store at -20ºC 
Reagent Amount per litre Final Concentration 
MnCl2.4H20 10.88g 55mM 
CaCl2.2H2O 2.20g 15 mM 
KCl 18.65g 250mM 
PIPES(0.5M,Ph 6.7) 20ml 10mM 
H2O to 1 litre  
113 
 
Luria Bertani (LB) Broth (with Ampicillin) 
10g Bacto Tryptone 
5g Bacto Yeast Extract 
10g Nacl 
Make to 1 litre with DH2O 
pH 7.0 
Autoclave and allow to cool to about 400C then add Ampicillin to a final concentration of 100 
μg/ml. 
 
Luria Bertani (LB) Plates (with Ampicillin) 
10g Bacto Tryptone 
5g Bacto Yeast Extract 
10g Nacl 
Make to 1 litre with DH2O 
pH 7.0 
Autoclave and allow to cool to about 400C then add Ampicillin to a final concentration of 100 
μg/ml. Pour into 100 mm dishes and let the agar harden. Store at 40C  
 
10 X Loading Buffer 
0.25 % bromophenol blue in 40 % glycerol (v/v) 
 
10 x MOPS Buffer 
0.4M MOPS, pH 7.0 
0.1M Sodium acetate 
 
5 % non-fat milk blocking solution 
Dissolve 2.5 g non-fat milk powder in 30 ml TBST; make up to 50 ml with TBS-T 
 
1X PBS (pH 7.4) 
154 mM NaCl 
2.7 mM KCl 
5.6 mM Na2HPO4 or Na2HPO42H2O 
1mM KH2PO4 
Adjust pH to 7.4 using concentrated HCl or NaOH if necessary 
Dissolve into 1 liter distilled water and autoclave. 
 
Phenol: Chloroform: Isoamyl alcohol (25:24:1) 
Mix one part of phenol and one part of chloroform: isoamyl alcohol (24:1) 
 
5 x Protein loading dye 
200 μl 5 x protein loading buffer 
50 μl of β-mercaptoethanol, 10 μl of bromophenol blue 
 
RIPA Buffer 
200 μl RIPA solution 
2 μl of 2 mg/ml pepstatin 
2 μl of 10 mg/ml aprotinin 
2 μl of 100 μM PMSF 
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RNA Loading Buffer (25 ml) 
1 mM EDTA, pH 8.0   
0.25 % Bromophenol Blue (w/v) 
0.25% Xylene Cyanol 
50% Glycerol (v/v) 
50 μl DEPC 
Add distilled water to a final volume of 25 ml, Stir overnight and autoclave 
 
10 % SDS 
Dissolve 10 g sodium dodecyl sulphate in 80 ml distilled water (heat to 80°C), make up to 
100 ml with distilled water 
 
10 × Running buffer 
29 g Tris 
144 g Glycine 
10 g SDS 
Made to 1 Litre with distilled water 
 
SDS-PAGE Running Buffer (5 x) 
0.25 M Tris-HCl (pH 8.3) 
1.92 M Glycine 
0.5 % SDS 
SDS/Tris Buffer 
5% SDS (w/v) 
0.5 M Tris-HCl (pH 7.4) 
0.125 M EDTA 
 
Stripping Solution 
1.4 ml β-mercaptoethanol 
40 ml 10 % SDS 
12.5 ml Tris-HCl, pH 6.7 
Make up to 200 ml with distilled water 
 
TAE Electrophoresis Buffer (1 x) (pH 8.3) 
90 mM Tris 
90 mM Boric Acid, 2.5 mM EDTA. Adjust pH to 8.3.   
 
TBS-Tween 
50 ml 1M Tris base 
30 ml 5M NaCl 
250 μl Tween-20 
Make up to 1litre with distilled water 
 
1X TBE 
0.445M Tris (pH 8.0) 
0.445M boric acid 
0.01M EDTA (pH 8.0)) 
Add to 1 liter distilled water and autoclave. 
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TE buffer (10x) (pH 8.0) 
100 mM Tris-Cl 
10 mM EDTA 
Adjust pH to 8.0 
   
10×Transfer buffer 
144 g glycine 
38 g Tris 
Make up to 1 litre with distilled water. 
 
Tris Buffered Saline (TBS) 
25 mM Tris (pH 7.5) 
0.9% NaCl (w/v) 
 
1M Tris pH 7.5 (per litre) 
Add 121 g Tris base to 800 ml of distilled water 
Adjust pH with concentrated HCl to pH 7.5 and add distilled water up to one litre. Autoclave 
 
1M Tris pH 8.8 (per litre) 
Add 121 g Tris base to 800 ml of distilled water 
Adjust pH with concentrated HCl to pH 8.8 and then add distilled water up to one litre. 
Autoclave 
 
1 X Trypsin-EDTA solution 
0.05% (w/v) trypsin, 0.53 mM EDTA 
Prepare in a calcium and magnesium-free 1 x PBS 
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APPENDIX-A 
 
Table A1: Primer sequences and annealing temperatures 
Primer  Sequence  Annealing 
temperature 
BCLAF1 5’-CGCGTCGAAGGTAGCTCTAT-3’ 
5’-TTGGAGCGACCCATTTCTTTT-3’ 
60°C 
BRCA1 5’-GGCTATCCTCTCAGAGTGACATTTTA-3’ 
5’-GCTTTATCAGGTTATGTTGCATGGT-3’ 
60°C 
BUB1 5'-TCATTCATGGAGACATTAAAC-3' 
5'-CTGAGCATCTCAACACACTG-3' 
60°C 
CCL21 5’-CAAGCTTAGGCTGCTCCATC-3’ 
5’-TCAGTCCTCTTGCAGCCTTT-3’ 
60°C 
CCL26 5’- AACTCCGAAACAATTGTACTCAGCTG- 3’ 
5’-GTAACTCTGGGAGGAAACACCCTCTCC-3’ 
60°C 
CYP24A1 5’-CAA ACCGTG GAAGGCTATC-3’ 
5’-AGTCTTCCCCTTCCAGGATCA-3’ 
60°C 
GADD45A 5’-GAAGTCCGCGGCCAGGACACAGTTCC-3’ 
5’-GGTCCCCGCCGGGCTGTCACTCGG-3’ 
60°C 
GAPDH 5’- GGCTCTCCAGAACATCATCC - 3’ 
5’- GCCTGCTTCACCACCTTC- 3’ 
60°C 
HPV-11 E6 5’- AAGATGCCTCCACGTCTGCAA- 3’ 
5’- CTTGCAGTTCTAGCAACAGGC- 3’ 
60°C 
HPV-18E6 5’- CCAGAAACCGTTGAATCCAG - 3’ 
5’- GAGTCGTTCCTGTCGTGCTC - 3’ 
60°C 
IL8 5’-ACTGAGAGTGATTGAGAGTGGAC-3’ 
5’-AACCCTCTGCACCCAGTTTTC-3’ 
60°C 
JUN 5’-CCT TGAAAGCTCAGAACTCGG AG-3’ 
5’-TGCTGCGTTAGCATG AGTTGG C-3’ 
60°C 
MCM2 5’-GCTCTGGCCCTG TTTGGA-3’ 
5’-GAAGATGGCACGGCTAGACAC T-3’ 
60°C 
MCM6 5’-CTCTGAATGCCAGGACATCCA T-3’ 
5’-CATTGCATTCATCCACCAGAA-3’ 
60°C 
MMP1 5’-GGAGGGGATGCTCATTTTGATG-3’ 
5’-TAGGGAAGCCAAAGGAGCTGT-3’ 
60°C 
MMP9 5’-GGCCAACTACGACACCGACGAC-3’ 
5’-CGCCGCCACGAGGAACAAAC-3’ 
60°C 
MTTP 5’-GGACTT TTTGGATTTCAAAAGTGAC-3’ 
5’-GGAGAAACGGTCATAATTGTG-3’ 
60°C 
NOX1 5’-CACGCTGAGAAAGCCATTGGATCAC-3’ 
5’-GGATGGAATAGGCTGGAGAGAACA-3’ 
60°C 
P21 5’- ACCTCACCTGCTCTGCTGC-3’ 
5’- ATTAGGGCTTCCTCTTGGAGA-3’ 
65°C 
P53 5’- CATCATCACACTGGAAGACTCC-3’ 
5’- CAGTGCTCGCTTAGTGCTCC-3’ 
65°C 
PDK4 5’-CCCGCTGTCCATGAAGCAGC-3’ 
5’-CCAATGTGGCTTGGGTTTCC-3’ 
60°C 
STARD7 5’-GGTAATCAAGCTGGAGGTGATTG-3’ 
5’-GAGTACATTGGATAAGGAAAATGGGT-3’ 
60°C 
TP53INP1 5’-TGAACACATTTGCCTTGTGAA-3’ 
5’-GGCAAAGTGCTGTGCTGTT-3’ 
60°C 
TSHB 5’-GGCAAACTGTTTCTTCCCAA-3’ 
5’-TCTGTGGCTTGGTGCAGTAG-3’ 
60°C 
ZIC1 5’-AAACTGGTTAACCACATCCGC-3’ 
5’-CTCAAACTCGCACTTGAAGG-3’ 
60°C 
BCLAF1 
Deletion 
5’-TGTGGGGAAAGGCAGAAAGG-3’ 
5’-CATCCACCATAAGCCGTGTA-3’ 
60°C 
T7-Promoter 5’-TAATAC GACTCACTATAGGG-3’ DNA Plasmid 
Primers CMV-Promoter 5’-GGCGGTAGGCGTGTA-3’ 
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APPENDIX-B 
 
Table A2: Selected viral sequences identified from un-mapped reads (50). Based on a minimum of 
95% identity match and a minimum of 90% sequence coverage on BWA alignments against NCBI's 
RefSeq Viral Genomes (build 64) 
NCBI_RefSeq Virus 
NC_001694.1 Human papillomavirus  61, complete genome 
NC_001493.2  Ictalurid herpesvirus 1 strain Auburn 1, complete genome 
NC_022518.1 Human endogenous retrovirus K113 complete genome 
NC_001782.1 Saccharomyces cerevisiae killer virus M1, complete genome 
NC_004102.1 Hepatitis C virus genotype 1, complete genome 
NC_001348.1 Human herpesvirus 3 
NC_007346.1 Emiliania huxleyi virus 86, complete genome 
NC_002229.3 Gallid herpesvirus 2, complete genome 
NC_009334.1 Human herpesvirus 4 
NC_001479.1 Encephalomyocarditis virus, complete genome 
NC_009127.1 Cyprinid herpesvirus 3, complete genome 
NC_001716.2 Human herpesvirus 7, complete genome 
NC_009333.1 Human herpesvirus 8 
NC_002641.1 Meleagrid herpesvirus 1, complete genome 
NC_001806.1 Human herpesvirus 1, complete genome 
NC_000898.1 Human herpesvirus 6B, complete genome 
NC_001596.1 Human papillomavirus type 9, complete genome 
NC_001664.2 Human herpesvirus 6A, complete genome 
NC_014637.1 Cafeteria roenbergensis virus BV-PW1, complete genome 
NC_007605.1 Human herpesvirus 4 type 1, complete genome 
NC_009824.1 Hepatitis C virus genotype 3 
NC_014567.1 Saimiriine herpesvirus 1, complete genome 
NC_016447.1 Aotine herpesvirus 1 strain S34E, complete genome 
NC_001847.1 Bovine herpesvirus 1, complete genome 
NC_001526.2 Human papillomavirus type 16, complete genome 
NC_001798.1 Human herpesvirus 2, complete genome 
NC_001611.1 Variola virus, complete genome 
NC_009827.1 Hepatitis C virus genotype 6 
NC_007821.1 Enterobacteria phage WA13, complete genome 
NC_002169.1 Spodoptera exigua MNPV, complete genome 
NC_001897.1 Human parechovirus, genome 
NC_002645.1 Human coronavirus 2 
NC_001357.1 Human papillomavirus - 18, complete genome 
NC_001987.1 Ateline herpesvirus 3 complete genome 
NC_001457.1 Human papillomavirus type 4, complete genome 
NC_006273.2 Human herpesvirus 5 strain Merlin 
NC_001623.1 Autographa californica nucleopolyhedrovirus, complete genome 
NC_009823.1 Hepatitis C virus genotype 2, complete genome 
AC_000017.1 Human adenovirus type 1 
NC_019445.1 Escherichia phage TL-2011b, complete genome 
NC_002188.1 Fowlpox virus, complete genome 
NC_008349.1 Plutella xylostella multiple nucleopolyhedrovirus, complete genome 
NC_001954.1 Enterobacteria phage If1, complete genome 
NC_011357.1 Stx2-converting phage 1717, complete prophage genome 
NC_005294.1 Streptococcus prophage EJ-1, complete genome 
AC_000007.1 Human adenovirus 2 
NC_017972.1 Pseudomonas phage Lu11, complete genome 
NC_001655.1 Hepatitis GB virus B, complete genome 
NC_001330.1 Enterobacteria phage alpha3, complete genome 
NC_001697.1 Haemophilus phage HP1, complete genome 
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